ML14232A656
| ML14232A656 | |
| Person / Time | |
|---|---|
| Issue date: | 02/14/2014 |
| From: | Henderson P NRC/FSME/DMSSA |
| To: | State of AZ |
| Schneider K | |
| Shared Package | |
| ML14232A317 | List: |
| References | |
| Download: ML14232A656 (93) | |
Text
Volume 20, Issue 7 Page 324 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking NOTICES OF FINAL RULEMAKING NOTICE OF FINAL RULEMAKING TITLE 12. NATURAL RESOURCES CHAPTER 1. RADIATION REGULATORY AGENCY Editors Note: The following Notice of Final Rulemaking was reviewed per Executive Order 2012-03 as issued by Governor Brewer. (See the text of the executive order on page 417.) The Governors Office authorized the notice to proceed through the rulemaking process on July 18, 2013.
[R14-01]
PREAMBLE 1.
Article, Part, or Section Affected (as applicable)
Rulemaking Action R12-1-102 Amend R12-1-303 Amend R12-1-304 Amend R12-1-306 Amend R12-1-308 Amend R12-1-311 Amend R12-1-313 Amend R12-1-320 Amend Exhibit B Amend Exhibit D Amend R12-1-408 Amend R12-1-434 Amend R12-1-438 Amend R12-1-438.01 New Section R12-1-439 Amend R12-1-446 Amend Appendix B Amend R12-1-703 Amend R12-1-705 Amend R12-1-710 Amend R12-1-711 Amend R12-1-712 Amend R12-1-713 Amend R12-1-717 Amend R12-1-719 Amend R12-1-720 Amend R12-1-721 Amend R12-1-723 Amend R12-1-727 Amend R12-1-728 Amend R12-1-744 Amend Exhibit A Amend R12-1-1004 Amend 2.
Citations to the agencys statutory rulemaking authority to include the authorizing statute (general) and the imple-menting statute (specific):
Authorizing statute: A.R.S. §30-654(B)(5)
Implementing statutes: A.R.S. §§30-651, 30-654,30-657, 30-671(B),30-672, 30-673,30-681, 30-687,30-688, and 30-689.
The Administrative Procedure Act requires the publication of the final rules of the states agencies. Final rules are those which have appeared in the Register first as proposed rules and have been through the formal rulemaking process including approval by the Gover-nors Regulatory Review Council or the Attorney General. The Secretary of State shall publish the notice along with the Preamble and the full text in the next available issue of the Register after the final rules have been submitted for filing and publication.
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 325 Volume 20, Issue 7 3.
The effective date of the rule:
March 8, 2014 4.
Citations to all related notices published in the Register as specified in R1-1-409(A) that pertain to the record of the proposed rule:
Notice of Rulemaking Docket Opening: 19 A.A.R. 1992, August 2, 2013 Notice of Proposed Rulemaking: 19 A.A.R. 2642, August 30, 2013 5.
The agencys contact person who can answer questions about the rulemaking:
Name:
Jerry W. Perkins Address:
Arizona Radiation Regulatory Agency 4814 S. 40th St.
Phoenix, AZ 85040 Telephone:
(602) 255-4845, ext. 272 Fax:
(602) 437-0705 E-mail:
jperkins@azrra.gov Website:
www.azrra.gov 6.
An agencys justification and reason why a rule should be made, amended, repealed or renumbered, to include an explanation about the rulemaking:
This rulemaking package amends several rules to ensure that Arizona radiation compliance remains compatible with the Nuclear Regulatory Commission regulations. This compatibility is a requirement under Arizonas agreement state status. Arizona has entered into an agreement with the NRC that gives the state the authority to license and inspect byproduct, source, and special nuclear materials used or possessed within the states borders since 1967 as a portion of the existing radiation protection program adopted by the state. This allows Arizona to retain local jurisdiction with-out duplication of effort in a continuing effort to protect the health and safety of the public. In addition, A.R.S. §30-654(B)(6) requires the Agency to be as nearly as possible in conformity with the regulations of the NRC.
7.
A reference to any study relevant to the rule that the agency reviewed and proposes either to rely on or not to rely on in its evaluation of or justification for the rule, where the public may obtain or review each study, all data underlying each study, and any analysis of each study and other supporting material:
None 8.
A showing of good cause why the rulemaking is necessary to promote a statewide interest if the rulemaking will diminish a previous grant of authority of a political subdivision of this state:
Not applicable 9.
A summary of the economic, small business, and consumer impact:
There is little or minimal economic impact from any of the proposed rules in this rulemaking. Currently all licensees and registrants pay an annual fee which covers the administrative cost and inspection fees for each facility registra-tion number. This package has no fee increase or new requirements that would markedly change the way businesses operate with radiation safety concerns in mind. The amendments in this rulemaking brings the Arizona Regulatory program closer to federal regulations in accordance with the Agreement State document signed by the state Governor on March 30, 1967. No new FTEs were needed for this rulemaking package so additional notice was not sent to the Joint Legislative Budge Committee (JLBC).
- 10. A description of any changes between the proposed rulemaking, to include supplemental notices, and the final rulemaking:
Several grammatical, clarifying, and formatting changes were made to the proposed rules following the suggestions presented by the U.S. Nuclear Regulatory Commission in a written comments letter dated August 14, 2013. R12 711, Exhibit A: Group 100, R12-1-719, Exhibit A: Group 200, R12-1-721, R12-1-723, R12-1-727, and R12-1-744 were corrected to include NRC in the referencing equivalent requirements as well as clarifying specific subsections referred to within the rule. A typographical correction to a cross-reference was made to the definition of Authorized user in R12-1-102. In addition, incorporations of 10 CFR 101, 101, and 103 required removal as the 2013 code of federal regulations no longer included these regulations. The second alphabetical listing for Radiation Safety officer (RSO) was struck as it was a duplicate of the language in the second portion of the first listing of the definition.
Original language in R12-1-303 and R12-1-306 was inaccurately noticed in the proposed rules and corrected as it did not include language modifications that were already final but had not yet been included in the Administrative Code by the Secretary of States Office when the rulemaking was first being drafted for comments. In addition, the change on R12-1-310 was a typographical mistake that did not change the rule and was not needed. R12-1-408 title in the rule was modified to match the existing title in the table of contents as well as the title used in 10 FCR 20.1201. In several rules the abbreviated term Commission was replaced by NRC for clarity.
Volume 20, Issue 7 Page 326 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking R12-1-311(G) incorrectly proposed removing incorporated material in favor of training already listed in the rules.
However, the intent was to all additional entities to manufacture radioactive medications so the incorporated material was not removed and an additional incorporation was included. In addition, a definition for FDA was included in Article one to match the one listed in Article 14. The cross-reference in R12-1-703(C)(2) was corrected.
- 11. An agencys summary of the public or stakeholder comments made about the rulemaking and the agencies response to the comments:
Agency received 12 written comments that were presented and discussed by the Radiation Regulatory Hearing Board from the U.S. Nuclear Regulatory Commission. The first comment requested that Arizona adopt language in the rules to allow a consortium to apply for a positron radioactive drug production license. This was originally considered a significant change from the proposed rulemaking, however, the original incorporated material was retained and adjustment to not restrict previously approved entities was made. The use of state specific language instead of incor-poration will be made in a further rulemaking package. The second and forth comments requested changes to the definitions of Preceptor and training requirements for a radiation safety officer. No change was made as this was previously completed in rulemaking package 0072, however the Secretary of States version of the code was several years behind at the time that the staff of the NRC was reviewing the rules in Arizona and they did not notice the pub-lished registers that showed these changes. Comment number three addressed a needed correction to a cross reference typo in the definition of Authorized user and this correction was made. Comments number five through twelve clarified the cross-reference section in the specific training rules R12-1-711, Exhibit A: Group 100, R12-1-719, Exhibit A: Group 200, R12-1-721, R12-1-723, R12-1-727, and R12-1-744 as well as the need to include NRC in the verbiage related to equivalent regulations. These corrections were all made with the Approval of the Radiation Hearing Board. Two members of the Agency staff were observing the proceeding and were listed as Public Mem-bers in the transcript by the court reporter. The Agency staff also acknowledged agreement with the rules modifica-tions as recorded in the public record.
- 12. All agencies shall list other matters prescribed by statute applicable to the specific agency or to any specific rule or class of rules. Additionally, an agency subject to Council review under A.R.S. §§ 41-1052 and 41-1055 shall respond to the following questions:
a.
Whether the rule requires a permit, whether a general permit is used and if not, the reasons why a general per-mit is not used:
The Agency believes that it is exempt from A.R.S. § 41-1037 due to paragraph (A)(3) as the issuance of a general permit would not meet the statutory requirement of A.R.S. §30-656 which allows Arizona to be an Agreement State and compatibility of licensing is one of the requirements of the agreement. The agency also believes that it is exempt from A.R.S. § 41-1037 due to paragraph (A)(2) as the issuance of an alternative type of permit is authorized under the statutory requirement of A.R.S. §30-672 to protect the public health and safety.
b.
Whether a federal law is applicable to the subject of the rule, whether the rule is more stringent than federal law and if so, citation to the statutory authority to exceed the requirements of federal law:
The rule amendments are compatible with existing federal regulations and are not more stringent except for those types of radiation protection use whose regulation is authorized by Arizona statute that are not in the jurisdiction of an equivalent federal regulating body.
c.
Whether a person submitted an analysis to the agency that compares the rules impact of the competitiveness of business in this state to the impact on business in other states:
No analysis has been completed as the regulated community must be in compliance with either federal regula-tions (if not under a state jurisdiction) or agreement state rules.
Other matters prescribed by statute applicable to the specific agency or to any specific rule or class of rules:
The Arizona Radiation Regulatory Hearing Board (ARRHB) is required to review and approve rules and sub-stantive policy statements as defined in A.R.S. § 41-1001 adopted by the agency. A.R.S. §30-655(D). After reviewing the rules and requested changes during a public meeting, the ARRHB approved the rules on October 3, 2013.
- 13. A list of any incorporated by reference material as specified in A.R.S. § 41-1028 and its location in the rules:
Rule Incorporated Material R12-1-102 A1 10 CFR 71, Appendix A A2 10 CFR 71, Appendix A Certifiable cabinet x-ray system 21 CFR 1020.40 Certified cabinet x-ray system 21 CFR 1010.2 and 21 CFR 1020.40 Generally applicable environmental radiation standards 40 CFR 190 and 191 Major processor 10 CFR 71.4 Nuclear waste 49 CFR 173.403 Regulations of the U.S. Department of Transportation 49 CFR 107, and 171 through 180
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 327 Volume 20, Issue 7 Special form radioactive material 10 CFR 71.75 R12-1-304(A)(1) 10 CFR 30.3 R12-1-306(B)(1) 10 CFR 31.5(b), (c), and (d)
R12-1-306(B)(4)(g) 10 CFR 110 R12-1-306(D)(1) 10 CFR 32.57 or 10 CFR 70.39 R12-1-306(E)(3) 10 CFR 32.21 R12-1-306(I)(3) 10 CFR part 110 R12-1-308(G) 10 CFR 32.210(c)
R12-1-308(G)(1)(a) 10 CFR 32.210(c)
R12-1-311(A)(1)(f) 10 CFR 31.5(c)(13)(i)
R12-1-311(A)(4)(b)(i) 10 CFR 32.52 R12-1-311(B)(2) 10 CFR 32.53 through 32.56 R12-1-311(C)(2) 10 CFR 32.57, 32.58, 32.59, and 70.39 R12-1-311(F)(2) 10 CFR 32.61 and 32.62 R12-1-311(G) 10 CFR 32.32(j) and 32.72 R12-1-311(I) 10 CFR 32.74 R12-1-311(K) 10 CFR 32.201 R12-1-439 10 CFR 20 Appendix G and 10 CFR 20.2006 R12-1-723(B) 10 CFR 35.392 R12-1-723(C) 10 CFR 35.394 R12-1-723(D) 10 CFR 35.396 R12-1-727(B) 10 CFR 35.491
- 14. Whether the rule was previously made, amended or repealed as an emergency rule. If so, cite the notice published in the Register as specified in R1-1-409(A). Also, the agency shall state where the text was changed between the emergency and the final rulemaking packages:
Not applicable
- 15. The full text of the rules follows:
TITLE 12. NATURAL RESOURCES CHAPTER 1. RADIATION REGULATORY AGENCY ARTICLE 1. GENERAL PROVISIONS Section R12-1-102.
Definitions ARTICLE 3. RADIOACTIVE MATERIAL LICENSING Section R12-1-303.
Radioactive Material Other Than Source Material; Exemptions R12-1-304.
License Types R12-1-306.
General License - Radioactive Material Other Than Source Material R12-1-308.
Filing Application for Specific Licenses R12-1-311.
Special Requirements for a Specific License to Manufacture, Assemble, Repair, or Distribute Commodities, Products, or Devices that Contain Radioactive Material R12-1-313.
Specific Terms and Conditions R12-1-320.
Reciprocal Recognition of Licenses Exhibit B.
Exempt Quantities Exhibit D.
Radioactive Material Quantities Requiring Consideration for an Emergency Plan (R12-1-322)
ARTICLE 4. STANDARDS FOR PROTECTION AGAINST IONIZING RADIATION Section R12-1-408.
Occupational Dose Limits for Adults R12-1-434.
General Requirements for Waste Disposal R12-1-438.
Disposal of Specific Wastes R12-1-438.01 Disposal of Certain Radioactive Material R12-1-439.
Transfer for Disposal and Manifests R12-1-446.
Notifications and Reports to Individuals
Volume 20, Issue 7 Page 328 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Appendix B. Annual Limits on Intake (ALI) and Derived Air Concentrations (DAC) of Radionuclides for Occupational Exposure; Effluent Concentrations; Concentrations for Release to Sanitary Sewerage ARTICLE 7. MEDICAL USES OF RADIOACTIVE MATERIAL Section R12-1-703.
License for Medical Use of Radioactive Material R12-1-705.
Authority and Responsibilities for the Radiation Protection Program R12-1-710.
Radiation Safety Officer Training R12-1-711.
Authorized Medical Physicist Training R12-1-712.
Authorized Nuclear Pharmacist Training R12-1-713.
Determination of Prescribed Dosages, and Possession, Use, and Calibration of Instruments R12-1-717.
Release of Individuals Containing Radioactive Material or Implants Containing Radioactive Material R12-1-719.
Training for Uptake, Dilution, and Excretion Studies R12-1-720.
Permissible Molybdenum-99, Strontium-82, and Strontium-85 Concentrations R12-1-721.
Training for Imaging and Localization Studies Not Requiring a Written Directive R12-1-723.
Training for Use of Unsealed Radioactive Material Requiring a Written Directive, Including Treatment of Hyperthyroidism, and Treatment of Thyroid Carcinoma R12-1-727.
Training for Use of Manual Brachytherapy Sources and Training for the Use of Strontium-90 Sources for Treatment of Ophthalmic Disease R12-1-728.
Training for Use of Sealed Sources for Diagnosis R12-1-744.
Training for Use of Remote Afterloader Units, Teletherapy Units, and Gamma Stereotactic Radiosurgery Units Exhibit A.
Medical Use Groups ARTICLE 10. NOTICES, INSTRUCTIONS, AND REPORTS TO IONIZING RADIATION WORKERS; INSPECTIONS Section R12-1-1004.
Notifications and Reports to Individuals ARTICLE 1. GENERAL PROVISIONS R12-1-102.
Definitions Terms defined in A.R.S. §30-651 have the same meanings when used in this Chapter, unless the context otherwise requires.
Additional subject-specific definitions are used in other Articles.
A1 means the maximum activity of special form radioactive material permitted in a type A package. These values are either listed in 10 CFR 71, Appendix A, Table A-1, or may be derived in accordance with the procedures prescribed in 10 CFR 71, Appendix A, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
A2 means the maximum activity of radioactive material, other than special form radioactive material, low specific activity (LSA) material, and surface contaminated object (SCO) material, permitted in a Type A package. These values are either listed in 10 CFR 71, Appendix A, Table A-1, or may be derived in accordance with the procedure prescribed in 10 CFR 71, Appendix A, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
Absorbed dose No change Accelerator No change Accelerator produced material No change Act No change Activity No change Adult No change Agency, or ARRA No change Agreement State No change Airborne radioactive material No change Airborne radioactivity area No change ALARA No change Analytical x-ray equipment No change Analytical x-ray system No change Annual No change Authorized medical physicist means an individual who meets the requirements in R12-1-711; or is identified as an authorized medical physicist or teletherapy physicist on:
A specific medical use license issued by the Agency, NRC, or another Agreement State; A medical use permit issued by a NRC master material licensee;
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 329 Volume 20, Issue 7 A permit issued by an Agency, NRC, or another Agreement State broad scope medical use licensee; or A permit issued by a NRC master material license broad scope medical use permittee.
Authorized nuclear pharmacist means a pharmacist who meets the requirements in R12-1-712; or is identified as an authorized nuclear pharmacist on:
A specific license issued by an Agency, NRC, or another Agreement State that authorizes medical use or the practice of nuclear pharmacy; A permit issued by a NRC master material licensee that authorizes medical use or the practice of nuclear pharmacy; A permit issued by an Agency, NRC, or another Agreement State broad scope medical use licensee that authorizes medical use or the practice of nuclear pharmacy; or A permit issued by a NRC master material license broad scope medical use permittee that authorizes medical use or the practice of nuclear pharmacy; or Is identified as an authorized nuclear pharmacist by a commercial nuclear pharmacy that has been authorized to iden-tify authorized nuclear pharmacists; or Is designated as an authorized nuclear pharmacist in accordance with R12-1-311(G).
Authorized user means a physician, dentist, or podiatrist who meets the requirements in R12-1-719, R12-1-723, R12 727, R12-1-728, or R12-1-744; or is identified as an authorized user on:
An Agency, NRC, or another Agreement State license that authorizes the medical use of radioactive material; A permit issued by a NRC master material licensee that is authorized to permit the medical use of radioactive mate-rial; A permit issued by an Agency, NRC, or another Agreement State specific licensee of broad scope that is authorized to permit the medical use of radioactive material; or A permit issued by a NRC master material license broad scope permittee that is authorized to permit the medical use of radioactive material.
Background radiation No change Becquerel No change Bioassay No change Brachytherapy No change Byproduct material means:
Any radioactive material, except special nuclear material, yielded in or made radioactive by exposure to the radiation incident to the process of producing or utilizing special nuclear material; and The tailings or wastes produced by the extraction or concentration of uranium or thorium from ore processed primar-ily for its source material content, including discrete surface wastes resulting from uranium or thorium solution extraction processes. Underground ore bodies depleted by these solution extraction operations do not constitute byproduct material within this definition.;
Any discrete source of radium-226 that is produced, extracted, or converted after extraction, for use for a commercial, medical, or research activity; or any material that, has been made radioactive by use of a particle accelerator; and is produced, extracted, or converted after extraction, for use for a commercial, medical, or research activity; and Any discrete source of naturally occurring radioactive material, other than source material, that the NRC, in consulta-tion with the Administrator of the Environmental Protection Agency, the Secretary of Energy, the Secretary of Home-land Security, and the head of any other appropriate federal agency, determines would pose a threat similar to the threat posed by a discrete source of radium-226 to the public health and safety or the common defense and security and; before, on, or after August 8, 2005, is extracted or converted after extraction for use in a commercial, medical, or research activity.
Calendar quarter No change Calibration No change Certifiable cabinet x-ray system means an existing uncertified x-ray system that meets or has been modified to meet the certification requirements specified in 21 CFR 1020.40, revised April 1, 2008 2013, incorporated by reference, and avail-able under R12-1-101. This incorporated material contains no future editions or amendments.
Certified cabinet x-ray system means an x-ray system that has been certified in accordance with 21 CFR 1010.2, as being manufactured and assembled on or after April 10, 1975, in accordance with the provisions of 21 CFR 1020.40, both sections revised April 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated mate-rial contains no future editions or amendments.
CFR No change Chelating agent No change Civil penalty No change Collective dose No change Committed dose equivalent No change Committed effective dose equivalent No change Consortium means an association of medical use licensees and a PET radionuclide production facility in the same geo-
Volume 20, Issue 7 Page 330 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking graphical area that jointly own or share in the operation and maintenance cost of the PET radionuclide production facility that produces PET radionuclides for use in producing radioactive drugs within the consortium for noncommercial distri-butions among its associated members for medical use. The PET radionuclide production facility within the consortium must be located at an educational institution or a federal facility or a medical facility.
Curie No change Current license or registration No change Deep-dose equivalent No change Depleted uranium No change Discrete source means a radionuclide that has been processed so that its concentration within a material has been pur-posely increased for use for commercial, medical, or research activities.
Dose No change Dose equivalent No change Dose limits No change Dosimeter No change Effective dose equivalent No change Effluent release No change Embryo/fetus No change Enclosed beam x-ray system No change Enclosed radiography No change Entrance or access point No change Exhibit No change Explosive material No change Exposure No change Exposure rate No change External dose No change Extremity No change Fail-safe characteristics No change FDA means the United States Food and Drug Administration Field radiography No change Field station No change Former U.S. Atomic Energy Commission (AEC) or U.S. Nuclear Regulatory Commission (NRC) licensed facilities No change Generally applicable environmental radiation standards means standards issued by the U.S. Environmental Protection Agency (EPA), 40 CFR 190 and 191, revised July 1, 2008 2013, incorporated by reference, and available under R12 101, under the authority of the Atomic Energy Act of 1954, as amended, that impose limits on radiation exposures or lev-els, or concentrations or quantities of radioactive material, in the general environment outside the boundaries of locations under the control of persons possessing or using radioactive material. This incorporated material contains no future edi-tions or amendments.
Gray No change Hazardous waste No change Healing arts No change Health care institution No change High radiation area No change Human use No change Impound No change Individual No change Individual monitoring No change Individual monitoring device No change Individual monitoring equipment No change Industrial radiography No change Injection tool No change Inspection No change Interlock No change Internal dose No change Irradiate No change Laser No change Lens dose equivalent No change License No change Licensed material No change
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 331 Volume 20, Issue 7 Licensed practitioner No change Licensee No change Licensing State No change Limits No change Local components No change Logging supervisor No change Logging tool No change Lost or missing licensed or registered source of radiation No change Low-level waste No change Major processor means a user processing, handling, or manufacturing radioactive material exceeding Type A quantities as unsealed sources or material or exceeding four times Type B quantities as sealed sources but does not include nuclear medicine programs, universities, industrial radiographers, or small industrial programs. Type A and B quantities are defined in 10 CFR 71.4, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
Medical dose No change Member of the public No change MeV No change Mineral logging No change Minor No change Monitoring No change Multiplier No change NARM No change Normal operating procedures No change Natural radioactivity No change NRC No change Nuclear waste means any highway route controlled quantity (defined in 49 CFR 173.403, revised October 1, 2007 2012, incorporated by reference, and available under R12-1-101; this incorporated material contains no future editions or amendments) of source, byproduct, or special nuclear material required to be in NRC-approved packaging while trans-ported to, through, or across state boundaries to a disposal site, or to a collection point for transport to a disposal site.
Additional requirements associated with transportation of radioactive material can be found in Article 15.
Occupational dose No change Open beam system No change Package No change Particle accelerator No change Permanent radiographic installation No change Personnel dosimeter No change Personnel monitoring equipment No change Personal supervision No change PET (See Positron Emission Tomography (PET))
Pharmacist No change Physician No change Positron Emission Tomography (PET) means an imaging technique using radionuclides to produce high resolution images of the bodys biological functions.
Positron Emission Tomography radionuclide production facility means a facility operating a cyclotron or accelerator for the purpose of producing PET radionuclides.
Preceptor No change Primary beam No change Public dose No change Pyrophoric liquid No change Pyrophoric solid No change Qualified expert No change Quality Factor No change Quarter No change Rad No change Radiation No change Radiation area No change Radiation dose No change Radiation machine No change Radiation Safety Officer (RSO) means the individual and who for license conditions:
Volume 20, Issue 7 Page 332 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Meets the requirements of R12-1-407, and for a medical license meets the training requirements of R12-1-710 in10 CFR 35.50(a) or (c)(1) and 10 CFR 35.59, (revised January 1, 2010, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.); or is identified as a Radiation Safety Officer on a specific medical use license issued by the Agency, NRC or an, or another Agreement State; or a medical use permit issued by a NRC master material licensee; Or, who meets the requirements in R12-1-512 on a specific industrial license issued by the Agency, NRC, or another Agreement State; or an industrial use permit issued by a NRC master material licensee; Or, who, for registration conditions, is designated by the registrant as the individual who has the knowledge, author-ity, and responsibility to apply appropriate radiation protection principles to ensure radiation safety and compliance with the Act, this Chapter and any registration conditions.
Radiation safety officer (RSO) means the individual designated by the licensee or registrant who has the knowledge, authority, and responsibility to apply appropriate radiation protection principles to ensure radiation safety and compliance with the Act, this Chapter and any license, or registration conditions.
Radioactive marker No change Radioactive material No change Radioactivity No change Radiographer No change Radiographer's assistant No change Registrant No change Registration No change Regulations of the U.S. Department of Transportation means the federal regulations in 49 CFR 107, 171 through 180, revised October 1, 2007 2013, incorporated by reference, and available under R12-1-101. This incorporated material con-tains no future editions or amendments.
Rem No change Research and Development No change Restricted area No change Roentgen No change Safety system No change Sealed source No change Sealed Source and Device Registry No change Shallow dose equivalent No change Shielded position No change Sievert No change Site boundary No change Source changer No change Source holder No change Source material No change Source material milling No change Source of radiation or source No change Special form radioactive material means radioactive material that satisfies all of the following conditions:
It is either a single solid piece or is contained in a sealed capsule that can be opened only by destroying the capsule; The piece or capsule has at least one dimension not less than 5 millimeters (0.2 inch); and It satisfies the test requirements specified in 10 CFR 71.75, revised January 1, 2008 2013, incorporated by reference, available under R12-1-101. This incorporated material contains no future editions or amendments. A special form encapsulation designed in accordance with the U.S. Nuclear Regulatory Commission requirements in effect on June 30, 1983, and constructed prior to July 1, 1985, may continue to be used. A special form encapsulation constructed after June 30, 1985, shall meet requirements of this definition applicable at the time of its construction.
Special nuclear material in quantities not sufficient to form a critical mass No change Storage area No change Storage container No change Subsurface tracer study No change Survey No change TEDE No change Teletherapy No change Temporary job site No change Test No change These rules No change Total Effective Dose Equivalent (TEDE) means total effective dose equivalent, the sum of the deep-dose equivalent for external exposures and the committed effective dose equivalent for internal exposures. the sum of the effective dose
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 333 Volume 20, Issue 7 equivalent (for external exposures) and the committed effective dose equivalent (for internal exposures).
Total Organ Dose Equivalent No change Unrefined and unprocessed ore No change Unrestricted area No change U.S. Department of Energy No change Very high radiation area No change Waste No change Waste handling licensees No change Week No change Well-bore No change Well-logging No change Whole body No change Wireline No change Wireline service operation No change Worker No change WL No change WLM No change Workload No change Year No change ARTICLE 3. RADIOACTIVE MATERIAL LICENSING R12-1-303.
Radioactive Material Other Than Source Material; Exemptions A.
No change 1.
No change 2.
This Section shall not be deemed to authorize the import of byproduct radioactive material or products containing byproduct radioactive material.
3.
A manufacturer, processor, or producer of a product or material is exempt from the requirements for a license issued under R12-1-311(A) or the requirements of this Article to the extent that this person transfers byproduct radioactive material contained in a product or material in concentrations not in excess of those specified in Exhibit A of this Arti-cle and introduced into the product or material by a licensee holding a specific license issued by the Commission NRC expressly authorizing such introduction. This exemption does not apply to the transfer of byproduct radioactive material contained in any food, beverage, cosmetic, drug, or other commodity or product designed for ingestion or inhalation by, or application to, a human being.
4.
No change B.
No change 1.
No change a.
No change i.
No change ii.
No change iii. 555 megabecquerels (15 millicuries) of tritium per dial (bezels when used shall be are considered part of the dial),
iv.
No change v.
No change vi. 2.22. megabecquerels (60 microcuries) of promethium-147 per watch dial or 4.44 MBq (120 microcuries) of promethium-147 per other timepiece dial (bezels, when used, shall be are considered part of the dial),
vii. No change (1) No change (2) No change (3) No change viii. 37 kBq (1 microcurie) of radium-226 in time pieces per timepiece in intact timepieces manufactured prior to October 1, 1978 November 30, 2007; b.
Static elimination devices which contain, as a sealed source or sources, radioactive material consisting of a total of not more than 18.5 MBq (500 Ci) of polonium-210 per device.
i.
Ion generating tubes designed for ionization of air that contain, as a sealed source or sources, radioactive material consisting of a total of not more than 18.5 MBq (500 Ci) of polonium-210 per device or of a total of not more than 1.85 GBq (50 mCi) of hydrogen-3 (tritium) per device.
ii.
Such devices authorized before October 23, 2012 for use under the general license then provided in R12 306 and equivalent regulations of the NRC or Agreement State and manufactured, tested, and labeled by the manufacturer in accordance with the specifications contained in a specific license issued by the NRC.
Volume 20, Issue 7 Page 334 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking b.c. Balances of precision containing not more than 37 megabecquerels (1 millicurie) of tritium per balance or not more than 18.5 megabecquerels (0.5 millicurie) of tritium per balance part manufactured before December 17, 2007; c.d. Marine compasses containing not more than 27.75 gigabecquerels (750 millicuries) of tritium gas and other marine navigational instruments containing not more than 9.25 gigabecquerels (250 millicuries) of tritium gas manufactured before December 17, 2007; e.
Ionization chamber smoke detectors containing not more than 37 kBq (1 microcurie) of americium-241 per detector in the form of a foil and designed to protect life and property from fires; d.f. Electron tubes: Provided that each tube does not contain more than one of the following specified quantities of radioactive material:
i.
No change ii.
No change iii. No change iv.
No change v.
No change vi. No change vii. And provided further, that the level of radiation due to radioactive material contained in each electron tube does not exceed 10 Gy (1 millirad) per hour) at 1 centimeter from any surface when measured through 7 milligrams per square centimeter of absorber. The term electron tubes includes spark gap tubes, power tubes, gas tubes, including glow lamps, receiving tubes, microwave tubes, indicator tubes, pick-up tubes, radiation detection tubes, and any other completely sealed tube that is designed to conduct or control electri-cal current; e.g. Ionizing radiation measuring instruments containing, for purposes of internal calibration or standardization, one or more sources of radioactive material provided that:
i.
No change ii.
No change iii. No change h.
Any person who desires to apply radioactive material to, or to incorporate radioactive material into, the products exempted in subsection (B)(1)(a), or who desires to initially transfer for sale or distribution such products con-taining radioactive material, should apply for a specific license pursuant to R-12-311 of this Article, which license states that the product may be distributed by the licensee to persons exempt from the rules pursuant R12-1-303 (A)(1).
f.
Ionization chamber smoke detectors containing not more than 1 microcurie ([micro]Ci) of americium-241 per detector in the form of a foil and designed to protect life and property from fires.
2.
No change a.
No change b.
No change 3.
No change a.
Except for persons who manufacture, process, initially transfer for sale or distribution, or produce gas and aero-sol detectors containing radioactive material, a person is exempt from this Chapter if the person receives, pos-sesses, uses, transfers, owns, or acquires radioactive material in gas and aerosol detectors designed to protect life or property from fires and airborne hazards, provided that detectors containing radioactive material shall be man-ufactured, imported, or transferred according to a specific license issued by the U.S. Nuclear Regulatory Com-mission and described in 10 CFR 32.26, or equivalent regulations of an Agreement or Licensing State, this exemption also covers gas and aerosol detectors manufactured or distributed before November 30, 2007 in accor-dance with a specific license issued by the U.S. Nuclear Regulatory Commission, or equivalent regulations of an Agreement or Licensing State and the license authorizes the transfer of the detectors to persons who are exempt from regulatory requirements.
b.
No change C.
No change 1.
No change 2.
No change 3.
No change 4.
No change 5.
No change 6.
Any person, who possesses byproduct radioactive material received or acquired before September 25, 1971, under the general license issued under R12-1-311(A) of this Article or similar general license of an Agreement State or the NRC, is exempt from the requirements for a license issued under R12-1-311(A) of this Article to the extent that this person possesses, uses, transfers, or owns byproduct radioactive material.
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 335 Volume 20, Issue 7 7.
No person may, for purposes of producing an increased radiation level, combine quantities of byproduct radioactive material covered by the exemption described in subsection (C)(6) so that the aggregate quantity exceeds the limits set forth in Exhibit B, except for byproduct radioactive material combined within a device placed in use before May 3, 1999, or as otherwise permitted by the rules in this Section.
R12-1-304.
License Types A.
Activities requiring license. Except as provided in 10 CFR 30.3 (revised January 1, 2013, incorporated by reference, and available under R12-1-101; this incorporated material contains no future editions or amendments) this Section and for persons exempt as provided in R12-1-302 and R12-1-303 of this Article, no person shall manufacture, produce, transfer, receive, acquire, own, possess, or use byproduct material except as authorized in a specific or general license issued in accordance with the regulations in this chapter and in accordance with 10 CFR 30.3.
B.
Licenses for radioactive materials are of two types: general and specific.
1.
No change 2.
No change R12-1-306.
General License - Radioactive Material Other Than Source Material A.
No change 1.
No change 2.
No change B.
Certain measuring, gauging or controlling devices and certain devices for producing light or an ionized atmosphere.
1.
This subsection grants a general license that authorizes to a commercial or industrial firm; a research, educational or medical institution; an individual conducting business; or a state or local government agency to receive, acquire, pos-sess, use, or transfer radioactive material contained in devices designed and manufactured for the purpose of detect-ing, measuring, gauging or controlling thickness, density, level, interface location, radiation, leakage, or qualitative or quantitative chemical composition, or for producing light or an ionized atmosphere, according to the provisions of 10 CFR 31.5(b), (c), and (d), (Revised January 1, 2010 2013, incorporated by reference, and available under R12-1-101.
The incorporated material contains no future editions or amendments.); contained in devices designed and manufac-tured for the purpose of detecting, measuring, gauging or controlling thickness, density, level, interface location, radi-ation, leakage, or qualitative or quantitative chemical composition, or for producing light or an ionized atmosphere.).
2.
No change 3.
No change a.
No change b.
No change c.
An equivalent specific license issued by a State with rules or regulations comparable to this Section.
4.
A person who acquires, receives, possesses, uses, or transfers radioactive material in a device licensed under subsec-tion (B)(1) or through a transfer made under subsection (B)(4)(h), shall:
a.
Ensure that all labels and safety statements affixed to a device at the time of receipt and bearing a statement that removal of the label is prohibited are maintained and not removed, and comply with all instructions and precau-tions on the labels.
b.
No change i.
A general licensee need not test a device that contains only krypton for leakage of radioactive material; and ii.
A general licensee need not test a device for leakage of radioactive material if the device contains only tri-tium, not more than 3.7 Mbq megabecquerels (100 microcuries) of other beta and/or gamma emitting mate-rial, or 370 kBq kilobecquerels (10 microcuries) of alpha emitting material, or the device is held in storage, in the original shipping container, before initial installation.
c.
No change i.
No change ii.
No change d.
No change e.
Immediately suspend operation of a device if there is a failure of, or damage to, or any indication of a possible failure of or damage to, the shielding of the radioactive material or the on-off mechanism or indicator, or upon the detection of 185 Becquerel becquerel (0.005 microcurie) or more of removable radioactive material.
- i.
No change ii. No change iii. No change f.
No change g.
Not export a device that contains radioactive material except in accordance with 10 CFR 110, revised January 1, 2010, revised January 1, 2013 incorporated by reference, and available under R12-1-101. The incorporated mate-rial contains no future editions or amendments.
h.
No change
Volume 20, Issue 7 Page 336 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking i.
No change i.
No change ii.
No change iii. No change j.
No change k.
No change i.
No change ii.
No change
- l.
No change
- m. No change
- n.
No change
- o.
No change
- p.
No change
- q.
No change
- i.
No change ii. No change iii. No change iv. No change
- v.
No change vi. No change r.
No change s.
No change 5.
No change 6.
No change 7.
No change C.
No change 1.
No change 2.
No change
- a.
No change
- b.
No change
- c.
No change
- d.
No change
- e.
No change D.
No change 1.
This subsection grants a general license for calibration or reference sources that have been manufactured according to the specifications contained in a specific license issued to the manufacturer or importer of the sources by the U.S.
Nuclear Regulatory Commission under 10 CFR 32.57 or 10 CFR 70.39. This general license also governs calibration or reference sources that have been manufactured according to specifications contained in a specific license issued to the manufacturer by the Agency, an Agreement State, or a Licensing State, according to licensing requirements equivalent to those contained in 10 CFR 32.57 or 10 CFR 70.39, revised January 1, 2010, revised January 1, 2013, incorporated by reference, and available under R12-1-101. The incorporated material contains no future editions or amendments.
2.
No change a.
No change b.
No change i.
No change ii.
No change c.
No change d.
No change e.
No change 3.
No change 4.
No change E.
No change 1.
No change 2.
No change 3.
A physician who desires to manufacture, prepare, process, produce, package, repackage, or transfer carbon-14 urea capsules for commercial distribution shall obtain a specific license from the Agency, issued according to the require-ments in 10 CFR 32.21, (Revised January 1, 2010 2013, incorporated by reference, and available under R12-1-101.
This incorporated material contains no future editions or amendments.)
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 337 Volume 20, Issue 7 4.
No change F.
No change
- 1.
No change
- a.
No change
- b.
No change
- c.
No change
- d.
No change
- e.
No change
- f.
No change
- g.
No change
- 2.
No change
- a.
No change
- b.
No change
- 3.
No change
- a.
No change
- b.
No change
- c.
No change
- d.
No change
- e.
No change f.
Package or prepackage a unit bearing a durable, clearly visible label: identifying the radioactive contents as to chemical form and radionuclide, and indicating that the amount of radioactivity does not exceed 0.37 megabec-querel (10 microcuries) of iodine-131, iodine-125, selenium-75, or carbon-14; 1.85 megabecquerels (50 micro-curies) of hydrogen-3 (tritium); or 0.74 megabecquerel (20 microcuries) of iron-59; or Mock Iodine-125 in units not exceeding 1.85 kilobecquerels (0.05 microcurie) of iodine-129 and 0.185 kilobecquerel (0.005 microcurie) of americium-241 each; or cobalt-57 in units not exceeding 0.37 megabecquerel (10 microcuries).
g.
Package to display the radiation caution symbol and the words, Caution, Radioactive Material, and Not for Internal or External Use in Humans or Animals.
4.
No change a.
No change b.
No change i.
No change ii. No change 5.
No change
- a.
No change
- b.
No change 6.
No change G. No change 1.
No change 2.
No change 3.
No change 4.
No change 5.
No change H.
This subsection grants a general license that authorizes a person to acquire, receive, possess, use, or transfer, in accor-dance with the provisions of subsections (I) and (J), radium-226 contained in the following products manufactured prior to November 30, 2007.
1.
Antiquities originally intended for use by the general public. For the purposes of this paragraph, antiquities mean products originally intended for use by the general public and distributed in the late 19th and early 20th centuries, such as radium emanator jars, revigators, radium water jars, radon generators, refrigerator cards, radium bath salts, and healing pads.
2.
Intact timepieces containing greater than 0.037 megabecquerel (1 microcurie), nonintact timepieces, and timepiece hands and dials no longer installed in timepieces.
3.
Luminous items installed in air, marine, or land vehicles.
4.
All other luminous products, provided that no more than 100 items are used or stored at the same location at any one time.
5.
Small radium sources containing no more than 0.037 megabecquerel (1 microcurie) of radium-226. For the purposes of this paragraph, small radium sources means discrete survey instrument check sources, sources contained in radi-ation measuring instruments, sources used in educational demonstrations (such as cloud chambers and spinthari-scopes), electron tubes, lightning rods, ionization sources, static eliminators, or as designated by the NRC.
I.
Persons who acquire, receive, possess, use, or transfer byproduct material under the general license issued in subsection
Volume 20, Issue 7 Page 338 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (H) are exempt from the provisions 12 A.A.C. 1, Articles 1, 3, 4, 7, 10, 12, and 15 and A.R.S. §§30-654(B)(13),30-657(A) and (B),30-681, and 30-685 through 30-689, to the extent that the receipt, possession, use, or transfer of byprod-uct material is within the terms of the general license; provided, however, that this exemption shall not be deemed to apply to any such person specifically licensed under this chapter. Any person who acquires, receives, possesses, uses, or trans-fers byproduct material in accordance with the general license in subsection (H):
1.
Shall notify the Agency should there be any indication of possible damage to the product so that it appears it could result in a loss of the radioactive material. A report containing a brief description of the event, and the remedial action taken, must be furnished to the Agency within 30 days.
2.
Shall not abandon products containing radium-226. The product, and any radioactive material from the product, may only be disposed of according to Article 4 or by transfer to a person authorized by a specific license to receive the radium-226 in the product or as otherwise approved by the Agency.
3.
Shall not export products containing radium-226 except in accordance with 10 CFR 110 revised January 1, 2013, incorporated by reference, and available under R12-1-101. The incorporated material contains no future editions or amendments.
4.
Shall dispose of products containing radium-226 at a disposal facility authorized to dispose of radioactive material in accordance with any federal or state solid or hazardous waste law, including the Solid Waste Disposal Act, as autho-rized under the Energy Policy Act of 2005, by transfer to a person authorized to receive radium-226 by a specific license issued under Article 3, equivalent regulations of an Agreement State, or the NRC.
5.
Shall respond to written requests from the Agency to provide information relating to the general license within 30 cal-endar days of the date of the request, or other time specified in the request. If the general licensee cannot provide the requested information within the allotted time, it shall, within that same time period, request a longer period to supply the information by providing the Agency Director a written justification for the request.
J.
The general license in subsection (H) does not authorize the manufacture, assembly, disassembly, repair, or import of products containing radium-226, except that timepieces may be disassembled and repaired.
R12-1-308.
Filing Application for Specific Licenses A.
No change B.
No change C.
No change D.
No change E.
No change F.
No change G.
Except as provided in subsections (G)(1), (2), and (3), an application for a specific license to use byproduct material in the form of a sealed source or in a device that contains the sealed source must either identify the source or device by manufac-turer and model number as registered with the Agency, NRC, or with an Agreement State, or, for a source or a device con-taining radium-226 or accelerator-produced radioactive material, with the Agency, NRC, or an Agreement State under 10 CFR 32.210(c) revised January 1, 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
1.
For sources or devices manufactured before October 23, 2012, that are not licensed under R12-1-306, R12-1-310, R12-1-311 or registered with the NRC or with an Agreement State, and for which the applicant is unable to provide all categories of information specified in 10 CFR 32.210(c) the application must include:
a.
All available information identified in 10 CFR 32.210(c) concerning the source, and, if applicable, the device; and b.
Sufficient additional information to demonstrate that there is reasonable assurance that the radiation safety prop-erties of the source or device are adequate to protect health and minimize danger to life and property. Such infor-mation must include a description of the source or device, a description of radiation safety features, the intended use and associated operating experience, and the results of a recent leak test.
2.
For sealed sources and devices allowed to be distributed without registration of safety information, the applicant may supply only the manufacturer, model number, and radionuclide and quantity.
3.
If it is not feasible to identify each sealed source and device individually, the applicant may propose constraints on the number and type of sealed sources and devices to be used and the conditions under which they will be used, in lieu of identifying each sealed source and device.
R12-1-311.
Special Requirements for a Specific License to Manufacture, Assemble, Repair, or Distribute Commod-ities, Products, or Devices that Contain Radioactive Material A.
No change 1.
No change a.
No change b.
No change i.
No change
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 339 Volume 20, Issue 7 ii.
No change iii. No change (1) No change (2) No change (3) No change c.
No change i.
No change ii.
No change iii. No change d.
No change e.
No change f.
Each device meets the criteria in 10 CFR 31.5(c)(13)(i) (revised January 1, 2008 2013, incorporated by refer-ence, and available under R12-1-101. This incorporated material contains no future editions or amendments) and bears a permanent (e.g., embossed, etched, stamped, or engraved) label affixed to the source housing, if separa-ble, or the device if the source housing is not separable, that includes the words, Caution-Radioactive Material, and, if practicable, the radiation symbol described in R12-1-428.
2.
No Change a.
No change b.
No change c.
No change d.
No change e.
No change f.
No change g.
No change h.
No change i.
No change j.
No change 3.
No change 4.
No change a.
No change i.
No change ii.
No change iii. No change iv.
No change v.
No change b.
No change i.
Report on a quarterly basis to the responsible Agreement State or NRC all transfers of devices to persons for use under a general license in accordance with 10 CFR 32.52, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amend-ments.
ii.
No change iii. No change 5.
No change a.
No change b.
No change c.
No change d.
No change 6.
No change 7.
No change 8.
No change a.
No change i.
No change ii.
No change iii. No change iv.
No change v.
No change b.
No change c.
No change i.
No change
Volume 20, Issue 7 Page 340 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking ii.
No change iii. No change iv.
No change d.
No change e.
No change f.
No change g.
No change 9.
No change B.
No change 1.
No change 2.
The requirements of 10 CFR 32.53 through 32.56 and 32.101, revised January 1, 2008 2013, incorporated by refer-ence, and available under R12-1-101. This incorporated material contains no future editions or amendments.
C.
The Agency shall grant a specific license to manufacture or initially transfer calibration or reference sources that contain americium-241, radium-226, or plutonium for distribution to persons generally licensed under R12-1-306(D) if the appli-cant satisfies:
1.
No change 2.
The requirements of 10 CFR 32.57, 32.58, 32.59, 32.102, and 70.39, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
D.
No change 1.
No change 2.
No change a.
No change b.
No change E.
No change 1.
No change 2.
No change a.
No change b.
No change c.
No change d.
No change e.
No change f.
No change g.
No change 3.
No change a.
No change b.
No change 4.
No change a.
No change b.
No change 5.
No change F.
No change 1.
No change 2.
The criteria of 10 CFR 32.61, and 32.62, and 32.103, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
G.
The Agency shall grant a specific license to manufacture, prepare, or transfer for commercial distribution radioactive drugs that contain radioactive material for use by a person authorized in accordance with Article 7 of this Chapter, if the applicant meets all of the requirements in 10 CFR 30.32(j) or 10 CFR 32.72, revised January 1, 2008 2013, incorporated by reference, and available under R12 101. This incorporated material contains no future editions or amendments.
1.
Authorization under this Section to produce Positron Emission Tomography (PET) radioactive drugs for noncommer-cial transfer to medical use licensees in its consortium does not relieve the licensee from complying with applicable FDA, other federal, and state requirements governing radioactive drugs.
2.
Each licensee authorized under this Section to produce PET radioactive drugs for noncommercial transfer to medical use licensees in its consortium shall:
a.
Satisfy the labeling requirements in R12-1-431 for each PET radioactive drug transport radiation shield and each syringe, vial, or other container used to hold a PET radioactive drug intended for noncommercial distribution to members of its consortium.
b.
Possess and use instrumentation to measure the radioactivity of the PET radioactive drugs intended for noncom-mercial distribution to members of its consortium and meet the procedural, radioactivity measurement, instru-ment test, instrument check, and instrument adjustment requirements in R12-1-449.
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 341 Volume 20, Issue 7 3.
A licensee that is a pharmacy authorized under this Section to produce PET radioactive drugs for noncommercial transfer to medical use licensees in its consortium shall require that any individual who prepares PET radioactive drugs be an:
a.
Authorized nuclear pharmacist that meets the requirements in § R12-1-712, or b.
Individual under the supervision of an authorized nuclear pharmacist as specified in R12-1-706.
4.
A pharmacy, authorized under this Section to produce PET radioactive drugs for noncommercial transfer to medical use licensees in its consortium that allows an individual to work as an authorized nuclear pharmacist, shall meet the requirements of R12-1-712.
H.
No change 1.
No change 2.
No change a.
No change b.
No change 3.
No change 4.
No change 5.
No change a.
No change b.
No change I.
The Agency shall grant a specific license to manufacture and distribute sources and devices that contain radioactive mate-rial to a person licensed in accordance with Article 7 of this Chapter for use as a calibration, transmission, or reference source or for medical purposes, if the applicant meets all of the requirements in 10 CFR 32.74, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
J.
No change 1.
No change a.
No change b.
No change c.
No change 2.
No change 3.
No change 4.
No change a.
No change b.
No change i.
No change ii.
No change c.
No change d.
No change e.
No change f.
No change i.
No change ii.
No change iii. No change iv.
No change v.
No change vi. No change K.
No change 1.
Serialize the sources in accordance with 10 CFR 32.201, revised January 1, 2008 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments; and 2.
No change R12-1-313.
Specific Terms and Conditions A.
No change B.
No change C.
No change D.
No change 1.
No change a.
No change b.
No change c.
No change 2.
No change
Volume 20, Issue 7 Page 342 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking a.
No change b.
No change c.
No change E.
Each licensee preparing technetium-99m radiopharmaceuticals from molybdenum-99/technetium-99m generators or rubidium-82 from strontium-82/rubidium-82 generators shall test the generator eluates for molybdenum-99 breakthrough or strontium-82 and strontium-85 contamination, respectively, in accordance with R12-1-720. The licensee shall record the results of each test and retain each record for 3 years after the record is made.
R12-1-320.
Reciprocal Recognition of Licenses A.
No change 1.
The license does not limit the activity to specified specific installations or locations; 2.
The out-of-state licensee notifies the Agency in writing at least three days before engaging in the licensed activity Following the first notification, application, and payment of fees, the licensee shall notify the agency three days prior to entering the state and prior to each non-consecutive visit while reciprocity remains in effect. The notification shall indicate the location, period, and type of proposed possession and use within the State, and be accompanied by a copy of the pertinent licensing document. If, for a specific case, the three-day period would impose an undue hardship on the out-of-state licensee, the licensee may, upon application to the Agency, obtain permission to proceed sooner. The Agency may waive the requirement for filing additional written notifications during the remainder of the calendar year, following receipt of the initial notification from a person engaging in activities under the general license pro-vided in this Section; 3.
The out-of-state licensee complies with all applicable statutes, now or hereafter in effect, and rules, and orders of the Agency and with all the terms and conditions of the license, except those terms and conditions inconsistent with applicable statutes, and rules and orders of the Agency; 4.
The out-of-state licensee supplies any other information the Agency requests; and 5.
No change a.
No change b.
No change B.
No change 1.
No change 2.
No change 3.
No change 4.
No change C.
No change D.
No change E.
No change 1.
No change 2.
No change F.
No change Exhibit B.
Exempt Quantities Material Microcuries Antimony-122 (Sb-122) 100 Antimony-124 (Sb-124) 10 Antimony-125 (Sb-125) 10 Arsenic-73 (As-73) 100 Arsenic-74 (As-74) 10 Arsenic-76 (As-76) 10 Arsenic-77 (As-77) 100 Barium-131 (Ba-131) 10 Barium-133 (Ba-133) 10 Barium-140 (Ba-140) 10 Bismuth-210 (Bi-210) 1 Bromine-82 (Br-82) 10 Cadmium-109 (Cd-109) 10 Cadmium-115m (Cd-115m) 10 Cadmium-115 (Cd-115) 100 Calcium-45 (Ca-45) 10 Calcium-47 (Ca-47) 10 Carbon-14 (C-14) 100 Cerium-141 (Ce-141) 100 Cerium-143 (Ce-143) 100
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 343 Volume 20, Issue 7 Cerium-144 (Ce-144) 1 Cesium-129 (Cs-129) 100 Cesium-131 (Cs-131) 1,000 Cesium-134m (Cs-134m) 100 Cesium-134 (Cs-134) 1 Cesium-135 (Cs-135) 10 Cesium-136 (Cs-136) 10 Cesium-137 (Cs-137) 10 Chlorine-36 (Cl-36) 10 Chlorine-38 (Cl-38) 10 Chromium-51 (Cr-51) 1,000 Cobalt-57 (Co-57) 100 Cobalt-58m (Co-58m) 10 Cobalt-58 (Co-58) 10 Cobalt-60 (Co-60) 1 Copper-64 (Cu-64) 100 Dysprosium-165 (Dy-165) 10 Dysprosium-166 (Dy-166) 100 Erbium-169 (Er-169) 100 Erbium-171 (Er-171) 100 Europium-152 (Eu-152) (9.2 h) 100 Europium-152 (Eu-152) (13 yr) 1 Europium-154 (Eu-154) 1 Europium-155 (Eu-155) 10 Fluorine-18 (F-18) 1,000 Gadolinium-153 (Gd-153) 10 Gadolinium-159 (Gd-159) 100 Gallium-67 (Ga-67) 100 Gallium-72 (Ga-72) 10 Germanium-68 (Ge-68) 10 Germanium-71 (Ge-71) 100 Gold-195 (Au-195) 10 Gold-198 (Au-198) 100 Gold-199 (Au-199) 100 Hafnium-181 (Hf-181) 10 Holmium-166 (Ho-166) 100 Hydrogen-3 (H-3) 1,000 Indium-111 (In-111) 100 Indium-113m (In-113m) 100 Indium-114m (In-114m) 10 Indium-115m (In-115m) 100 Indium-115 (In-115) 10 Iodine-123 (I-123) 100 Iodine-125 (I-125) 1 Iodine-126 (I-126) 1 Iodine-129 (I-129) 0.1 Iodine-131 (I-131) 1 Iodine-132 (I-132) 10 Iodine-133 (I-133) 1 Iodine-134 (I-134) 10 Iodine-135 (I-135) 10 Iridium-192 (Ir-192) 10 Iridium-194 (Ir-194) 100 Iron-52 (Fe-52) 10 Iron-55 (Fe-55) 100 Iron-59 (Fe-59) 10 Krypton-85 (Kr-85) 100 Krypton-87 (Kr-87) 10 Lanthanum-140 (La-140) 10
Volume 20, Issue 7 Page 344 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Lutetium-177 (Lu-177) 100 Manganese-52 (Mn-52) 10 Manganese-54 (Mn-54) 10 Manganese-56 (Mn-56) 10 Mercury-197m (Hg-197m) 100 Mercury-197 (Hg-197) 100 Mercury-203 (Hg-203) 10 Molybdenum-99 (Mo-99) 100 Neodymium-147 (Nd-147) 100 Neodymium-149 (Nd-149) 100 Nickel-59 (Ni-59) 100 Nickel-63 (Ni-63) 10 Nickel-65 (Ni-65) 100 Niobium-93m (Nb-93m) 10 Niobium-95 (Nb-95) 10 Niobium-97 (Nb-97) 10 Osmium-185 (Os-185) 10 Osmium-191m (Os-191m) 100 Osmium-191(Os-191) 100 Osmium-193 (Os-193) 100 Palladium-103 (Pd-103) 100 Palladium-109 (Pd-109) 100 Phosphorus-32 (P-32) 10 Platinum-191 (Pt-191) 100 Platinum-193m (Pt-193m) 100 Platinum-193 (Pt-193) 100 Platinum-197m (Pt-197m) 100 Platinum-197 (Pt-197) 100 Polonium-210 (Po-210) 0.1 Potassium-42 (K-42) 10 Potassium-43 (K-43) 10 Praseodymium-142 (Pr-142) 100 Praseodymium-143 (Pr-143) 100 Promethium-147 (Pm-147) 10 Promethium-149 (Pm-149) 10 Rhenium-186 (Re-186) 100 Rhenium-188 (Re-188) 100 Rhodium-103m (Rh-103m) 100 Rhodium-105 (Rh-105) 100 Rubidium-81 (Rb-81) 10 Rubidium-86 (Rb-86) 10 Rubidium-87 (Rb-87) 10 Ruthenium-97 (Ru-97) 100 Ruthenium-103 (Ru-103) 10 Ruthenium-105 (Ru-105) 10 Ruthenium-106 (Ru-106) 1 Samarium-151 (Sm-151) 10 Samarium-153 (Sm-153) 100 Scandium-46 (Sc-46) 10 Scandium-47 (Sc-47) 100 Scandium-48 (Sc-48) 10 Selenium-75 (Se-75) 10 Silicon-31 (Si-31) 100 Silver-105 (Ag-105) 10 Silver-110m (Ag-110m) 1 Silver-111 (Ag-111) 100 Sodium-22 (Na-22) 10 Sodium-24 (Na-24) 10 Strontium-85 (Sr-85) 10
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 345 Volume 20, Issue 7 Strontium-89 (Sr-89) 1 Strontium-90 (Sr-90) 0.1 Strontium-91 (Sr-91) 10 Strontium-92 (Sr-92) 10 Sulfur-35 (S-35) 100 Tantalum-182 (Ta-182) 10 Technetium-96 (Tc-96) 10 Technetium-97m (Tc-97m) 100 Technetium-97 (Tc-97) 100 Technetium-99m (Tc-99m) 100 Technetium-99 (Tc-99) 10 Tellurium-125m (Te-125m) 10 Tellurium-127m (Te-127m) 10 Tellurium-127 (Te-127) 100 Tellurium-129m (Te-129m) 10 Tellurium-129 (Te-129) 100 Tellurium-131m (Te-131m) 10 Tellurium-132 (Te-132) 10 Terbium-160 (Tb-160) 10 Thallium-200 (Tl-200) 100 Thallium-201 (Tl-201) 100 Thallium-202 (Tl-202) 100 Thallium-204 (Tl-204) 10 Thulium-170 (Tm-170) 10 Thulium-171 (Tm-171) 10 Tin-113 (Sn-113) 10 Tin-125 (Sn-125) 10 Tungsten-181 (W-181) 10 Tungsten-185 (W-185) 10 Tungsten-187 (W-187) 100 Vanadium-43 (V-48) 10 Xenon-131m (Xe-131m) 1,000 Xenon-133 (Xe-133) 100 Xenon-135 (Xe-135) 100 Ytterbium-175 (Yb-175) 100 Yttrium-87 (Y-87) 10 Yttrium-88 (Y-88) 10 Yttrium-90 (Y-90) 10 Yttrium-91 (Y-91) 10 Yttrium-92 (Y-92) 100 Yttrium-93 (Y-93) 100 Zinc-65 (Zn-65) 10 Zinc-69m (Zn-69m) 100 Zinc-69 (Zn-69) 1,000 Zirconium-93 (Zr-93) 10 Zirconium-95 (Zr-95) 10 Zirconium-97 (Zr-97) 10 Any radionuclide material not listed above other than alpha-emitting radioactive material 0.1
Volume 20, Issue 7 Page 346 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Exhibit D.
Radioactive Material Quantities Requiring Consideration for an Emergency Plan (R12-1-322)
Radioactive Material Release Fraction Quantity (Ci)
Actinium-228 0.001 4,000 Americium-241
.001 2
Americium-242
.001 2
Americium-243
.001 2
Antimony-124
.01 4,000 Antimony-126
.01 6,000 Barium-133
.01 10,000 Barium-140
.01 30,000 Bismuth-207
.01 5,000 Bismuth-210
.01 600 Cadmium-109
.01 1,000 Cadmium-113
.01 80 Calcium-45
.01 20,000 Californium-252
.001 9 (20 mg)
Carbon-14 (Non CO)
.01 50,000 Cerium-141
.01 10,000 Cerium-144
.01 300 Cesium-134
.01 2,000 Cesium-137
.01 3,000 Chlorine-36
.5 100 Chromium-51
.01 300,000 Cobalt-60
.001 5,000 Copper-64
.01 200,000 Curium-242
.001 60 Curium-243
.001 3
Curium-244
.001 4
Curium-245
.001 2
Europium-152
.01 500 Europium-154
.01 400 Europium-155
.01 3,000 Gadolinium-153
.01 5,000 Germanium-68
.01 2,000 Gold-198
.01 30,000 Hafnium-172
.01 400 Hafnium-181
.01 7,000 Holmium-166m
.01 100 Hydrogen-3
.5 20,000 Indium-114m
.01 1,000 Iodine-125
.5 10 Iodine-131
.5 10 Iridium-192
.001 40,000 Iron-55
.01 40,000 Iron-59
.01 7,000 Krypton-85 1.0 6,000,000 Lead-210
.01 8
Manganese-56
.01 60,000 Mercury-203
.01 10,000 Molybdenum-99
.01 30,000 Neptunium-237
.001 2
Nickel-63
.01 20,000 Niobium-94
.01 300 Phosphorus-32
.5 100 Phosphorus-33
.5 1,000 Polonium-210
.01 10 Potassium-42
.01 9,000 Promethium-145
.01 4,000 Promethium-147
.01 4,000 Radium-226
.001 100 Ruthenium-106
.01 200 Samarium-151
.01 4,000 Scandium-46
.01 3,000 Selenium-75
.01 10,000
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 347 Volume 20, Issue 7 Silver-110m
.01 1,000 Sodium-22
.01 9,000 Sodium-24
.01 10,000 Strontium-89
.01 3,000 Strontium-90
.01 90 Sulfur-35
.5 900 Technetium-99
.01 10,000 Technetium-99m
.01 400,000 Tellurium-127m
.01 5,000 Tellurium-129m
.01 5,000 Terbium-160
.01 4,000 Thulium-170
.01 4,000 Tin-113
.01 10,000 Tin-123
.01 3,000 Tin-126
.01 1,000 Titanium-44
.01 100 Vanadium-48
.01 7,000 Xenon-133 1.0 900,000 Yttrium-91
.01 2,000 Zinc-65
.01 5,000 Zirconium-93
.01 400 Zirconium-95
.01 5,000 Any other beta-gamma emitter
.01 10,000 Mixed fission products
.01 1,000 Mixed corrosion products
.01 10,000 Contaminated equipment beta-gamma
.001 10,000 Irradiated material, any form other than solid non-combustible
.01 1,000 Irradiated material, solid noncombustible
.001 10,000 Mixed radioactive waste, beta-gamma
.01 1,000 Packaged mixed waste, beta gamma
.001 10,000 Any other alpha emitter
.001 2
Contaminated equipment, alpha
.0001 20 Packaged waste, alpha
.0001 20 Combinations of radioactive materials listed above:
For combinations of radioactive materials, consideration of the need for an emergency plan is required if the sum of the ratios of the quantity of each radioactive material authorized to the quantity listed for that material in Exhibit D exceeds 1.
NOTE: Waste packaged in Type B containers does not require an emergency plan.
ARTICLE 4. STANDARDS FOR PROTECTION AGAINST IONIZING RADIATION R12-1-408.
Occupational Dose Amounts Limits for Adults A.
No change 1.
No change a.
No change b.
No change 2.
No change a.
No change b.
No change B.
No change C.
No change 1.
No change 2.
If a protective apron is worn and monitoring is conducted as specified in R12-1-419(B)(6), the effective dose equiva-lent for external radiation shall be determined as follows:
a.
No change b.
No change 3.
When the external exposure is determined by measurement with an external personal monitoring device, the deep-dose equivalent must be used in place of the effective dose equivalent, unless the effective dose equivalent is deter-mined by a dosimetry method approved by the Agency. The assigned deep-dose equivalent shall be determined for
Volume 20, Issue 7 Page 348 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking the part of the body that receives the highest exposure. The assigned shallow-dose equivalent is the dose averaged over the contiguous 10 square centimeters of skin that receives the highest exposure. The deep-dose equivalent, lens-dose equivalent, and shallow-dose equivalent may be assessed from surveys or other radiation measurements for the purpose of demonstrating compliance with the occupational dose limits, if the individual monitoring device was not in the region of highest potential exposure, or the results of individual monitoring are unavailable.
D.
No change E.
No change F.
No change R12-1-434.
General Requirements for Waste Disposal A.
No change 1.
No change 2.
By decay in storage, according to subsection (C) R12-1-438(C) 3.
No change 4.
As authorized according to R12-1-435, R12-1-436, R12-1-437, or R12-1-438, or R12-1-438.01; B.
No change 1.
No change 2.
No change 3.
No change 4.
No change 5.
No change R12-1-438.
Disposal of Specific Wastes A.
No change 1.
No change 2.
No change 3.
No change B.
No change C.
A licensee is authorized to may hold radioactive material with a physical half-life of less than or equal to 120 days or less for decay in storage before disposal without regard to its radioactivity in ordinary trash, and is exempt from the require-ments of R12-1-434, provided:
1.
The licensee monitors the container of radioactive material at the surface before disposal to and determine determines that its radioactivity cannot be distinguished from the background radiation level with an appropriate radiation detec-tion survey meter set on its most sensitive scale and with no interposed shielding; and 2.
No change D.
No change R12-1-438.01 Disposal of Certain Radioactive Material A.
Licensed material as defined in the definition of radioactive material in R12-1-102 may be disposed of in accordance with this Article, even though it is not defined as low-level radioactive waste. Therefore, any licensed radioactive material being disposed of at a facility, or transferred for ultimate disposal at a facility licensed by the Agency, must meet the requirements of R12-1-439.
B.
A licensee may dispose of radioactive material, as defined in the definition of radioactive material in R12-1-102, at a dis-posal facility authorized to dispose of such material in accordance with any federal or state solid or hazardous waste law, including the Solid Waste Disposal Act, as authorized under the Energy Policy Act of 2005.
R12-1-439.
Transfer for Disposal and Manifests A.
Any licensee shipping radioactive waste intended for ultimate disposal at a licensed land disposal facility (for purposes of this rule land disposal facility means the land, buildings, structures, and equipment that are intended to be used for the disposal of radioactive waste. A geologic repository is not a land disposal facility) shall comply with 10 CFR 20.2006 and 10 CFR 20 Appendix G, 2003 edition, published January 1, 2003, by the Office of the Federal Register, National Archives and Records Administration, Washington, D.C. 20408 which is incorporated by reference and on file with the Agency.
This incorporation by reference contains no future editions or amendments. published January 1, 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments.
B.
No change R12-1-446.
Notifications and Reports to Individuals A.
No change B.
In addition to the reporting requirements in R12-1-444 and R12-1-445, each licensee or registrant shall notify the individ-ual exposed to radiation or radioactive material. The notice to the exposed individual shall be provided no later than the date the report is submitted to the Agency and shall comply with R12-1-1004(A).
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 349 Volume 20, Issue 7 Appendix B.
Annual Limits on Intake (ALI) and Derived Air Concentrations (DAC) of Radionuclides for Occupa-tional Exposure; Effluent Concentrations; Concentrations for Release to Sanitary Sewerage Introduction For each radionuclide, Table I indicates the chemical form which is to be used for selecting the appropriate ALI or DAC value. The ALIs and DACs for inhalation are given for an aerosol with an activity median aerodynamic diameter (AMAD) of 1 m, micron, and for three classes (D,W,Y) of radioactive material, which refer to their retention (approximately days, weeks, or years) in the pulmonary region of the lung.
This classification applies to a range of clearance half-times for D if less than 10 days, for W from 10 to 100 days, and for Y greater than 100 days. Table II provides concentration limits for airborne and liquid effluents released to the general environment. Table III provides concentration limits for discharges to sanitary sewerage.
Note:
The values in Tables I, II, and III are presented in the computer E notation. In this notation a value of 6E-02 represents a value of 6 x 10-2 or 0.06, 6E+2 represents 6 x 102 or 600, and 6E+0 represents 6 x 100 or 6.
Table I Occupational Values Note that the columns in Table I of this Appendix captioned Oral Ingestion ALI, Inhalation ALI, and DAC are applicable to occupational exposure to radioactive material.
The ALIs in this Appendix are the annual intakes of given radionuclide by Reference Man which would result in either (1) a committed effective dose equivalent of 0.05 Sv (5 rem), stochastic ALI, or (2) a committed dose equivalent of 0.5 Sv (50 rem) to an organ or tissue, nonstochastic ALI. The stochastic ALIs were derived to result in a risk, due to irradiation of organs and tissues, comparable to the risk associated with deep-dose equivalent to the whole body of 0.05 Sv (5 rem). The derivation includes multiplying the committed dose equivalent to an organ or tissue by a weighting factor, WT. This weighting factor is the proportion of the risk of stochastic effects resulting from irradiation of the organ or tissue, T, to the total risk of stochastic effects when the whole body is irradiated uniformly. The values of WT are listed under the definition of weighting factor in R12-1-403. The nonstochastic ALIs were derived to avoid nonstochastic effects, such as prompt damage to tissue or reduction in organ function.
A value of WT = 0.06 is applicable to each of the five organs or tissues in the remainder category receiving the highest dose equivalents, and the dose equivalents of all other remaining tissues may be disregarded. The following portions of the GI tract -- stomach, small intestine, upper large intestine, and lower large intestine -- are to be treated as four separate organs.
Note that the dose equivalents for an extremity, skin, and lens of the eye are not considered in computing the committed effective dose equivalent but are subject to limits that shall be met separately.
When an ALI is defined by the stochastic dose limit, this value alone is given. When an ALI is determined by the nonstochastic dose limit to an organ, the organ or tissue to which the limit applies is shown, and the ALI for the stochastic limit is shown in parentheses. Abbreviated organ or tissue designations are used:
LLI wall
=
lower large intestine wall, St. wall
=
stomach wall, Blad wall
=
bladder wall, and Bone surf
=
Bone surface.
The use of the ALIs listed first, the more limiting of the stochastic and nonstochastic ALIs, will ensure that nonstochastic effects are avoided and that the risk of stochastic effects is limited to an acceptably low value. If, in a particular situation involving a radionuclide for which the nonstochastic ALI is limiting, use of that nonstochastic ALI is considered unduly conservative, the licensee may use the stochastic ALI to determine the committed effective dose equivalent. However, the licensee shall also ensure that the 0.5 Sv (50 rem) dose equivalent limit for any organ or tissue is not exceeded by the sum of the external deep-dose equivalent plus the internal committed dose equivalent to that organ, not the effective dose. For the case where there is no external dose contribution, this would be demonstrated if the sum of the fractions of the nonstochastic ALIs (ALIns) that contribute to the committed dose equivalent to the organ receiving the highest dose does not exceed unity, that is, (intake (in Ci) of each radionuclide/ALIns) 1.0. If there is an external deep dose equivalent contribution of Hd, then this sum must be less than 1 - (Hd/50), instead of 1.0.
Note that the dose equivalents for an extremity, skin, and lens of the eye are not considered in computing the committed effective dose equivalent but are subject to limits that must be met separately.
The derived air concentration (DAC) values are derived limits intended to control chronic occupational exposures. The relationship between the DAC and the ALI is given by:
DAC = ALI(in Ci)/(2000 hours0.0231 days <br />0.556 hours <br />0.00331 weeks <br />7.61e-4 months <br /> per working year x 60 minutes/hour x 2 x 104 ml per minute) = [ALI/2.4 x 109] Ci/ml, where 2 x 104 ml is the volume of air breathed per minute at work by Reference Man under working conditions of light work.
The DAC values relate to one of two modes of exposure: either external submersion or the internal committed dose equivalents resulting from inhalation of radioactive materials. DACs based upon submersion are for immersion in a semi-infinite cloud of uniform concentration and apply to each radionuclide separately.
The ALI and DAC values include contributions to exposure by the single radionuclide named and any in-growth of daughter radionuclides produced in the body by decay of the parent. However, intakes that include both the parent and daughter radionuclides shall be treated by the general method appropriate for mixtures.
Volume 20, Issue 7 Page 350 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking The values of ALI and DAC do not apply directly when the individual both ingests and inhales a radionuclide, when the individual is exposed to a mixture of radionuclides by either inhalation or ingestion or both, or when the individual is exposed to both internal and external irradiation. See R12-1-407. When an individual is exposed to radioactive materials which fall under several of the translocation classifications of the same radionuclide, such as Class D, Class W, or Class Y, the exposure may be evaluated as if it were a mixture of different radionuclides.
It should be noted that the classification of a compound as Class D, W, or Y is based on the chemical form of the compound and does not take into account the radiological half-life of different radionuclides. For this reason, values are given for Class D, W, and Y compounds, even for very short-lived radionuclides.
Table II Effluent Concentrations The columns in Table II of this Appendix captioned Effluents, Air, and Water are applicable to the assessment and control of dose to the public, particularly in the implementation of the provisions of R12-1-415. The concentration values given in Columns 1 and 2 of Table II are equivalent to the radionuclide concentrations which, if inhaled or ingested continuously over the course of a year, would produce a total effective dose equivalent of 0.5 mSv (0.05 rem).
Consideration of nonstochastic limits has not been included in deriving the air and water effluent concentration limits because nonstochastic effects are presumed not to occur at or below the dose levels established for individual members of the public. For radionuclides, where the nonstochastic limit was governing in deriving the occupational DAC, the stochastic ALI was used in deriving the corresponding airborne effluent limit in Table II. For this reason, the DAC and airborne effluent limits are not always proportional as they were in earlier versions of Appendix A of Article 4.
The air concentration values listed in Table II, Column 1 were derived by one of two methods. For those radionuclides for which the stochastic limit is governing, the occupational stochastic inhalation ALI was divided by 2.4 x 109, relating the inhalation ALI to the DAC, as explained above, and then divided by a factor of 300. The factor of 300 includes the following components: a factor of 50 to relate the 0.05 Sv (5 rem) annual occupational dose limit to the 0.1 rem limit for members of the public, a factor of 3 to adjust for the difference in exposure time and the inhalation rate for a worker and that for members of the public; and a factor of 2 to adjust the occupational values, derived for adults, so that they are applicable to other age groups.
For those radionuclides for which submersion, that is external dose, is limiting, the occupational DAC in Table I, Column 3 was divided by 219. The factor of 219 is composed of a factor of 50, as described above, and a factor of 4.38 relating occupational exposure for 2,000 hours0 days <br />0 hours <br />0 weeks <br />0 months <br /> per year to full-time exposure (8,760 hours0.0088 days <br />0.211 hours <br />0.00126 weeks <br />2.8918e-4 months <br /> per year). Note that an additional factor of 2 for age considerations is not warranted in the submersion case.
The water concentrations were derived by taking the most restrictive occupational stochastic oral ingestion ALI and dividing by 7.3 x 107.
The factor of 7.3 x 107 (ml) includes the following components: the factors of 50 and 2 described above and a factor of 7.3 x 105 (ml) which is the annual water intake of Reference Man.
Note 2 of this Appendix provides groupings of radionuclides which are applicable to unknown mixtures of radionuclides. These groupings, including occupational inhalation ALIs and DACS, air and water effluent concentrations, and releases to sewer, require demonstrating that the most limiting radionuclides in successive classes are absent. The limit for the unknown mixture is defined when the presence of one of the listed radionuclides cannot be definitely excluded as being present either from knowledge of the radionuclide composition of the source or from actual measurements.
Table III Releases to Sewers The monthly average concentrations for release to sanitary sewerage are applicable to the provisions in R12-1-435. The concentration values were derived by taking the most restrictive occupational stochastic oral ingestion ALI and dividing by 7.3 x 106 (ml). The factor of 7.3 x 106 (ml) is composed of a factor of 7.3 x 105 (ml), the annual water intake by Reference Man, and a factor of 10, such that the concentrations, if the sewage released by the licensee were the only source of water ingested by a Reference Man during a year, would result in a committed effective dose equivalent of 0.5 rem.
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 351 Volume 20, Issue 7 LIST OF ELEMENTS Atomic Name Symbol Number Actinium Ac 89 Aluminum Al 13 Americium Am 95 Antimony Sb 51 Argon Ar 18 Arsenic As 33 Astatine At 85 Barium Ba 56 Berkelium Bk 97 Beryllium Be 4
Bismuth Bi 83 Bromine Br 35 Cadmium Cd 48 Calcium Ca 20 Californium Cf 98 Carbon C
6 Cerium Ce 58 Cesium Cs 55 Chlorine Cl 17 Chromium Cr 24 Cobalt Co 27 Copper Cu 29 Curium Cm 96 Dysprosium Dy 66 Einsteinium Es 99 Erbium Er 68 Europium Eu 63 Fermium Fm 100 Fluorine F
9 Francium Fr 87 Gadolinium Gd 64 Gallium Ga 31 Germanium Ge 32 Gold Au 79 Hafnium Hf 72 Holmium Ho 67 Hydrogen H
53 Iridium Ir 77 Iron Fe 26 Krypton Kr 36 Lanthanum La 57 Lead Pb 82 Lutetium Lu 71 Magnesium Mg 12 Manganese Mn 25 Mendelevium Md 101 Mercury Hg 80 Molybdenum Mo 42 Neodymium Nd 60 Neptunium Np 93 Nickel Ni 28 Niobium Nb 41 Nitrogen N
8 Palladium Pd 46 Phosphorus P
15 Platinum Pt 78 Plutonium Pu 94
Volume 20, Issue 7 Page 352 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Polonium Po 84 Potassium K
19 Praseodymium Pr 59 Promethium Pm 61 Protactinium Pa 91 Radium Ra 88 Radon Rn 86 Rhenium Re 75 Rhodium Rh 45 Rubidium Rb 37 Ruthenium Ru 44 Samarium Sm 62 Scandium Sc 21 Selenium Se 34 Silicon Si 14 Silver Ag 47 Sodium Na 11 Strontium Sr 38 Sulfur S
16 Tantalum Ta 73 Technetium Tc 43 Tellurium Te 52 Terbium Tb 65 Thallium Tl 81 Thorium Th 90 Thulium Tm 69 Tin Sn 50 Titanium Ti 22 Tungsten W
74 Uranium U
92 Vanadium V
23 Xenon Xe 54 Ytterbium Yb 70 Yttrium Y
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 353 Volume 20, Issue 7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 1 Hydrogen-3 Water, DAC includes skin absorption 8E+4 8E+4 2E-5 1E-7 1E-3 1E-2 Gas (HT or T2) Submersion1: Use above values as HT and T2 oxidize in air and in the body to HTO.
4 Beryllium-7 W, all compounds except 4E+4 2E+4 9E-6 3E-8 6E-4 6E-3 those given for Y Y, oxides, halides, and nitrates 2E+4 8E-6 3E-8 4
Beryllium-10 W, see 7Be 1E+3 2E+2 6E-8 2E-10 LLI wall (1E+3) 2E-5 2E-4 Y, see 7Be 1E+1 6E-9 2E-11 6
Carbon-112 Monoxide 1E+6 5E-4 2E-6 Dioxide 6E+5 3E-4 9E-7 Compounds 4E+5 4E+ 5 2E-4 6E-7 6E-3 6E-2 6
Carbon-14 Monoxide 2E+6 7E-4 2E-6 Dioxide 2E+5 9E-5 3E-7 Compounds 2E+3 2E+3 1E-6 3E-9 3E-5 3E-4 7
Nitrogen-132 Submersion1 4E-6 2E-8 8
Oxygen-152 Submersion1 4E-6 2E-8 9
Fluorine-182 D, fluorides of H, Li, Na, K, Rb, Cs, and Fr 5E+4 7E+4 3E-5 1E-7 St wall (5E+4) 7E-4 7E-3 W, fluorides of Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, As, Sb, Bi, Fe, Ru, Os, Co, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, V, Nb, Ta, Mn, Tc, and Re 9E+4 4E-5 1E-7 Y, Lanthanum fluoride 8E+-4 3E-5 1E-7 11 Sodium-22 D, all compounds 4E+2 6E+2 3E-7 9E-10 6E-6 6E-5 11 Sodium-24 D, all compounds 4E+3 5E+3 2E-6 7E-9 5E-5 5E-4 12 Magnesium-28 D, all compounds except those given for W 7E+2 2E+3 7E-7 2E-9 9E-6 9E-5 W, oxides, hydroxides, carbides, halides, and nitrates 1E+3 5E-7 2E-9 13 Aluminum-26 D, all compounds except those given for W 4E+2 6E+1 3E-8 9E-11 6E-6 6E-5 W, oxides, hydroxides, carbides, halides, and nitrates 9E+1 4E-8 1E-10 14 Silicon-31 D, all compounds except those given for W and Y 9E+3 3E+4 1E-5 4E-8 1E-4 1E-3 W, oxides, hydroxides, carbides, and nitrates 3E+4 1E-5 5E-8 Y, aluminosilicate glass 3E+4 1E-5 4E-8 14 Silicon-32 D. see 31Si 2E+3 2E+2 1E-7 3E-10 LLI wall
Volume 20, Issue 7 Page 354 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (3E+3) 4E-5 4E-4 W, see 31Si 1E+2 5E-8 2E-10 Y, see 31Si 5E+0 2E-9 7E-12 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 15 Phosphorus-32 D, all compounds except phosphates given for W 6E+2 9E+2 4E-7 1E-9 9E-6 9E-5 W, phosphates of Zn2+,
S3+, Mg2+, Fe3+, Bi3+,
and Lanthanides 4E+2 2E-7 5E-10 15 Phosphorus-33 D, see 32P 6E+3 8E+3 4E-6 1E-8 8E-5 8E-4 W, see 32P 3E+3 1E-6 4E-9 16 Sulfur-35 Vapor 1E+4 6E-6 2E-8 D, sulfides and sulfates except those given for W 1E+4 2E+4 7E-6 2E-8 LLI wall (8E+3) 1E-4 1E-3 W, elemental sulfur, 6E+3 sulfides of Sr, Ba, Ge, Sn, Pb, As, Sb, Bi, Cu, Ag, Au, Zn, Cd, Hg, W, and Mo. Sulfates of Ca, Sr, Ba, Ra, As, Sb, and Bi 2E+3 9E-7 3E-9 17 Chlorine-36 D, chlorides of H, Li, Na, K, Rb, Cs, and Fr 2E+3 2E+3 1E-6 3E-9 2E-5 2E-4 W, chlorides of Lanthanides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Tc, and Re 2E+2 1E-7 3E -
17 Chlorine-382 D, see 36Cl 2E+4 4E+4 2E-5 6E -
St wall (3E+4)
-3E-4 3E-3 W, see 36Cl 5E+4 2E-5 6E -
17 Chlorine-392 D, see 36Cl 2E+4 5E+4 2E-5 7E -
St wall (4E+4)
-5E-4 5E-3 W, see 36Cl 6E+4 2E-5 8E -
18 Argon-37 Submersion1 1E+0 6E -
18 Argon-39 Submersion1 2E-4 8E -
18 Argon-41 Submersion1 3E-6 1E -
19 Potassium-40 D, all compounds 3E+2 4E+2 2E-7 6E-10 4E-6 4E-5 19 Potassium-42 D, all compounds 5E+3 5E+3 2E-6 7E-9 6E-5 6E-4 19 Potassium-43 D, all compounds 6E+3 9E+3 4E-6 1E-8 9E-5 9E-4
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 355 Volume 20, Issue 7 19 Potassium-442 D, all compounds 2E+4 7E+4 3E-5 9E-8 St wall (4E+4) 5E-4 5E-3 19 Potassium-452 D, all compounds 3E+4 1E+5 5E-5 2E-7 St watt (5E+4) 7E-4 7E-3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 20 Calcium-41 W, all compounds 3E+3 4E+3 2E-6 Bone surf Bone surf (4E+3)
(4E+3) 5E-9 6E-5 6E-4 20 Calcium-45 W, all compounds 2E+3 8E+2 4E-7 1E-9 2E-5 2E-4 20 Calcium-47 W, all compounds 8E+2 9E+2 4E-7 1E-9 1E-5 1E-4 21 Scandium-43 Y, all compounds 7E+3 2E+4 9E-6 3E-8 1E-4 1E-3 21 Scandium-44m Y, all compounds 5E+2 7E+2 3E-7 1E-9 7E-6 7E-5 21 Scandium-44 Y, all compounds 4E+3 1E+4 5E-6 2E-8 5E-5 5E-4 21 Scandium-46 Y, all compounds 9E+2 2E+2 1E-7 3E-10 1E-5 1E-4 21 Scandium-47 Y, all compounds 2E+3 3E+3 1E-6 4E-9 LLI wall (3E+3) 4E-5 4E-4 21 Scandium-48 Y, all compounds 8E+2 1E+3 6E-7 2E-9 1E-5 1E-4 21 Scandium-492 Y, all compounds 2E+4 5E+4 2E-5 8E-8 3E-4 3E-3 22 Titanium-44 D, all compounds except those given for W and Y 3E+2 1E+1 5E-9 2E-11 4E-6 4E-5 W, oxides, hydroxides, carbides, halides, and nitrates 3E+1 1E-8 4E-11 Y, SrTiO 6E+0 2E-9 8E-12 22 Titanium-45 D, see 44Ti 9E+3 3E+4 1E-5 3E-8 1E-4 1E-3 W, see 44Ti 4E+4 1E-5 5E-8 Y, see 44Ti 3E+4 1E-5 4E-8 23 Vanadium-472 D, all compounds except those given for W 3E+4 8E+4 3E-5 1E-7 St wall (3E+4) 4E-4 4E-3 W, oxides, hydroxides, carbides, and halides 1E+5 4E-5 1E-7 23 Vanadium-48 D, see 47V 6E+2 1E+3 5E-7 2E-9 9E-6 9E-5 W, see 47V 6E+2 3E-7 9E-10 23 Vanadium-49 D, see 47V 7E+4 3E+4 1E-5 LLI wall Bone surf (9E+4)
(3E+4) 5E-8 1E-3 1E-2 W, see47V 2E+4 8E-6 2E-8 24 Chromium-48 D, all compounds except those given for W and Y 6E+3 1E+4 5E-6 2E-8 8E-5 8E-4 W, halides and nitrates 7E+3 3E-6 1E-8 Y, oxides and hydroxides 7E+3 3E-6 1E-8
Volume 20, Issue 7 Page 356 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 24 Chromium-492 D, see 48Cr 3E+4 8E+4 4E-5 1E-7 4E-4 4E-3 W, see 48Cr 1E+5 4E-5 1E-7 Y, see 48Cr 9E+4 4E-5 1E-7 24 Chromium-51 D, see 48Cr 4E+4 5E+4 2E-5 6E-8 5E-4 5E-3 W, see 48Cr 2E+4 1E-5 3E-8 Y, see 48Cr 2E+4 8E-6 3E-8 25 Manganese-512 D, all compounds except those given for W 2E+4 5E+4 2E-5 7E-8 3E-4 3E-3 W, oxides, hydroxides, halides, and nitrates 6E+4 3E-5 8E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 25 Manganese-52m2 D, see 51Mn 3E+4 9E+4 4E-5 1E-7 St wall (4E+4) 5E-4 5E-3 W, see 51Mn 1E+5 4E-5 1E-7 25 Manganese-52 D, see 51Mn 7E+2 1E+3 5E-7 2E-9 1E-5 1E-4 W, see 51Mn 9E+2 4E-7 1E-9 25 Manganese-53 D, see 51Mn 5E+4 1E+4 5E-6 7E-4 7E-3 Bone surf (2E+4) 3E-8 W, see 51Mn 1E+4 5E-6 2E-8 25 Manganese-54 D, see 51Mn 2E+3 9E+2 4E-7 1E-9 3E-5 3E-4 W, see 51Mn 8E+2 3E-7 1E-9 25 Manganese-56 D, see 51Mn 5E+3 2E+4 6E-6 2E-8 7E-5 7E-4 W, see 51Mn 2E+4 9E-6 3E-8 26 Iron-52 D, all compounds except those given for W 9E+2 3E+3 1E-6 4E-9 1E-5 1E-4 W, oxides, hydroxides, and halides 2E+3 1E-6 3E-9 26 Iron-55 D, see 52Fe 9E+3 2E+3 8E-7 3E-9 1E-4 1E-3 W, see 52Fe 4E+3 2E-6 6E-9 26 Iron-59 D, see 52Fe 8E+2 3E+2 1E-7 5E-10 1E-5 1E-4 W, see 52Fe 5E+2 2E-7 7E-10 26 Iron-60 D, see 52Fe 3E+1 6E+0 3E-9 9E-12 4E-7 4E-6 W, see 52Fe 2E+1 8E-9 3E-11 27 Cobalt-55 W, all compounds except those given for Y 1E+3 3E+3 1E-6 4E-9 2E-5 2E-4 Y, oxides, hydroxides, halides, and nitrates 3E+3 1E-6 4E-9 27 Cobalt-56 W, see 55Co 5E+2 3E+2 1E-7 4E-10 6E-6 6E-5 Y, see 55Co 4E+2 2E+2 8E-8 3E-10 27 Cobalt-57 W, see 55Co 8E+3 3E+3 1E-6 4E-9 6E-5 6E-4
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 357 Volume 20, Issue 7 Y, see 55Co 4E+3 7E+2 3E-7 9E-10 27 Cobalt-58m W, see 55Co 6E+4 9E+4 4E-5 1E-7 8E-4 8E-3 Y, see 55Co 6E+4 3E-5 9E-8 27 Cobalt-58 W, see 55Co 2E+3 1E+3 5E-7 2E-9 2E-5 2E-4 Y, see 55Co 1E+3 7E+2 3E-7 1E-9 27 Cobalt-60m2 W, see 55Co 1E+6 4E+6 2E-3 6E-6 St wall (1E+6) 2E-2 2E-1 Y, see 55Co 3E+6 1E-3 4E-6 27 Cobalt-60 W, see 55Co 5E+2 2E+2 7E-8 2E-10 3E-6 3E-5 Y, see 55Co 2E+2 3E+1 1E-8 5E-11 27 Cobalt-612 W, see 55Co 2E+4 6E+4 3E-5 9E-8 3E-4 3E-3 Y, see 55Co 2E+4 6E+4 2E-5 8E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 27 Cobalt-62m2 W, see 55Co 4E+4 2E+5 7E-5 2E-7 St wall (5E+4) 7E-4 7E-3 Y, see 55Co 2E+5 6E-5 2E-7 28 Nickel-56 D, all compounds except those given for W 1E+3 2E+3 8E-7 3E-9 2E-5 2E-4 W, oxides, hydroxides, and carbides 1E+3 5E-7 2E-9 Vapor 1E+3 5E-7 2E-9 28 Nickel-57 D, see 56Ni 2E+3 5E+3 2E-6 7E-9 2E-5 2E-4 W, see 56Ni 3E+3 1E-6 4E-9 Vapor 6E+3 3E-6 9E-28 Nickel-59 D, see 56Ni 2E+4 4E+3 2E-6 5E-9 3E-4 3E-3 W, see 56Ni 7E+3 3E-6 1E-8 Vapor 2E+3 8E-7 3E-9 28 Nickel-63 D, see 56Ni 9E+3 2E+3 7E-7 2E-9 1E-4 1E-3 W, see 56Ni 3E+3 1E-6 4E-9 Vapor 8E+2 3E-7 1E-9 28 Nickel-65 D, see 56Ni 8E+3 2E+4 1E-5 3E-8 1E-4 1E-3 W, see 56Ni 3E+4 1E-5 4E-8 Vapor 2E+4 7E-6 2E-8 28 Nickel-66 D, see 56Ni 4E+2 2E+3 7E-7 2E-9 LLI wall (5E+2) 6E-6 6E-5 W, see 56Ni 6E+2 3E-7 9E-10 Vapor 3E+3 1E-6 4E-9 29 Copper-602 D, all compounds except those given for W and Y 3E+4 9E+4 4E-5 1E-7
Volume 20, Issue 7 Page 358 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking St wall (3E+4) 4E-4 4E-3 W, sulfides, halides, and nitrates 1E+5 5E-5 2E-7 Y, oxides and hydroxides 1E+5 4E-5 1E-7 29 Copper-61 D, see 60Cu 1E+4 3E+4 1E-5 4E-8 2E-4 2E-3 W, see 60Cu 4E+4 2E-5 6E-8 Y, see 60Cu 4E+4 1E-5 5E-8 29 Copper-64 D, see 60Cu 1E+4 3E+4 1E-5 4E-8 2E-4 2E-3 W, see 60Cu 2E+4 1E-5 3E-8 Y, see 60Cu 2E+4 9E-6 3E-8 29 Copper-67 D, see 60Cu 5E+3 8E+3 3E-6 1E-8 6E-5 6E-4 W, see 60Cu 5E+3 2E-6 7E-9 Y, see 60Cu 5E+3 2E-6 6E-9 30 Zinc-62 Y, all compounds 1E+3 3E+3 1E-6 4E-9 2E-5 2E-4 30 Zinc-632 Y, all compounds 2E+4 7E+4 3E-5 9E-8 St wall (3E+4) 3E-4 3E-3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 30 Zinc-65 Y, all compounds 4E+2 3E+2 1E-7 4E-10 5E-6 5E-5 30 Zinc-69m Y, all compounds 4E+3 7E+3 3E-6 1E-8 6E-5 6E-4 30 Zinc-692 Y, all compounds 6E+4 1E+5 6E-5 2E-7 8E-4 8E-3 30 Zinc-71m Y, all compounds 6E+3 2E+4 7E-6 2E-8 8E-5 8E-4 30 Zinc-72 Y, all compounds 1E+3 1E+3 5E-7 2E-9 1E-5 1E-4 31 Gallium-652 D, all compounds except those given for W 5E+4 2E+5 7E-5 2E-7 St wall (6E+4),
9E-4 9E-3 W, oxides, hydroxides, carbides, halides, and nitrates 2E+5 8E-5 3E-7 31 Gallium-66 D, see 65Ga 1E+3 4E+3 1E-6 5E-9 1E-5 1E-4 W, see 65Ga 3E+3 1E-6 4E-9 31 Gallium-67 D, see 65Ga 7E+3 1E+4 6E-6 2E-8 1E-4 1E-3 W, see 65Ga 1E+4 4E-6 1E-8 31 Gallium-682 D, see 65Ga 2E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 65Ga 5E+4 2E-5 7E-8 31 Gallium-702 D, see 65Ga 5E+4 2E+5 7E-5 2E-7 St wall (7E+4) 1E-3 1E-2 W, see 65Ga 2E+5 8E-5 3E-7 31 Gallium-72 D, see 65Ga 1E+3 4E+3 1E-6 5E-9 2E-5 2E-4 W, see 65Ga 3E+3 1E-6 4E-9
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 359 Volume 20, Issue 7 31 Gallium-73 D, see 65Ga 5E+3 2E+4 6E-6 2E-8 7E-5 7E-4 W, see 65Ga 2E+4 6E-6 2E-8 32 Germanium-66 D, all compounds except those given for W 2E+4 3E+4 1E-5 4E-8 3E-4 3E-3 W, oxides, sulfides, and halides 2E+4 8E-6 3E-8 32 Germanium-672 D, see 66Ge 3E+4 9E+4 4E-5 1E-7 St wait (4E+4) 6E-4 6E-3 W, see 66Ge 1E+5 4E-5 1E-7 32 Germanium-68 D, see 66Ge 5E+3 4E+3 2E-6 5E-9 6E-5 6E-4 W, see 66Ge 1E+2 4E-8 1E-10 32 Germanium-69 D, see 66Ge 1E+4 2E+4 6E-6 2E-8 2E-4 2E-3 W, see 66Ge 8E+3 3E-6 1E-8 32 Germanium-71 D, see 66Ge 5E+5 4E+5 2E-4 6E-7 7E-3 7E-2 W, see 66Ge 4E+4 2E-5 6E-8 32 Germanium-752 D, see 66Ge 4E+4 8E+4 3E-5 1E-7 St wall (7E+4) 9E-4 9E-3 W, see 66Ge 8E+4 4E-5 1E-7 32 Germanium-77 D, see 66Ge 9E+3 1E+4 4E-6 1E-8 1E-4 1E-3 W, see 66Ge 6E+3 2E-6 8E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 32 Germanium-782 D, see 66Ge 2E+4 2E+4 9E-6 3E-8 St wall (2E+4) 3E-4 3E-3 W, see 66Ge 2E+4 9E-6 3E-8 33 Arsenic-692 W, all compounds 3E+4 1E+5 5E-5 2E-7 St wall (4E+4) 6E-4 6E-3 33 Arsenic-702 W, all compounds 1E+4 5E+4 2E-5 7E-8 2E-4 2E-3 33 Arsenic-71 W, all compounds 4E+3 5E+3 2E-6 6E-9 5E-5 5E-4 33 Arsenic-72 W, all compounds 9E+2 1E+3 6E-7 2E-9 1E-5 1E-4 33 Arsenic-73 W, all compounds 8E+3 2E+3 7E-7 2E-9 1E-4 1E-3 33 Arsenic-74 W, all compounds 1E+3 8E+2 3E-7 1E-9 2E-5 2E-4 33 Arsenic-76 W, all compounds 1E+3 1E+3 6E-7 2E-9 1E-5 1E-4 33 Arsenic-77 W, all compounds 4E+3 5E+3 2E-6 7E-9 LLI wall (5E+3) 6E-5 6E-4 33 Arsenic-782 W, all compounds 8E+3 2E+4 9E-6 3E-8 1E-4 1E-3 34 Selenium-702 D, all compounds except those given for W 2E+4 4E+4 2E-5 5E-8 1E-4 1E-3
Volume 20, Issue 7 Page 360 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking W, oxides, hydroxides, carbides, and elemental Se 1E+4 4E+4 2E-5 6E-8 34 Selenium-73m2 D, see 70Se 6E+4 2E+5 6E-5 2E-7 4E-4 4E-3 W, see 70Se 3E+4 1E+5 6E-5 2E-7 34 Selenium-73 D, see 70Se 3E+3 1E+4 5E-6 2E-8 4E-5 4E-4 W, see 70Se 2E+4 7E-6 2E-8 34 Selenium-75 D, see 70Se 5E+2 7E+2 3E-7 1E-9 7E-6 7E-5 W, see 70Se 6E+2 3E-7 8E-10 34 Selenium-79 D, see 70Se 6E+2 8E+2 3E-7 1E-9 8E-6 8E-5 W, see 70Se 6E+2 2E-7 8E-10 34 Selenium-81m2 D, see 70Se 4E+4 7E+4 3E-5 9E-8 3E-4 3E-3 W, see 70Se 2E+4 7E+4 3E-5 1E-7 34 Selenium-812 D, see 70Se 6E+4 2E+5 9E-5 3E-7 St wall (8E+4) 1E-3 1E-2 W, see 70Se 2E+5 1E-4 3E-7 34 Selenium-832 D, see 70Se 4E+4 1E+5 5E-5 2E-7 4E-4 4E-3 W, see 70Se 3E+4 1E+5 5E-5 2E-7 35 Bromine-74m2 D, bromides of H, Li, Na, K, Rb, Cs, and Fr 1E+4 4E+4 2E-5 5E-8 St wall (2E+4) 3E-4 3E-3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
W, Bromides of lanthanides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Mn, Tc, and Re 4E+4 2E-5 6E-8 35 Bromine-742 D, see 74mBr 2E+4 7E+4 3E-5 1E-7 St wall (4E+4) 5E-4 5E-3 W, see 74mBr 8E+4 4E-5 1E-7 35 Bromine-752 D, see 74mBr 3E+4 5E+4 2E-5 7E-8 St wall (4E+4) 5E-4 5E-3 W, see 74mBr 5E+4 2E-5 7E-8 35 Bromine-76 D, see 74mBr 4E+3 5E+3 2E-6 7E-9 5E-5 5E-4 W, see 74mBr 4E+3 2E-6 6E-9 35 Bromine-77 D, see 74mBr 2E+4 2E+4 1E-5 3E-8 2E-4 2E-3
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 361 Volume 20, Issue 7 W, see 74mBr 2E+4 8E-6 3E-8 35 Bromine-80m D, see 74mBr 2E+4 2E+4 7E-6 2E-8 3E-4 3E-3 W, see 74mBr 1E+4 6E-6 2E-8 35 Bromine-802 D, see 74mBr 5E+4 2E+5 8E-5 3E-7 St wall (9E+4) 1E-3 1E-2 W, see 74mBr 2E+5 9E-5 3E-7 35 Bromine-82 D, see 74mBr 3E+3 4E+3 2E-6 6E-9 4E-5 4E-4 W, see 74mBr 4E+3 2E-6 5E-9 35 Bromine-83 D, see 74mBr 5E+4 6E+4 3E-5 9E-8 St wall (7E+4) 9E-4 9E-3 W, see 74mBr 6E+4 3E-5 9E-8 35 Bromine-842 D, see 74mBr 2E+4 6E+4 2E-5 8E-8 St wall (3E+4) 4E-4 4E-3 W, see 74mBr 6E+4 3E-5 9E-8 36 Krypton-742 Submersion1 3E-6 1E-8 36 Krypton-76 Submersion1 9E-6 4E-8 36 Krypton-772 Submersion1 4E-6 2E-8 36 Krypton-79 Submersion1 2E-5 7E-8 36 Krypton-81 Submersion1 7E-4 3E-6 36 Krypton-83m2 Submersion1 1E-2 5E-5 36 Krypton-85m Submersion1 2E-5 1E-7 36 Krypton-85 Submersion1 1E-4 7E-7 36 Krypton-872 Submersion1 5E-6 2E-8 36 Krypton-88 Submersion1 2E-6 9E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 37 Rubidium-792 D, all compounds 4E+4 1E+5 5E-5 2E-7 St wall (6E+4) 8E-4 8E-3 37 Rubidium-81m2 D, all compounds 2E+5 3E+5 1E-4 5E-7 St wall (3E+5) 4E-3 4E-2 37 Rubidium-81 D, all compounds 4E+4 5E+4 2E-5 7E-8 5E-4 5E-3 37 Rubidium 82m D, all compounds 1E+4 2E+4 7E-6 2E-8 2E-4 2E-3 37 Rubidium-83 D, all compounds 6E+2 1E+3 4E-7 1E-9 9E-6 9E-5 37 Rubidium-84 D, all compounds 5E+2 8E+2 3E-7 1E-9 7E-6 7E-5 37 Rubidium-86 D, all compounds 5E+2 8E+2 3E-7 1E-9 7E-6 7E-5 37 Rubidium-87 D, all compounds 1E+3 2E+3 6E-7 2E-9 1E-5 1E-4 37 Rubidium-882 D, all compounds 2E+4 6E+4 3E-5 9E-8 St wall
Volume 20, Issue 7 Page 362 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (3E+4) 4E-4 4E-3 37 Rubidium-892 D, all compounds 4E+4 1E+5 6E-5 2E-7 St wall (6E+4) 9E-4 9E-3 38 Strontium-802 D, all soluble compounds except SrTi0 4E+3 1E+4 5E-6 2E-8 6E-5 6E-4 Y, all insoluble compounds and SrTi0 1E+4 5E-6 2E-8 38 Strontium-812 D, see 80Sr 3E+4 8E+4 3E-5 1E-7 3E-4 3E-3 Y, see 80Sr 2E+4 8E+4 3E-5 1E-7 38 Strontium-82 D, see 80Sr 3E+2 4E+2 2E-7 6E-10 LLI wall (2E+2) 3E-6 3E-5 Y, see 80Sr 2E+2 9E+1 4E-8 1E-10 38 Strontium-83 D, see 80Sr 3E+3 7E+3 3E-6 1E-8 3E-5 3E-4 Y, see 80Sr 2E+3 4E+3 1E-6 5E-9 38 Strontium-85m2 D, see 80Sr 2E+5 6E+5 3E-4 9E-7 3E-3 3E-2 Y, see 80Sr 8E+5 4E-4 1E-6 38 Strontium-85 D, see 80Sr 3E+3 3E+3 1E-6 4E-9 4E-5 4E-4 Y, see 80Sr 2E+3 6E-7 2E-9 38 Strontium-87m D, see 80Sr 5E+4 1E+5 5E-5 2E-7 6E-4 6E-3 Y, see 80Sr 4E+4 2E+5 6E-5 2E-7 38 Strontium-89 D, see 80Sr 6E+2 8E+2 4E-7 1E-9 LLI wall (6E+2) 8E-6 8E-5 Y, see 80Sr 5E+2 1E+2 6E-8 2E-10 38 Strontium-90 D, see 80Sr 3E+1 2E+1 8E-9 Bone surf Bone surf (4E+1)
(2E+1) 3E-11 5E-7 5E-6 Y, see 80Sr 4E+0 2E-9 6E-12 38 Strontium-91 D, see 80Sr 2E+3 6E+3 2E-6 8E-9 2E-5 2E-4 Y, see 80Sr 4E+3 1E-6 5E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 38 Strontium-92 D, see 80Sr 3E+3 9E+3 4E-6 1E-8 4E-5 4E-4 Y, see 80Sr 7E+3 3E-6 9E-9 39 Yttrium-86m2 W, all compounds except those given for Y 2E+4 6E+4 2E-5 8E-8 3E-4 3E-3 Y, oxides and hydroxides 5E+4 2E-5 8E-8 39 Yttrium-86 W, see 86mY 1E+3 3E+3 1E-6 5E-9 2E-5 2E-4 Y, see 86mY 3E+3 1E-6 5E-9 39 Yttrium-87 W, see 86m Y 2E+3 3E+3 1E-6 5E-9 3E-5 3E-4
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 363 Volume 20, Issue 7 Y, see 86mY 3E+3 1E-6 5E-9 39 Yttrium-88 W, see 86mY 1E+3 3E+2 1E-7 3E-10 1E-5 1E-4 Y, see 86mY 2E+2 1E-7 3E-10 39 Yttrium-90m W, see 86mY 8E+3 1E+4 5E-6 2E-8 1E-4 1E-3 Y, see 86mY 1E+4 5E-6 2E-8 39 Yttrium-90 W, see 86mY 4E+2 7E+2 3E-7 9E-10 LLI wall (5E+2) 7E-6 7E-5 Y, see 86mY 6E+2 3E-7 9E-10 39 Yttrium-91m2 W, see 86mY 1E+5 2E+5 1E-4 3E-7 2E-3 2E-2 Y, see 86mY 2E+5 7E-5 2E-7 39 Yttrium-91 W, see 86mY 5E+2 2E+2 7E-8 2E-10 LLI wall (6E+2) 8E-6 8E-5 Y, see 86mY 1E+2 5E-8 2E-10 39 Yttrium-92 W, see 86mY 3E+3 9E+3 4E-6 1E-8 4E-5 4E-4 Y, see 86mY 8E+3 3E-6 1E-8 39 Yttrium-93 W, see 86mY 1E+3 3E+3 1E-6 4E-9 2E-5 2E-4 Y, see 86mY 2E+3 1E-6 3E-9 39 Yttrium-942 W, see 86mY 2E+4 8E+4 3E-5 1E-7 St wall (3E+4) 4E-4 4E-3 Y, see 86mY 8E+4 3E-5 1E-7 39 Yttrium-952 W, see 86mY 4E+4 2E+5 6E-5 2E-7 St wall (5E+4) 7E-4 7E-3 Y, see 86mY 1E+5 6E-5 2E-7 40 Zirconium-86 D, all compounds except those given for W and Y 1E+3 4E+3 2E-6 6E-9 2E-5 2E-4 W, oxides, hydroxides, halides, and nitrates 3E+3 1E-6 4E-9 Y, carbide 2E+3 1E-6 3E-9 40 Zirconium-88 D, see 86Zr 4E+3 2E+2 9E-8 3E-10 5E-5 5E-4 W, see 86Zr 5E+2 2E-7 7E-10 Y, see 86Zr 3E+2 1E-7 4E-10 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 40 Zirconium-89 D, see 86Zr 2E+3 4E+3 1E-6 5E-9 2E-5 2E-4 W, see 86Zr 2E+3 1E-6 3E-9 Y, see 86Zr 2E+3 1E--6 3E-9 40 Zirconium-93 D, see 86Zr 1E+3 6E+0 3E-9
Volume 20, Issue 7 Page 364 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Bone surf Bone surf (3E+3)
(2E+1) 2E-11 4E-5 4E-4 W, see 86Zr 2E+1 1E-8 Bone surf (6E+1) 9E-11 Y, see 86Zr 6E+1 2E-8 Bone surf (7E+1) 9E-11 40 Zirconium-95 D, see 86Zr 1E+3 1E+2 5E-8 2E-5 2E-4 Bone surf (3E+2) 4E-10 W, see 86Zr 4E+2 2E-7 5E-10 Y, see 86Zr 3E+2 1E-7 4E-10 40 Zirconium-97 D, see 86Zr 6E+2 2E+3 8E-7 3E-9 9E-6 9E-5 W, see 86Zr 1E+3 6E-7 2E-9 Y, see 86Zr 1E+3 5E-7 2E-9 41 Niobium-882 W, all compounds except those given for Y 5E+4 2E+5 9E-5 3E-7 St wall (7E+4) 1E-3 1E-2 Y, oxides and hydroxides 2E+5 9E-5 3E-7 41 Niobium-892 W, see 88Nb 1E+4 4E+4 2E-5 6E-8 1E-4 1E-3 (66 min)
Y, see 88Nb 4E+4 2E-5 5E-8 41 Niobium-89 W, see 88Nb 5E+3 2E+4 8E-6 3E-8 7E-5 7E-4 (122 min)
Y, see 88Nb 2E+4 6E-6 2E-8 41 Niobium-90 W, see 88Nb 1E+3 3E+3 1E-6 4E-9 1E-5 1E-4 Y, see 88Nb 2E+3 1E-6 3E-9 41 Niobium-93m W, see 88Nb 9E+3 2E+3 8E-7 3E-9 LLI wall (1E+4) 2E-4 2E-3 Y, see 88Nb 2E+2 7E-8 2E-10 41 Niobium-94 W, see 88Nb 9E+2 2E+2 8E-8 3E-10 1E-5 1E-4 Y, see 88Nb 2E+1 6E-9 2E-11 41 Niobium-95m W, see 88Nb 2E+3 3E+3 1E-6 4E-9 LLI wall (2E+3) 3E-5 3E-4 Y, see 88Nb 2E+3 9E-7 3E -
41 Niobium-95 W, see 88Nb 2E+3 1E+3 5E-7 2E-9 3E-5 3E-4 Y, see 88Nb 1E+3 5E-7 2E -
Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 365 Volume 20, Issue 7 41 Niobium-96 W, see 88Nb 1E+3 3E+3 1E-6 4E-9 2E-5 2E-4 Y, see 88Nb 2E+3 1E-6 3E-9 41 Niobium-972 W, see 88Nb 2E+4 8E+4 3E-5 1E-7 3E-4 3E-3 Y, see 88Nb 7E+4 3E-5 1E-7 41 Niobium-982 W, see 88Nb 1E+4 5E+4 2E-5 8E-8 2E-4 2E-3 Y, see 88Nb 5E+4 2E-5 7E-8 42 Molybdenum-90 D, all compounds except those given for Y 4E+3 7E+3 3E-6 1E-8 3E-5 3E-4 Y, oxides, hydroxides, and MoS 2E+3 5E+3 2E-6 6E-9 42 Molybdenum-93m D, see 90Mo 9E+3 2E+4 7E-6 2E-8 6E-5 6E-4 Y, see 90Mo 4E+3 1E+4 6E-6 2E-8 42 Molybdenum-93 D, see 90Mo 4E+3 5E+3 2E-6 8E-9 5E-5 5E-4 Y, see 90Mo 2E+4 2E+2 8E-8 2E-10 42 Molybdenum-99 D, see 90Mo 2E+3 3E+3 1E-6 4E-9 LLI wall (1E+3) 2E-5 2E-4 Y, see 90Mo 1E+3 1E+3 6E-7 2E-9 42 Molybdenum-1012 D, see 90Mo 4E+4 1E+5 6E-5 2E-7 St wall (5E+4) 7E-4 7E-3 Y, see 90Mo 1E+5 6E-5 2E-7 43 Technetium-93m2 D, All compounds except those given for W 7E+4 2E+5 6E-5 2E-7 1E-3 1E-2 W, oxides, hydroxides, halides, and nitrates 3E+5 1E-4 4E-7 43 Technetium-93 D, see 93mTc 3E+4 7E+4 3E-5 1E-7 4E-4 4E-3 W, see 93mTc 1E+5 4E-5 1E-7 43 Technetium-94m2 D, see 93mTc 2E+4 4E+4 2E-5 6E-8 3E-4 3E-3 W, see 93mTc 6E+4 2E-5 8E-8 43 Technetium-94 D, see 93mTc 9E+3 2E+4 8E-6 3E-8 1E-4 1E-3 W, see 93mTc 2E+4 1E-5 3E-8 43 Technetium-95m D, see 93mTc 4E+3 5E+3 2E-6 8E-9 5E-5 5E-4 W, see 93mTc 2E+3 8E-7 3E-9 43 Technetium-95 D, see 93mTc 1E+4 2E+4 9E-6 3E-8 1E-4 1E-3 W, see 93mTc 2E+4 8E-6 3E-8 43 Technetium-96m2 D, see 93mTc 2E+5 3E+5 1E-4 4E-7 2E-3 2E-2 W, see 93mTc 2E+5 1E-4 3E-7 43 Technetium-96 D, see 93mTc 2E+3 3E+3 1E-6 5E-9 3E-5 3E-4 W, see 93mTc 2E+3 9E-7 3E-9 43 Technetium-97m D, see 93mTc 5E+3 7E+3 3E-6 6E-5 6E-4 St wall (7E+3) 1E-8 W, see 93mTc 1E+3 5E-7 2E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers
Volume 20, Issue 7 Page 366 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 43 Technetium-97 D, see 93mTc 4E+4 5E+4 2E-5 7E-8 5E-4 5E-3 W, see 93mTc 6E+3 2E-6 8E-9 43 Technetium-98 D, see 93mTc 1E+3 2E+3 7E-7 2E-9 1E-5 1E-4 W, see 93mTc 3E+2 1E-7 4E-10 43 Technetium-99m D, see 93mTc 8E+4 2E+5 6E-5 2E-7 1E-3 1E-2 W, see 93mTc 2E+5 1E-4 3E-7 43 Technetium-99 D, see 93mTc 4E+3 5E+3 2E-6 6E-5 6E-4 St wall (6E+3) 8E-9 W, see 93mTc 7E+2 3E-7 9E-10 43 Technetium-1012 D, see 93mTc 9E+4 3E+5 1E-4 5E-7 St wall (1E+5) 2E-3 2E-2 W, see 93mTc 4E+5 2E-4 5E-7 43 Technetium-1042 D, see 93mTc 2E+4 7E+4 3E-5 1E-7 St wall (3E+4) 4E-4 4E-3 W, see 93mTc 9E+4 4E-5 1E-7 44 Ruthenium-942 D, all compounds except those given for W and Y 2E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, halides 6E+4 3E-5 9E-8 Y, oxides and hydroxides 6E+4 2E-5 8E-8 44 Ruthenium-97 D, see 94Ru 8E+3 2E+4 8E-6 3E-8 1E-4 1E-3 W, see 94Ru 1E+4 5E-6 2E-8 Y, see 94Ru 1E+4 5E-6 2E-8 44 Ruthenium-103 D, see 94Ru 2E+3 2E+3 7E-7 2E-9 3E-5 3E-4 W, see 94Ru 1E+3 4E-7 1E-9 Y, see 94Ru 6E+2 3E-7 9E-10 44 Ruthenium-105 D, see 94Ru 5E+3 1E+4 6E-6 2E-8 7E-5 7E-4 W, see 94Ru 1E+4 6E-6 2E-8 Y, see 94Ru 1E+4 5E-6 2E-8 44 Ruthenium-106 D, see 94Ru 2E+2 9E+1 4E-8 1E-10 LLI wall (2E+2) 3E-6 3E-5 W, see 94Ru 5E+1 2E-8 8E-11 Y, see 94Ru 1E+1 5E-9 2E-11 45 Rhodium-99m D, all compounds except those given for W and Y 2E+4 6E+4 2E-5 8E-8 2E-4 2E-3 W, halides 8E+4 3E-5 1E-7 Y, oxides and hydroxides 7E+4 3E-5 9E-8 45 Rhodium-99 D, see 99mRh 2E+3 3E+3 1E-6 4E-9 3E-5 3E-4 W, see 99mRh 2E+3 9E-7 3E-9 Y, see 99mRh 2E+3 8E-7 3E-9
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 367 Volume 20, Issue 7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 45 Rhodium-100 D, see 99mRh 2E+3 5E+3 2E-6 7E-9 2E-5 2E-4 W, see 99mRh 4E+3 2E-6 6E-9 Y, see 99mRh 4E+ 3 2E-6 5E-9 45 Rhodium-101m D, see 99mRh 6E+3 1E+4 5E-6 2E-8 8E-5 8E-4 W, see 99mRh 8E+3 4E-6 1E-8 Y, see 99mRh 8E+3 3E-6 1E-8 45 Rhodium-101 D, see 99mRh 2E+3 5E+2 2E-7 7E-10 3E-5 3E-4 W, see 99mRh 8E+2 3E-7 1E-9 Y, see 99mRh 2E+2 6E-8 2E-10 45 Rhodium-102m D, see 99mRh 1E+3 5E+2 2E-7 7E-10 LLI wall (1E+3) 2E-5 2E-4 W, see 99mRh 4E+2 2E-7 5E-10 Y, see 99mRh 1E+2 5E-8 2E-10 45 Rhodium-102 D, see 99mRh 6E+2 9E+1 4E-8 1E-10 8E-6 8E-5 W, see 99mRh 2E+2 7E-8 2E-10 Y, see 99mRh 6E+1 2E-8 8E-11 45 Rhodium-103m2 D, see 99mRh 4E+5 1E+6 5E-4 2E-6 6E-3 6E-2 W, see 99mRh 1E+6 5E-4 2E-6 Y, see 99mRh 1E+6 5E-4 2E-6 45 Rhodium-105 D, see 99mRh 4E+3 1E+4 5E-6 2E-8 LLI wall (4E+3) 5E-5 5E-4 W, see 99mRh 6E+3 3E-6 9E-9 Y, see 99mRh 6E+3 2E-6 8E-9 45 Rhodium-106m D, see 99mRh 8E+3 3E+4 1E-5 4E-8 1E-4 1E-3 W, see 99mRh 4E+4 2E-5 5E-8 Y, see 99mRh 4E+4 1E-5 5E-8 45 Rhodium-1072 D, see 99mRh 7E+4 2E+5 1E-4 3E-7 St wall (9E+4) 1E-3 1E-2 W, see 99mRh 3E+5 1E-4 4E-7 Y, see 99mRh 3E+5 1E-4 3E-7 46 Palladium-100 D, all compounds except those given for W and Y 1E+3 1E+3 6E-7 2E-9 2E-5 2E-4 W, nitrates 1E+3 5E-7 2E-9 Y, oxides and hydroxides 1E+3 6E-7 2E-9 46 Palladium-101 D, see 100Pd 1E+4 3E+4 1E-5 5E-8 2E-4 2E-3
Volume 20, Issue 7 Page 368 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking W, see 100Pd 3E+4 1E-5 5E-8 Y, see 100Pd 3E+4 1E-5 4E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 46 Palladium-103 D, see 100Pd 6E+3 6E+3 3E-6 9E-9 LLI wall (7E+3) 1E-4 1E-3 W, see 100Pd 4E+3 2E-6 6E-9 Y, see 100Pd 4E+3 1E-6 5E-9 46 Palladium-107 D, see 100Pd 3E+4 2E+4 9E-6 LLI wall Kidneys (4E+4)
(2E+4) 3E-8 5E-4 5E-3 W, see 100Pd 7E+3 3E-6 1E-8 Y, see 100Pd 4E+2 2E-7 6E-10 46 Palladium-109 D, see 100Pd 2E+3 6E+3 3E-6 9E-9 3E-5 3E-4 W, see 100Pd 5E+3 2E-6 8E-9 Y, see,100Pd 5E+3 2E-6 6E-9 47 Silver-1022 D, all compounds except those given for W and Y 5E+4 2E+5 8E-5 2E-7 St wall (6E+4) 9E-4 9E-3 W, nitrates and sulfides 2E+5 9E-5 3E-7 Y, oxides and hydroxides 2E+5 8E-5 3E-7 47 Silver-1032 D, see 102Ag 4E+4 1E+5 4E-5 1E-7 5E-4 5E-3 W, see 102Ag 1E+5 5E-5 2E-7 Y, see 102Ag 1E+5 5E-5 2E-7 47 Silver-104m2 D, see 102Ag 3E+4 9E+4 4E-5 1E-7 4E-4 4E-3 W, see 102Ag 1E+5 5E-5 2E-7 Y, see 102Ag 1E+5 5E-5 2E-7 47 Silver-1042 D, see 102Ag 2E+4 7E+4 3E-5 1E-7 3E-4 3E-3 W, see 102Ag 1E+5 6E-5 2E-7 Y, see 102Ag 1E+5 6E-5 2E-7 47 Silver-105 D, see 102Ag 3E+3 1E+3 4E-7 1E-9 4E-5 4E-4 W, see 102Ag 2E+3 7E-7 2E-9 Y, see 102Ag 2E+3 7E-7 2E-9 47 Silver-106m D, see 102Ag 8E+2 7E+2 3E-7 1E-9 1E-5 1E-4 W, see 102Ag 9E+2 4E-7 1E-9 Y, see 102Ag 9E+2 4E-7 1E-9 47 Silver-1062 D, see 102Ag 6E+4 2E+5 8E-5 3E-7
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 369 Volume 20, Issue 7 St Wall (6E+4) 9E-4 9E-3 W, see 102Ag 2E+5 9E-5 3E-7 Y, see 102Ag 2E+5 8E-5 3E-7 47 Silver-108m D, see 102Ag 6E+2 2E+2 8E-8 3E-10 9E-6 9E-5 W, see 102Ag 3E+2 1E-7 4E-10 Y, see 102Ag 2E+1 1E-8 3E-11 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 47 Silver-110m D, see 102Ag 5E+2 1E+2 5E-8 2E-10 6E-6 6E-5 W, see 102Ag 2E+2 8E-8 3E-10 Y, see 102Ag 9E+1 4E-8 1E-10 47 Silver-111 D, see 102Ag 9E+2 2E+3 6E-7 LLI wall Liver (1E+3)
(2E+3) 2E-9 2E-5 2E-4 W, see 102Ag 9E+2 4E-7 1E-9 Y, see 102Ag 9E+2 4E-7 1E-9 47 Silver-112 D, see 102Ag 3E+3 8E+3 3E-6 1E-8 4E-5 4E-4 W, see 102Ag 1E+4 4E-6 1E-8 Y, see 102Ag 9E+3 4E-6 1E-8 47 Silver-1152 D, see 102Ag 3E+4 9E+4 4E-5 1E-7 St wall (3E+4) 4E-4 4E-3 W, see 102Ag 9E+4 4E-5 1E-7 Y, see 102Ag 8E+4 3E-5 1E-7 48 Cadmium-1042 D, all compounds except those given for W and Y 2E+4 7E+4 3E-5 9E-8 3E-4 3E-3 W, sulfides, halides, and nitrates 1E+5 5E-5 2E-7 Y, oxides and hydroxides 1E+5 5E-5 2E-7 48 Cadmium-107 D, see 104Cd 2E+4 5E+4 2E-5 8E-8 3E-4 3E-3 W, see 104Cd 6E+4 2E-5 8E-8 Y, see 104Cd 5E+4 2E-5 7E-8 48 Cadmium-109 D, see 104Cd 3E+2 4E+1 1E-8 Kidneys Kidneys (4E+2)
(5E+1) 7E-11 6E-6 6E-5 W, see 104Cd 1E+2 5E-8 Kidneys (1E+2) 2E-10 Y, see 104Cd 1E+2 5E-8 2E-10 48 Cadmium-113m D, see 104Cd 2E+1 2E+0 1E-9 Kidneys Kidneys
Volume 20, Issue 7 Page 370 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (4E+1)
(4E+0) 5E-12 5E-7 5E-6 W, see 104Cd 8E+0 4E-9 Kidneys (1E+1) 2E-11 Y, see 104Cd 1E+1 5E-9 2E-11 48 Cadmium-113 D, see 104Cd 2E+1 2E+0 9E-10 Kidneys Kidneys (3E+1)
(3E+0) 5E-12 4E-7 4E-6 W, see 104Cd 8E+0 3E-9 Kidneys (1E+1) 2E-11 Y, see 104Cd 1E+1 6E-9 2E-11 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 48 Cadmium-115m D, see 104Cd 3E+2 5E+1 2E-8 4E-6 4E-5 Kidneys (8E+1) 1E-10 W, see 104Cd 1E+2 5E-8 2E-10 Y, see 104Cd 1E+2 6E-8 2E-10 48 Cadmium-115 D, see 104Cd 9E+2 1E+3 6E-7 2E-9 LLI wall (1E+3) 1E-5 1E-4 W, see 104Cd 1E+3 5E-7 2E-9 Y, see 104Cd 1E+3 6E-7 2E-9 48 Cadmium-117m D, see 104Cd 5E+3 1E+4 5E-6 2E-8 6E-5 6E-4 W, see 104Cd 2E+4 7E-6 2E-8 Y, see 104Cd 1E+4 6E-6 2E-8 48 Cadmium-117 D, see 104Cd 5E+3 1E+4 5E-6 2E-8 6E-5 6E-4 W, see 104Cd 2E+4 7E-6 2E-8 Y, see 104Cd 1E+4 6E-6 2E-8 49 Indium-109 D, all compounds except those given for W 2E+4 4E+4 2E-5 6E-8 3E-4 3E-3 W, oxides, hydroxides, halides, and nitrates 6E+4 3E-5 9E-8 49 Indium-1102 D, see 109In 2E+4 4E+4 2E-5 6E-8 2E-4 2E-3 (69.1 min)
W, see 109In 6E+4 2E-5 8E-8 49 Indium-110 D, see 109In 5E+3 2E+4 7E-6 2E-8 7E-5 7E-4 (4.9 h)
W, see 109In 2E+4 8E-6 3E-8 49 Indium-111 D, see 109In 4E+3 6E+3 3E-6 9E-9 6E-5 6E-4 W, see 109In 6E+3 3E-6 9E-9 49 Indium-1122 D, see 109In 2E+5 6E+5 3E-4 9E-7 2E-3 2E-2 W, see 109In 7E+5 3E-4 1E-6 49 Indium-113m2 D, see 109In 5E+4 1E+5 6E-5 2E-7 7E-4 7E-3
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 371 Volume 20, Issue 7 W, see 109In 2E+5 8E-5 3E-7 49 Indium-114m D, see 109In 3E+2 6E+1 3E-8 9E-11 LLI wall (4E+2) 5E-6 5E-5 W, see 109In 1E+2 4E-8 1E-10 49 Indium-115m D, see 109In 1E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 109In 5E+4 2E-5 7E-8 49 Indium-115 D, see 109In 4E+1 1E+0 6E-10 2E-12 5E-7 5E-6 W, see 109In 5E+0 2E-9 8E-12 49 Indium-116m2 D, see 109In 2E+4 8E+4 3E-5 1E-7 3E-4 3E-3 W, see 109In 1E+5 5E-5 2E-7 49 Indium-117m2 D, see 109In 1E+4 3E+4 1E-5 5E-8 2E-4 2E-3 W, see 109In 4E+4 2E-5 6E-8 49 Indium-1172 D, see 109In 6E+4 2E+5 7E-5 2E-7 8E-4 8E-3 W, see 109In 2E+5 9E-5 3E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 49 Indium-119m2 D, see 109In 4E+4 1E+5 5E-5 2E-7 St wall (5E+4) 7E-4 7E-3 W, see 109In 1E+5 6E-5 2E-7 50 Tin-110 D, all compounds except those given for W 4E+3 1E+4 5E-6 2E-8 5E-5 5E-4 W, sulfides, oxides, hydroxides, halides, nitrates, and stannic phosphate 1E+4 5E-6 2E-8 50 Tin-1112 D, see 110Sn 7E+4 2E+5 9E-5 3E-7 1E-3 1E-2 W, see 110Sn 3E+5 1E-4 4E-7 50 Tin-113 D, see 110Sn 2E+3 1E+3 5E-7 2E-9 LLI wall (2E+3) 3E-5 3E-4 W, see 110Sn 5E+2 2E-7 8E-10 50 Tin-117m D, see 110Sn 2E+3 1E+3 5E-7 LLI wall Bone surf (2E+3)
(2E+3) 3E-9 3E-5 3E-4 W, see 110Sn 1E+3 6E-7 2E-9 50 Tin-119m D, see 110Sn 3E+3 2E+3 1E-6 3E-9 LLI wall (4E+3) 6E-5 6E-4 W, see 110Sn 1E+3 4E-7 1E-9 50 Tin-121m D, see 110Sn 3E+3 9E+2 4E-7 1E-9 LLI wall
Volume 20, Issue 7 Page 372 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (4E+3) 5E-5 5E-4 W, see 110Sn 5E+2 2E-7 8E-10 50 Tin-121 D, see 110Sn 6E+3 2E+4 6E-6 2E-8 LLI wall (6E+3) 8E-5 8E-4 W, see 110Sn 1E+4 5E-6 2E-8 50 Tin-123m2 D, see 110Sn 5E+4 1E+5 5E-5 2E-7 7E-4 7E-3 W, see 110Sn 1E+5 6E-5 2E-7 50 Tin-123 D, see 110Sn 5E+2 6E+2 3E-7 9E-10 LLI wall (6E+2) 9E-6 9E-5 W, see 110Sn 2E+2 7E-8 2E-10 50 Tin-125 D, see 110Sn 4E+2 9E+2 4E-7 1E-9 LLI wall (5E+2) 6E-6 6E-5 W, see 110Sn 4E+2 1E-7 5E-10 50 Tin-126 D, see 110Sn 3E+2 6E+1 2E-8 8E-11 4E-6 4E-5 W, see 110Sn 7E+1 3E-8 9E-11 50 Tin-127 D, see 110Sn 7E+3 2E+4 8E-6 3E-8 9E-5 9E-4 W, see 110Sn 2E+4 8E-6 3E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 50 Tin-1282 D, see 110Sn 9E+3 3E+4 1E-5 4E-8 1E-4 1E-3 W, see 110Sn 4E+4 1E-5 5E-8 51 Antimony-1152 D, all compounds except those given for W 8E+4 2E+5 1E-4 3E-7 1E-3 1E-2 W, oxides, hydroxides, halides, sulfides, sulfates, and nitrates 3E+5 1E-4 4E-7 51 Antimony-116m2 D, see 115Sb 2E+4 7E+4 3E-5 1E-7 3E-4 3E-3 W, see 115Sb 1E+5 6E-5 2E-7 51 Antimony-1162 D, see 115Sb 7E+4 3E+5 1E-4 4E-7 St wall (9E+4) 1E-3 1E-2 W, see 115Sb 3E+5 1E-4 5E-7 51 Antimony-117 D, see 115Sb 7E+4 2E+5 9E-5 3E-7 9E-4 9E-3 W, see 115Sb 3E+5 1E-4 4E-7 51 Antimony-118m D, see 115Sb 6E+3 2E+4 8E-6 3E-8 7E-5 7E-4 W, see 115Sb 5E+3 2E+4 9E-6 3E-8 51 Antimony-119 D, see 115Sb 2E+4 5E+4 2E-5 6E-8 2E-4 2E-3 W, see 115Sb 2E+4 3E+4 1E-5 4E-8 51 Antimony-1202 D, see 115Sb 1E+5 4E+5 2E-4 6E-7 (16 min)
St wall (2E+5) 2E-3 2E-2
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 373 Volume 20, Issue 7 W, see 115Sb 5E+5 2E-4 7E-7 51 Antimony-120 D, see 115Sb 1E+3 2E+3 9E-7 3E-9 1E-5 1E-4 (5.76 d)
W, see 115Sb 9E+2 1E+3 5E-7 2E-9 51 Antimony-122 D, see 115Sb 8E+2 2E+3 1E-6 3E-9 LLI wall (8E+2) 1E-5 1E-4 W, see 115Sb 7E+2 1E+3 4E-7 2E-9 51 Antimony-124m2 D, see 115Sb 3E+5 8E+5 4E-4 1E-6 3E-3 3E-2 W, see 115Sb 2E+5 6E+5 2E-4 8E-7 51 Antimony-124 D, see 115Sb 6E+2 9E+2 4E-7 1E-9 7E-6 7E-5 W, see 115Sb 5E+2 2E+2 1E-7 3E-10 51 Antimony-125 D, see 115Sb 2E+3 2E+3 1E-6 3E-9 3E-5 3E-4 W, see 115Sb 5E+2 2E-7 7E-10 51 Antimony-126m2 D, see 115Sb 5E+4 2E+5 8E-5 3E-7 St wall (7E+4) 9E-4 9E-3 W, see 115Sb 2E+5 8E-5 3E-7 51 Antimony-126 D, see 115Sb 6E+2 1E+3 5E-7 2E-9 7E-6 7E-5 W, see 115Sb 5E+2 5E+2 2E-7 7E-10 51 Antimony-127 D, see 115Sb 8E+2 2E+3 9E-7 3E-9 LLI wall (8E+2) 1E-5 1E-4 W, see 115Sb 7E+2 9E+2 4E-7 1E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 51 Antimony-1282 D, see 115Sb 8E+4 4E+5 2E-4 5E-7 (10.4 min)
St wall (1E+5) 1E-3 1E-2 W, see 115Sb 4E+5 2E-4 6E-7 51 Antimony-128 D, see 115Sb 1E+3 4E+3 2E-6 6E-9 2E-5 2E-4 (9.01 h)
W, see 115Sb 3E+3 1E-6 5E-9 51 Antimony-129 D, see 115Sb 3E+3 9E+3 4E-6 1E-8 4E-5 4E-4 W, see 115Sb 9E+3 4E-6 1E-8 51 Antimony-1302 D, see 115Sb 2E+4 6E+4 3E-5 9E-8 3E-4 3E-3 W, see 115Sb 8E+4 3E-5 1E-7 51 Antimony-1312 D, see 115Sb 1E+4 2E+4 1E-5 Thyroid Thyroid (2E+4)
(4E+4) 6E-8 2E-4 2E-3 W, see 115Sb 2E+4 1E-5 Thyroid (4E+4) 6E-8 52 Tellurium-116 D, all compounds except those given for W 8E+3 2E+4 9E-6 3E-8 1E-4 1E-3
Volume 20, Issue 7 Page 374 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking W, oxides, hydroxides, and nitrates 3E+4 1E-5 4E-8 52 Tellurium-121m D, see 116Te 5E+2 2E+2 8E-8 Bone surf Bone surf (7E+2)
(4E+2) 5E-10 1E-5 1E-4 W, see 116Te 4E+2 2E-7 6E-10 52 Tellurium-121 D, see 116Te 3E+3 4E+3 2E-6 6E-9 4E-5 4E-4 W, see 116Te 3E+3 1E-6 4E-9 52 Tellurium-123m D, see 116Te 6E+2 2E+2 9E-8 Bone surf Bone surf (1E+3)
(5E+2) 8E-10 1E-5 1E-4 W, see 116Te 5E+2 2E-7 8E-10 52 Tellurium-123 D, see 116Te 5E+2 2E+2 8E-8 Bone surf Bone surf (1E+3)
(5E+2) 7E-10 2E-5 2E-4 W, see 116Te 4E+2 2E-7 Bone surf (1E+3) 2E-9 52 Tellurium-125m D, see 116Te 1E+3 4E+2 2E-7 Bone surf Bone surf (1E+3)
(1E+3) 1E-9 2E-5 2E-4 W, see 116Te 7E+2 3E-7 1E-9 52 Tellurium-127m D, see 116Te 6E+2 3E+2 1E-7 9E-6 9E-5 Bone surf (4E+2) 6E-10 W, see 116Te 3E+2 1E-7 4E-10 52 Tellurium-127 D, see 116Te 7E+3 2E+4 9E-6 3E-8 1E-4 1E-3 W, see 116Te 2E+4 7E-6 2E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 52 Tellurium-129m D, see 116Te 5E+2 6E+2 3E-7 9E-10 7E-6 7E-5 W, see 116Te 2E+2 1E-7 3E-10 52 Tellurium-1292 D, see 116Te 3E+4 6E+4 3E-5 9E-8 4E-4 4E-3 W, see 116Te 7E+4 3E-5 1E-7 52 Tellurium-131m D, see 116Te 3E+2 4E+2 2E-7 Thyroid Thyroid (6E+2)
(1E+3) 2E-9 8E-6 8E-5 W, see 116Te 4E+2 2E-7 Thyroid (9E+2) 1E-9 52 Tellurium-1312 D, see 116Te 3E+3 5E+3 2E-6 Thyroid Thyroid (6E+3)
(1E+4) 2E-8 8E-5 8E-4 W, see 116Te 5E+3 2E-6 Thyroid
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 375 Volume 20, Issue 7 (1E+4) 2E-8 52 Tellurium-132 D, see 116Te 2E+2 2E+2 9E-8 Thyroid Thyroid (7E+2)
(8E+2) 1E-9 9E-6 9E-5 W, see 116Te 2E+2 9E-8 Thyroid (6E+2) 9E-10 52 Tellurium-133m2 D, see 116Te 3E+3 5E+3 2E-6 Thyroid Thyroid (6E+3)
(1E+4) 2E-8 9E-5 9E-4 W, see 116Te 5E+3 2E-6 Thyroid (1E+4) 2E-8 52 Tellurium-1332 D, see 116Te 1E+4 2E+4 9E-6 Thyroid Thyroid (3E+4)
(6E+4) 8E-8 4E-4 4E-3 W, see 116Te 2E+4 9E-6 Thyroid (6E+4) 8E-8 52 Tellurium-1342 D, see 116Te 2E+4 2E+4 1E-5 Thyroid Thyroid (2E+4)
(5E+4) 7E-8 3E-4 3E-3 W, see 116Te 2E+4 1E-5 Thyroid (5E+4) 7E-8 53 Iodine-120m2 D, all compounds 1E+4 2E+4 9E-6 3E-8 Thyroid (1E+4) 2E-4 2E-3 53 Iodine-1202 D, all compounds 4E+3 9E+3 4E-6 Thyroid Thyroid (8E+3)
(1E+4) 2E-8 1E-4 1E-3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 53 Iodine-121 D, all compounds 1E+4 2E+4 8E-6 Thyroid Thyroid (3E+4)
(5E+4) 7E-8 4E-4 4E-3 53 Iodine-123 D, all compounds 3E+3 6E+3 3E-6 Thyroid Thyroid (1E+4)
(2E+4) 2E-8 1E-4 1E-3 53 Iodine-124 D, all compounds 5E+1 8E+1 3E-8 Thyroid Thyroid (2E+2)
(3E+2) 4E-10 2E-6 2E-5 53 Iodine-125 D, all compounds 4E+1 6E+1 3E-8 Thyroid Thyroid (1E+2)
(2E+2) 3E-10 2E-6 2E-5 53 Iodine-126 D, all compounds 2E+1 4E+1 1E-8 Thyroid Thyroid
Volume 20, Issue 7 Page 376 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (7E+1)
(1E+2) 2E-10 1E-6 1E-5 53 Iodine-1282 D, all compounds 4E+4 1E+5 5E-5 2E-7 St wall (6E+4) 8E-4 8E-3 53 Iodine-129 D, all compounds 5E+0 9E+0 4E-9 Thyroid Thyroid (2E+1)
(3E+1) 4E-11 2E-7 2E-6 53 Iodine-130 D, all compounds 4E+2 7E+2 3E-7 Thyroid Thyroid (1E+3)
(2E+3) 3E-9 2E-5 2E-4 53 Iodine-131 D, all compounds 3E+1 5E+1 2E-8 Thyroid Thyroid (9E+1)
(2E+2) 2E-10 1E-6 1E-5 53 Iodine-132m2 D, all compounds 4E+3 8E+3 4E-6 Thyroid Thyroid (1E+4)
(2E+4) 3E-8 1E-4 1E-3 53 Iodine-132 D, all compounds 4E+3 8E+3 3E-6 Thyroid Thyroid (9E+3)
(1E+4) 2E-8 1E-4 1E-3 53 Iodine-133 D, all compounds 1E+2 3E+2 1E-7 Thyroid Thyroid (5E+2)
(9E+2) 1E-9 7E-6 7E-5 53 Iodine-1342 D, all compounds 2E+4 5E+4 2E-5 6E-8 Thyroid (3E+4) 4E-4 4E-3 53 Iodine-135 D, all compounds 8E+2 2E+3 7E-7 Thyroid Thyroid (3E+3)
(4E+3) 6E-9 3E-5 3E-4 54 Xenon-1202 Submersion1 1E-5 4E-8 54 Xenon-1212 Submersion1 2E-6 1E-8 54 Xenon-122 Submersion1 7E-5 3E-7 54 Xenon-123 Submersion1 6E-6 3E-8 54 Xenon-125 Submersion1 2E-5 7E-8 54 Xenon-127 Submersion1 1E-5 6E-8 54 Xenon-129m Submersion1 2E-4 9E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 54 Xenon-131m Submersion1 4E-4 2E-6 54 Xenon-133m Submersion1 1E-4 6E-7 54 Xenon-133 Submersion1 1E-4 5E-7 54 Xenon-135m2 Submersion1 9E-6 4E-8 54 Xenon-135 Submersion1 1E-5 7E-8 54 Xenon-1382 Submersion1 4E-6 2E-8 55 Cesium-1252 D, all compounds 5E+4 1E+5 6E-5 2E-7 St wall (9E+4) 1E-3 1E-2
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 377 Volume 20, Issue 7 55 Cesium-127 D, all compounds 6E+4 9E+4 4E-5 1E-7 9E-4 9E-3 55 Cesium-129 D, all compounds 2E+4 3E+4 1E-5 5E-8 3E-4 3E-3 55 Cesium-1302 D, all compounds 6E+4 2E+5 8E-5 3E-7 St wall (1E+5) 1E-3 1E-2 55 Cesium-131 D, all compounds 2E+4 3E+4 1E-5 4E-8 3E-4 3E-3 55 Cesium-132 D, all compounds 3E+3 4E+3 2E-6 6E-9 4E-5 4E-4 55 Cesium-134m D, all compounds 1E+5 1E+5 6E-5 2E-7 St wall (1E+5) 2E-3 2E-2 55 Cesium-134 D, all compounds 7E+1 1E+2 4E-8 2E-10 9E-7 9E-6 55 Cesium-135m2 D, all compounds 1E+5 2E+5 8E-5 3E-7 1E-3 1E-2 55 Cesium-135 D, all compounds 7E+2 1E+3 5E-7 2E-9 1E-5 1E-4 55 Cesium-136 D, all compounds 4E+2 7E+2 3E-7 9E-10 6E-6 6E-5 55 Cesium-137 D, all compounds 1E+2 2E+2 6E-8 2E-10 1E-6 1E-5 55 Cesium-1382 D, all compounds 2E+4 6E+4 2E-5 8E-8 St wall (3E+4) 4E-4 4E-3 56 Barium-1262 D, all compounds 6E+3 2E+4 6E-6 2E-8 8E-5 8E-4 56 Barium-128 D, all compounds 5E+2 2E+3 7E-7 2E-9 7E-6 7E-5 56 Barium-131m2 D, all compounds 4E+5 1E+6 6E-4 2E-6 St wall (5E+5) 7E-3 7E-2 56 Barium-131 D, all compounds 3E+3 8E+3 3E-6 1E-8 4E-5 4E-4 56 Barium-133m D, all compounds 2E+3 9E+3 4E-6 1E-8 LLI wall (3E+3) 4E-5 4E-4 56 Barium-133 D, all compounds 2E+3 7E+2 3E-7 9E-10 2E-5 2E-4 56 Barium-135m D, all compounds 3E+3 1E+4 5E-6 2E-8 4E-5 4E-4 56 Barium-1392 D, all compounds 1E+4 3E+4 1E-5 4E-8 2E-4 2E-3 56 Barium-140 D, all compounds 5E+2 1E+3 6E-7 2E-9 LLI wall (6E+2) 8E-6 8E-5 56 Barium-1412 D, all compounds 2E+4 7E+4 3E-5 1E-7 3E-4 3E-3 56 Barium-1422 D, all compounds 5E+4 1E+5 6E-5 2E-7 7E-4 7E-3 57 Lanthanum-1312 D, all compounds except those given for W 5E+4 1E+5 5E-5 2E-7 6E-4 6E-3 W, oxides and hydroxides 2E+5 7E-5 2E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 57 Lanthanum-132 D, see 131La 3E+3 1E+4 4E-6 1E-8 4E-5 4E-4 W, see 131La 1E+4 5E-6 2E-8 57 Lanthanum-135 D, see 131La 4E+4 1E+5 4E-5 1E-7 5E-4 5E-3 W, see 131La 9E+4 4E-5 1E-7 57 Lanthanum-137 D, see 131La 1E+4 6E+1 3E-8 2E-4 2E-3 Liver
Volume 20, Issue 7 Page 378 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (7E+1) 1E-10 W, see 131La 3E+2 1E-7 Liver (3E+2) 4E-10 57 Lanthanum-138 D, see 131La 9E+2 4E+0 1E-9 5E-12 1E-5 1E-4 W, see 131La 1E+1 6E-9 2E-11 57 Lanthanum-140 D, see 131La 6E+2 1E+3 6E-7 2E-9 9E-6 9E-5 W, see 131La 1E+3 5E-7 2E-9 57 Lanthanum-141 D, see 131La 4E+3 9E+3 4E-6 1E-8 5E-5 5E-4 W, see 131La 1E+4 5E-6 2E-8 57 Lanthanum-1422 D, see 131La 8E+3 2E+4 9E-6 3E-8 1E-4 1E-3 W, see 131La 3E+4 1E-5 5E-8 57 Lanthanum-1432 D, see 131La 4E+4 1E+5 4E-5 1E-7 St wall (4E+4) 5E-4 5E-3 W, see 131La 9E+4 4E-5 1E-7 58 Cerium-134 W, all compounds except those given for Y 5E+2 7E+2 3E-7 1E-9 LLI wall (6E+2) 8E-6 8E-5 Y, oxides, hydroxides, and fluorides 7E+2 3E-7 9E-10 58 Cerium-135 W, see 134Ce 2E+3 4E+3 2E-6 5E-9 2E-5 2E-4 Y, see 134Ce 4E+3 1E-6 5E-9 58 Cerium-137m W, see 134Ce 2E+3 4E+3 2E-6 6E-9 LLI wall (2E+3) 3E-5 3E-4 Y, see 134Ce 4E+3 2E-6 5E-9 58 Cerium-137 W, see 134Ce 5E+4 1E+5 6E-5 2E-7 7E-4 7E-3 Y, see 134Ce 1E+5 5E-5 2E-7 58 Cerium-139 W, see 134Ce 5E+3 8E+2 3E-7 1E-9 7E-5 7E-4 Y, see 134Ce 7E+2 3E-7 9E-10 58 Cerium-141 W, see 134Ce 2E+3 7E+2 3E-7 1E-9 LLI wall (2E+3) 3E-5 3E-4 Y, see 134Ce 6E+2 2E-7 8E-10 58 Cerium-143 W, see 134Ce 1E+3 2E+3 8E-7 3E-9 LLI wall (1E+3) 2E-5 2E-4 Y, see 134Ce 2E+3 7E-7 2E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 58 Cerium-144 W, see 134Ce 2E+2 3E+1 1E-8 4E-11 LLI wall (3E+2) 3E-6 3E-5
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 379 Volume 20, Issue 7 Y, see 134Ce 1E+1 6E-9 2E-11 59 Praseodymium-1362 W, all compounds except those given for Y 5E+4 2E+5 1E-4 3E-7 St wall (7E+4) 1E-3 1E-2 Y, oxides, hydroxides, carbides, and fluorides 2E+5 9E-5 3E-7 59 Praseodymium-1372 W, see 136Pr 4E+4 2E+5 6E-5 2E-7 5E-4 5E-3 Y, see 136Pr 1E+5 6E-5 2E-7 59 Praseodymium-138m W, see 136Pr 1E+4 5E+4 2E-5 8E-8 1E-4 1E-3 Y, see 136Pr 4E+4 2E-5 6E-8 59 Praseodymium-139 W, see 136Pr 4E+4 1E+5 5E-5 2E-7 6E-4 6E-3 Y, see 136Pr 1E+5 5E-5 2E-7 59 Praseodymium-142m2 W, see 136Pr 8E+4 2E+5 7E-5 2E-7 1E-3 1E-2 Y, see 136Pr 1E+5 6E-5 2E-7 59 Praseodymium-142 W, see 136Pr 1E+3 2E+3 9E-7 3E-9 1E-5 1E-4 Y, see 136Pr 2E+3 8E-7 3E-9 59 Praseodymium-143 W, see 136Pr 9E+2 8E+2 3E-7 1E-9 LLI wall (1E+3) 2E-5 2E-4 Y, see 136Pr 7E+2 3E-7 9E-10 59 Praseodymium-1442 W, see 136Pr 3E+4 1E+5 5E-5 2E-7 St wall (4E+4) 6E-4 6E-3 Y, see 136Pr 1E+5 5E-5 2E-7 59 Praseodymium-145 W, see 136Pr 3E+3 9E+3 4E-6 1E-8 4E-5 4E-4 Y, see 136Pr 8E+3 3E-6 1E-8 59 Praseodymium-1472 W, see 136Pr 5E+4 2E+5 8E-5 3E-7 St wall (8E+4) 1E-3 1E-2 Y, see 136Pr 2E+5 8E-5 3E-7 60 Neodymium-1362 W, all compounds except those given for Y 1E+4 6E+4 2E-5 8E-8 2E-4 2E-3 Y, oxides, hydroxides, carbides, and fluorides 5E+4 2E-5 8E-8 60 Neodymium-138 W, see 136Nd 2E+3 6E+3 3E-6 9E-9 3E-5 3E-4 Y, see 136Nd 5E+3 2E-6 7E-9 60 Neodymium-139m W, see 136Nd 5E+3 2E+4 7E-6 2E-8 7E-5 7E-4 Y, see 136Nd 1E+4 6E-6 2E-8 60 Neodymium-1392 W, see 136Nd 9E+4 3E+5 1E-4 5E-7 1E-3 1E-2 Y, see 136Nd 3E+5 1E-4 4E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
Volume 20, Issue 7 Page 380 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 60 Neodymium-141 W, see 136Nd 2E+5 7E+5 3E-4 1E-6 2E-3 2E-2 Y, see 136Nd 6E+5 3E-4 9E-7 60 Neodymium-147 W, see 136Nd 1E+3 9E+2 4E-7 1E-9 LLI wall (1E+3) 2E-5 2E-4 Y, see 136Nd 8E+2 4E-7 1E-9 60 Neodymium-1492 W, see 136Nd 1E+4 3E+4 1E-5 4E-8 1E-4 1E-3 Y, see 136Nd 2E+4 1E-5 3E-8 60 Neodymium-1512 W, see 136Nd 7E+4 2E+5 8E-5 3E-7 9E-4 9E-3 Y, see 136Nd 2E+5 8E-5 3E-7 61 Promethium-1412 W, all compounds except those given for Y 5E+4 2E+5 8E-5 3E-7 St wall (6E+4) 8E-4 8E-3 Y, oxides, hydroxides, carbides, and fluorides 2E+5 7E-5 2E-7 61 Promethium-143 W, see 141Pm 5E+3 6E+2 2E-7 8E-10 7E-5 7E-4 Y, see 141Pm 7E+2 3E-7 1E-9 61 Promethium-144 W, see 141Pm 1E+3 1E+2 5E-8 2E-10 2E-5 2E-4 Y, see 141Pm 1E+2 5E-8 2E-10 61 Promethium-145 W, see 141Pm 1E+4 2E+2 7E-8 1E-4 1E-3 Bone surf (2E+2) 3E-10 Y, see 141Pm 2E+2 8E-8 3E-10 61 Promethium-146 W, see 141Pm 2E+3 5E+1 2E-8 7E-11 2E-5 2E-4 Y see 141Pm 4E+1 2E-8 6E-11 61 Promethium-147 W see 141Pm 4E+3 1E+2 5E-8 LLI wall Bone surf (5E+3)
(2E+2) 3E-10 7E-5 7E-4 Y, see 141Pm 1E+2 6E-8 2E-10 61 Promethium-148m W, see 141Pm 7E+2 3E+2 1E-7 4E-10 1E-5 1E-4 Y, see 141Pm 3E+2 1E-7 5E-10 61 Promethium-148 W, see 141Pm 4E+2 5E+2 2E-7 8E-10 LLI wall (5E+2) 7E-6 7E-5 Y, see 141Pm 5E+2 2E-7 7E-10 0
LLI wall (1E+3) 2E-5 2E-4 Y, see 141Pm 2E+3 8E-7 2E-9 61 Promethium-150 W, see 141Pm 5E+3 2E+4 8E-6 3E-8 7E-5 7E-4 Y, see 141Pm 2E+4 7E-6 2E-8 61 Promethium-151 W, see 141Pm 2E+3 4E+3 1E-6 5E-9 2E-5 2E-4 Y, see 141Pm 3E+3 1E-6 4E-9 62 Samarium-141m2 W, all compounds 3E+4 1E+5 4E-5 1E-7 4E-4 4E-3
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 381 Volume 20, Issue 7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 62 Samarium-1412 W, all compounds 5E+4 2E+5 8E-5 2E-7 St wall (6E+4) 8E-4 8E-3 62 Samarium-1422 W, all compounds 8E+3 3E+4 1E-5 4E-8 1E-4 1E-3 62 Samarium-145 W, all compounds 6E+3 5E+2 2E-7 7E-10 8E-5 8E-4 62 Samarium-146 W, all compounds 1E+1 4E2 1E-11 Bone surf Bone surf (3E+1)
(6E-2) 9E-14 3E-7 3E-6 62 Samarium-147 W, all compounds 2E+1 4E2 2E-11 Bone surf Bone surf (3E+1)
(7E-2) 1E-13 4E-7 4E-6 62 Samarium-151 W, all compounds 1E+4 1E+2 4E-8 LLI wall Bone surf (1E+4)
(2E+2) 2E-10 2E-4 2E-3 62 Samarium-153 W, all compounds 2E+3 3E+3 1E-6 4E-9 LLI wall (2E+3) 3E-5 3E-4 62 Samarium-1552 W, all compounds 6E+4 2E+5 9E-5 3E-7 St wall (8E+4) 1E-3 1E-2 62 Samarium-156 W, all compounds 5E+3 9E+3 4E-6 1E-8 7E-5 7E-4 63 Europium-145 W, all compounds 2E+3 2E+3 8E-7 3E-9 2E-5 2E-4 63 Europium-146 W, all compounds 1E+3 1E+3 5E-7 2E-9 1E-5 1E-4 63 Europium-147 W, all compounds 3E+3 2E+3 7E-7 2E-9 4E-5 4E-4 63 Europium-148 W, all compounds 1E+3 4E+2 1E-7 5E-10 1E-5 1E-4 63 Europium-149 W, all compounds 1E+4 3E+3 1E-6 4E-9 2E-4 2E-3 63 Europium-150 W, all compounds 3E+3 8E+3 4E-6 1E-8 4E-5 4E-4 (12.62 h) 63 Europium-150 W, all compounds 8E+2 2E+1 8E-9 3E-11 1E-5 1E-4 (34.2 y) 63 Europium-152m W, all compounds 3E+3 6E+3 3E-6 9E-9 4E-5 4E-4 63 Europium-152 W, all compounds 8E+2 2E+1 1E-8 3E-11 1E-5 1E-4 63 Europium-154 W, all compounds 5E+2 2E+1 8E-9 3E-11 7E-6 7E-5 63 Europium-155 W, all compounds 4E+3 9E+1 4E-8 5E-5 5E-4 Bone surf (1E+2) 2E-10 63 Europium-156 W, all compounds 6E+2 5E+2 2E-7 6E-10 8E-6 8E-5 63 Europium-157 W, all compounds 2E+3 5E+3 2E-6 7E-9 3E-5 3E-4 63 Europium-1582 W, all compounds 2E+4 6E+4 2E-5 8E-8 3E-4 3E-3 64 Gadolinium-1452 D, all compounds except those given for W 5E+4 2E+5 6E-5 2E-7 St wall (5E+4) 6E-4 6E-3 W, oxides, hydroxides, and fluorides 2E+5 7E-5 2E-7 64 Gadolinium-146 D, see 145Gd 1E+3 1E+2 5E-8 2E-10 2E-5 2E-4 W, see 145Gd 3E+2 1E-7 4E-10 64 Gadolinium-147 D, see 145Gd 2E+3 4E+3 2E-6 6E-9 3E-5 3E-4
Volume 20, Issue 7 Page 382 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking W, see 145Gd 4E+3 1E-6 5E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 64 Gadolinium-148 D, see 145Gd 1E+1 8E+3 3E-12 Bone surf Bone surf (2E+1)
(2E+2) 2E-14 3E-7 3E-6 W, see 145Gd 3E-2 1E-11 Bone surf (6E-2) 8E-14 64 Gadolinium-149 D, see 145Gd 3E+3 2E+3 9E-7 3E-9 4E-5 4E-4 W, see 145Gd 2E+3 1E-6 3E-9 64 Gadolinium-151 D, see 145Gd 6E+3 4E+2 2E-7 9E-5 9E-4 Bone surf (6E+2) 9E-10 W, see 145Gd 1E+3 5E-7 2E-9 64 Gadolinium-152 D, see 145Gd 2E+1 1E-2 4E-12 Bone surf Bone surf (3E+1)
(2E-2) 3E-14 4E-7 4E-6 W, see 145Gd 4E-2 2E-11 Bone surf (8E-2) 1E-13 64 Gadolinium-153 D, see 145Gd 5E+3 1E+2 6E-8 6E-5 6E-4 Bone surf (2E+2) 3E-10 W, see 145Gd 6E+2 2E-7 8E-10 64 Gadolinium-159 D, see 145Gd 3E+3 8E+3 3E-6 1E-8 4E-5 4E-4 W, see 145Gd 6E+3 2E-6 8E-9 65 Terbium-1472 W, all compounds 9E+3 3E+4 1E-5 5E-8 1E-4 1E-3 65 Terbium-149 W, all compounds 5E+3 7E+2 3E-7 1E-9 7E-5 7E-4 65 Terbium-150 W, all compounds 5E+3 2E+4 9E-6 3E-8 7E-5 7E-4 65 Terbium-151 W, all compounds 4E+3 9E+3 4E-6 1E-8 5E-5 5E-4 65 Terbium-153 W, all compounds 5E+3 7E+3 3E-6 1E-8 7E-5 7E-4 65 Terbium-154 W, all compounds 2E+3 4E+3 2E-6 6E-9 2E-5 2E-4 65 Terbium-155 W, all compounds 6E+3 8E+3 3E-6 1E-8 8E-5 8E-4 65 Terbium-156m W, all compounds 2E+4 3E+4 1E-5 4E-8 2E-4 2E-3 (5.0 h) 65 Terbium-156m W, all compounds 7E+3 8E+3 3E-6 1E-8 1E-4 1E-3 (24.4 h) 65 Terbium-156 W, all compounds 1E+3 1E+3 6E-7 2E-9 1E-5 1E-4 65 Terbium-157 W, all compounds 5E+4 3E+2 1E-7 LLI wall Bone surf (5E+4)
(6E+2) 8E-10 7E-4 7E-3 65 Terbium-158 W, all compounds 1E+3 2E+1 8E-9 3E-11 2E-5 2E-4 65 Terbium-160 W, all compounds 8E+2 2E+2 9E-8 3E-10 1E-5 1E-4 65 Terbium-161 W, all compounds 2E+3 2E+3 7E-7 2E-9 LLI wall
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 383 Volume 20, Issue 7 (2E+3) 3E-5 3E-4 66 Dysprosium-155 W, all compounds 9E+3 3E+4 1E-5 4E-8 1E-4 1E-3 66 Dysprosium-157 W, all compounds 2E+4 6E+4 3E-5 9E-8 3E-4 3E-3 66 Dysprosium-159 W, all compounds 1E+4 2E+3 1E-6 3E-9 2E-4 2E-3 66 Dysprosium-165 W, all compounds 1E+4 5E+4 2E-5 6E-8 2E-4 2E-3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 66 Dysprosium-166 W, all compounds 6E+2 7E+2 3E-7 1E-9 LLI wall (8E+2) 1E-5 1E-4 67 Holmium-1552 W, all compounds 4E+4 2E+5 6E-5 2E-7 6E-4 6E-3 67 Holmium-1572 W, all compounds 3E+5 1E+6 6E-4 2E-6 4E-3 4E-2 67 Holmium-1592 W, all compounds 2E+5 1E+6 4E-4 1E-6 3E-3 3E-2 67 Holmium-161 W, all compounds 1E+5 4E+5 2E-4 6E-7 1E-3 1E-2 67 Holmium-162m2 W, all compounds 5E+4 3E+5 1E-4 4E-7 7E-4 7E-3 67 Holmium-1622 W, all compounds 5E+5 2E+6 1E-3 3E-6 St wall (8E+5) 1E-2 1E-1 67 Holmium-164m2 W, all compounds 1E+5 3E+5 1E-4 4E-7 1E-3 1E-2 67 Holmium-1642 W, all compounds 2E+5 6E+5 3E-4 9E-7 St wall (2E+5) 3E-3 3E-2 67 Holmium-166m W, all compounds 6E+2 7E+0 3E-9 9E-12 9E-6 9E-5 67 Holmium-166 W, all compounds 9E+2 2E+3 7E-7 2E-9 LLI wall (9E+2) 1E-5 1E-4 67 Holmium-167 W, all compounds 2E+4 6E+4 2E-5 8E-8 2E-4 2E-3 68 Erbium-161 W, all compounds 2E+4 6E+4 3E-5 9E-8 2E-4 2E-3 68 Erbium-165 W, all compounds 6E+4 2E+5 8E-5 3E-7 9E-4 9E-3 68 Erbium-169 W, all compounds 3E+3 3E+3 1E-6 4E-9 LLI wall (4E+3) 5E-5 5E-4 68 Erbium-171 W, all compounds 4E+3 1E+4 4E-6 1E-8 5E-5 5E-4 68 Erbium-172 W, all compounds 1E+3 1E+3 6E-7 2E-9 LLI wall (E+3) 2E-5 2E-4 69 Thulium-1622 W, all compounds 7E+4 3E+5 1E-4 4E-7 St wall (7E+4) 1E-3 1E-2 69 Thulium-166 W, all compounds 4E+3 1E+4 6E-6 2E-8 6E-5 6E-4 69 Thulium-167 W, all compounds 2E+3 2E+3 8E-7 3E-9 LLI wall (2E+3) 3E-5 3E-4 69 Thulium-170 W, all compounds 8E+2 2E+2 9E-8 3E-10 LLI wall (1E+3) 1E-5 1E-4 69 Thulium-171 W, all compounds 1E+4 3E+2 1E-7 LLI wall Bone surf (1E+4)
Volume 20, Issue 7 Page 384 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 69 Thulium-172 W, all compounds 7E+2 1E+3 5E-7 2E-9 LLI wall (8E+2) 1E-5 1E-4 69 Thulium-173 W, all compounds 4E+3 1E+4 5E-6 2E-8 6E-5 6E-4 69 Thulium-1752 W, all compounds 7E+4 3E+5 1E-4 4E-7 St wall (9E+4) 1E-3 1E-2 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 70 Ytterbium-1622 W, all compounds except those given for Y 7E+4 3E+5 1E-4 4E-7 1E-3 1E-2 Y, oxides, hydroxides, and fluorides 3E+5 1E-4 4E-7 70 Ytterbium-166 W, see 162Yb 1E+3 2E+3 8E-7 3E-9 2E-5 2E-4 Y, see 162Yb 2E+3 8E-7 3E-9 70 Ytterbium-1672 W, see 162Yb 3E+5 8E+5 3E-4 1E-6 4E-3 4E-2 Y, see 162Yb 7E+5 3E-4 1E-6 70 Ytterbium-169 W, see 162Yb 2E+3 8E+2 4E-7 1E-9 2E-5 2E-4 Y, see 162Yb 7E+2 3E-7 1E-9 70 Ytterbium-175 W, see 162Yb 3E+3 4E+3 1E-6 5E-9 LLI wall (3E+3) 4E-5 4E-4 Y, see 162Yb 3E+3 1E-6 5E-9 70 Ytterbium-1772 W, see 162Yb 2E+4 5E+4 2E-5 7E-8 2E-4 2E-3 Y, see 162Yb 5E+4 2E-5 6E-8 70 Ytterbium-1782 W, see 162Yb 1E+4 4E+4 2E-5 6E-8 2E-4 2E-3 Y, see 162Yb 4E+4 2E-5 5E-8 71 Lutetium-169 W, all compounds except those given for Y 3E+3 4E+3 2E-6 6E-9 3E-5 3E-4 Y, oxides, hydroxides, and fluorides 4E+3 2E-6 6E-9 71 Lutetium-170 W, see 169Lu 1E+3 2E+3 9E-7 3E-9 2E-5 2E-4 Y, see 169Lu 2E+3 8E-7 3E-9 71 Lutetium-171 W, see 169Lu 2E+3 2E+3 8E-7 3E-9 3E-5 3E-4 Y, see 169Lu 2E+3 8E-7 3E-9 71 Lutetium-172 W, see 169Lu 1E+3 1E+3 5E-7 2E-9 1E-5 1E-4 Y, see 169Lu 1E+3 5E-7 2E-9 71 Lutetium-173 W, see 169Lu 5E+3 3E+2 1E-7 7E-5 7E-4 Bone surf (5E+2) 6E-10 Y, see 169Lu 3E+2 1E-7 4E-10 71 Lutetium-174m W, see 169Lu 2E+3 2E+2 1E-7 LLI wall Bone surf (3E+3)
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 385 Volume 20, Issue 7 Y, see 169Lu 2E+2 9E-8 3E-10 71 Lutetium-174 W, see 169Lu 5E+3 1E+2 5E-8 7E-5 7E-4 Bone surf (2E+2) 3E-10 Y, see 169Lu 2E+2 6E-8 2E-10 71 Lutetium-176m W, see 169Lu 8E+3 3E+4 1E-5 3E-8 1E-4 1E-3 Y, see 169Lu 2E+4 9E-6 3E-8 71 Lutetium-176 W, see 169Lu 7E+2 5E+0 2E-9 1E-5 1E-4 Bone surf (1E+1) 2E-11 Y, see 169Lu 8E+0 3E-9 1E-1 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 71 Lutetium-177m W, see 169Lu 7E+2 1E+2 5E-8 1E-5 1E-4 Bone surf (1E+2) 2E-10 Y, see 169Lu 8E+1 3E-8 1E-10 71 Lutetium-177 W, see 169Lu 2E+3 2E+3 9E-7 3E-9 LLI wall (3E+3) 4E-5 4E-4 Y, see 169Lu 2E+3 9E-7 3E-9 71 Lutetium-178m2 W, see 169Lu 5E+4 2E+5 8E-5 3E-7 St. wall (6E+4) 8E-4 8E-3 Y, see 169Lu 2E+5 7E-5 2E-7 71 Lutetium-1782 W, see 169Lu 4E+4 1E+5 5E-5 2E-7 St wall (4E+4) 6E-4 6E-3 Y, see 169Lu 1E+5 5E-5 2E-7 71 Lutetium-179 W, see 169Lu 6E+3 2E+4 8E-6 3E-8 9E-5 9E-4 Y, see 169Lu 2E+4 6E-6 3E-8 72 Hafnium-170 D, all compounds except those given for W 3E+3 6E+3 2E-6 8E-9 4E-5 4E-4 W, oxides, hydroxides, carbides, and nitrates 5E+3 2E-6 6E-9 72 Hafnium-172 D, see 170Hf 1E+3 9E+0 4E-9 2E-5 2E-4 Bone surf (2E+1) 3E-11 W, see 170Hf 4E+1 2E-8 Bone surf (6E+1) 8E-11 72 Hafnium-173 D, see 170Hf 5E+3 1E+4 5E-6 2E-8 7E-5 7E-4 W, see 170Hf 1E+4 5E-6 2E-8 72 Hafnium-175 D, see 170Hf 3E+3 9E+2 4E-7 4E-5 4E-4
Volume 20, Issue 7 Page 386 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Bone surf (1E+3) 1E-9 W, see 170Hf 1E+3 5E-7 2E-9 72 Hafnium-177m2 D, see 170Hf 2E+4 6E+4 2E-5 8E-8 3E-4 3E-3 W, see 170Hf 9E+4 4E-5 1E-7 72 Hafnium-178m D, see 170Hf 3E+2 1E+0 5E-10 3E-6 3E-5 Bone surf (2E+0) 3E-12 W, see 170Hf 5E+0 2E-9 Bone surf (9E+0) 1E-11 72 Hafnium-179m D, see 170Hf 1E+3 3E+2 1E-7 1E-5 1E-4 Bone surf (6E+2) 8E-10 W, see 170Hf 6E+2 3E-7 8E-10 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 72 Hafnium-180m D, see 170Hf 7E+3 2E+4 9E-6 3E-8 1E-4 1E-3 W, see 170Hf 3E+4 1E-5 4E-8 72 Hafnium-181 D, see 170Hf 1E+3 2E+2 7E-8 2E-5 2E-4 Bone surf (4E+2) 6E-10 W, see 170Hf 4E+2 2E-7 6E-10 72 Hafnium-182m2 D, see 170Hf 4E+4 9E+4 4E-5 1E-7 5E-4 5E-3 W, see 170Hf 1E+5 6E-5 2E-7 72 Hafnium-182 D, see 170Hf 2E+2 8E-1 3E-10 Bone surf Bone surf (4E+2)
(2E+0) 2E-12 5E-6 5E-5 W, see170Hf 3E+0 1E-9 Bone surf (7E+0) 1E-11 72 Hafnium-1832 D, see 170Hf 2E+4 5E+4 2E-5 6E-8 3E-4 3E-3 W, see 170Hf 6E+4 2E-5 8E-8 72 Hafnium-184 D, see 170Hf 2E+3 8E+3 3E-6 1E-8 3E-5 3E-4 W, see 170Hf 6E+3 3E-6 9E-9 73 Tantalum-1722 W, all compounds except those given for Y 4E+4 1E+5 5E-5 2E-7 5E-4 5E-3 Y, elemental Ta, oxides, hydroxides, halides, carbides, nitrates, and nitrides 1E+5 4E-5 1E-7 73 Tantalum-173 W, see 172Ta 7E+3 2E+4 8E-6 3E-8 9E-5 9E-4 Y, see 172Ta 2E+4 7E-6 2E-8 73 Tantalum-1742 W, see 172Ta 3E+4 1E+5 4E-5 1E-7 4E-4 4E-3
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 387 Volume 20, Issue 7 Y, see 172Ta 9E+4 4E-5 1E-7 73 Tantalum-175 W, see 172Ta 6E+3 2E+4 7E-6 2E-8 8E-5 8E-4 Y, see 172Ta 1E+4 6E-6 2E-8 73 Tantalum-176 W, see 172Ta 4E+3 1E+4 5E-6 2E-8 5E-5 5E-4 Y, see 172Ta 1E+4 5E-6 2E-8 73 Tantalum-177 W, see 172Ta 1E+4 2E+4 8E-6 3E-8 2E-4 2E-3 Y, see 172Ta 2E+4 7E-6 2E-8 73 Tantalum-178 W, see 172Ta 2E+4 9E+4 4E-5 1E-7 2E-4 2E-3 Y, see 172Ta 7E+4 3E-5 1E-7 73 Tantalum-179 W, see 172Ta 2E+4 5E+3 2E-6 8E-9 3E-4 3E-3 Y, see 172Ta 9E+2 4E-7 1E-9 73 Tantalum-180m W, see 172Ta 2E+4 7E+4 3E-5 9E-8 3E-4 3E-3 Y, see 172Ta 6E+4 2E-5 8E-8 73 Tantalum-180 W, see 172Ta 1E+3 4E+2 2E-7 6E-10 2E-5 2E-4 Y, see 172Ta 2E+1 1E-8 3E-11 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 73 Tantalum-182m2 W, see 172Ta 2E+5 5E+5 2E-4 8E-7 St wall (2E+5) 3E-3 3E-2 Y, see 172Ta 4E+5 2E-4 6E-7 73 Tantalum-182 W, see 172Ta 8E+2 3E+2 1E-7 5E-10 1E-5 1E-4 Y, see 172Ta 1E+2 6E-8 2E-10 73 Tantalum-183 W, see 172Ta 9E+2 1E+3 5E-7 2E-9 LLI wall (1E+3) 2E-5 2E-4 Y, see 172Ta 1E+3 4E-7 1E-9 73 Tantalum-184 W, see 172Ta 2E+3 5E+3 2E-6 8E-9 3E-5 3E-4 Y, see 172Ta 5E+3 2E-6 7E-9 73 Tantalum-1852 W, see 172Ta 3E+4 7E+4 3E-5 1E-7 4E-4 4E-3 Y, see 172Ta 6E+4 3E-5 9E-8 73 Tantalum-1862 W, see 172Ta 5E+4 2E+5 1E-4 3E-7 St wall (7E+4) 1E-3 1E-2 Y, see 172Ta 2E+5 9E-5 3E-7 74 Tungsten-176 D, all compounds 1E+4 5E+4 2E-5 7E-8 1E-4 1E-3 74 Tungsten-177 D, all compounds 2E+4 9E+4 4E-5 1E-7 3E-4 3E-3 74 Tungsten-178 D, all compounds 5E+3 2E+4 8E-6 3E-8 7E-5 7E-4 74 Tungsten-1792 D, all compounds 5E+5 2E+6 7E-4 2E-6 7E-3 7E-2 74 Tungsten-181 D, all compounds 2E+4 3E+4 1E-5 5E-8 2E-4 2E-3
Volume 20, Issue 7 Page 388 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 74 Tungsten-185 D, all compounds 2E+3 7E+3 3E-6 9E-9 LLI wall (3E+3) 4E-5 4E-4 74 Tungsten-187 D, all compounds 2E+3 9E+3 4E-6 1E-8 3E-5 3E-4 74 Tungsten-188 D, all compounds 4E+2 1E+3 5E-7 2E-9 LLI wall (5E+2) 7E-6 7E-5 75 Rhenium-1772 D, all compounds except those given for W 9E+4 3E+5 1E-4 4E-7 St wall (1E+5) 2E-3 2E-2 W, oxides, hydroxides, and nitrates 4E+5 1E-4 5E-7 75 Rhenium-1782 D, see 177Re 7E+4 3E+5 1E-4 4E-7 St wall (1E+5) 1E-3 1E-2 W, see 177Re 3E+5 1E-4 4E-7 75 Rhenium-181 D, see 177Re 5E+3 9E+3 4E-6 1E-8 7E-5 7E-4 W, see 177Re 9E+3 4E-6 1E-8 75 Rhenium-182 D, see 177Re 7E+3 1E+4 5E-6 2E-8 9E-5 9E-4 (12.7 h)
W, see 177Re 2E+4 6E-6 2E-8 75 Rhenium-182 D, see 177Re 1E+3 2E+3 1E-6 3E-9 2E-5 2E-4 (64.0 h)
W, see 177Re 2E+3 9E-7 3E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 75 Rhenium-184m D, see 177Re 2E+3 3E+3 1E-6 4E-9 3E-5 3E-4 W, see 177Re 4E+2 2E-7 6E-10 75 Rhenium-184 D, see 177Re 2E+3 4E+3 1E-6 5E-9 3E-5 3E-4 W, see 177Re 1E+3 6E-7 2E-9 75 Rhenium-186m D, see 177Re 1E+3 2E+3 7E-7 St wall St wall (2E+3)
(2E+3) 3E-9 2E-5 2E-4 W, see 177Re 2E+2 6E-8 2E-10 75 Rhenium-186 D, see 177Re 2E+3 3E+3 1E-6 4E-9 3E-5 3E-4 W, see 177Re 2E+3 7E-7 2E-9 75 Rhenium-187 D, see 177Re 6E+5 8E+5 4E-4 8E-3 8E-2 St wall (9E+5) 1E-6 W, see 177Re 1E+5 4E-5 1E-7 75 Rhenium-188m2 D, see 177Re 8E+4 1E+5 6E-5 2E-7 1E-3 1E-2 W, see 177Re 1E+5 6E-5 2E-7 75 Rhenium-188 D, see 177Re 2E+3 3E+3 1E-6 4E-9 2E-5 2E-4 W, see 177Re 3E+3 1E-6 4E-9
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 389 Volume 20, Issue 7 75 Rhenium-189 D, see 177Re 3E+3 5E+3 2E-6 7E-9 4E-5 4E-4 W, see 177Re 4E+3 2E-6 6E-9 76 Osmium-1802 D, all compounds except those given for W and Y 1E+5 4E+5 2E-4 5E-7 1E-3 1E-2 W, halides and nitrates 5E+5 2E-4 7E-7 Y, oxides and hydroxides 5E+5 2E-4 6E-7 76 Osmium-1812 D, see 180Os 1E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 180Os 5E+4 2E-5 6E-8 Y, see 180Os 4E+4 2E-5 6E-8 76 Osmium-182 D, see 180Os 2E+3 6E+3 2E-6 8E-9 3E-5 3E-4 W, see 180Os 4E+3 2E-6 6E-9 Y, see 180Os 4E+3 2E-6 6E-9 76 Osmium-185 D, see 180Os 2E+3 5E+2 2E-7 7E-10 3E-5 3E-4 W, see 180Os 8E+2 3E-7 1E-9 Y, see 180Os 8E+2 3E-7 1E-9 76 Osmium-189m D, see 180Os 8E+4 2E+5 1E-4 3E-7 1E-3 1E-2 W, see 180Os 2E+5 9E-5 3E-7 Y, see 180Os 2E+5 7E-5 2E-7 76 Osmium-191m D, see 180Os 1E+4 3E+4 1E-5 4E-8 2E-4 2E-3 W, see 180Os 2E+4 8E-6 3E-8 Y, see 180Os 2E+4 7E-6 2E-8 76 Osmium-191 D, see 180Os 2E+3 2E+3 9E-7 3E-9 LLI wall (3E+3) 3E-5 3E-4 W, see 180Os 2E+3 7E-7 2E-9 Y, see 180Os 1E+3 6E-7 2E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 76 Osmium-193 D, see 180Os 2E+3 5E+3 2E-6 6E-9 LLI wall (2E+3) 2E-5 2E-4 W, see 180Os 3E+3 1E-6 4E-9 Y, see 180Os 3E+3 1E-6 4E-9 76 Osmium-194 D, see 180Os 4E+2 4E+1 2E-8 6E-11 LLI wall (6E+2) 8E-6 8E-5 W, see 180Os 6E+1 2E-8 8E-11 Y, see 180Os 8E+0 3E-9 1E-11 77 Iridium-1822 D, all compounds except those given for W and Y 4E+4 1E+5 6E-5 2E-7 St wall (4E+4) 6E-4 6E-3 W, halides, nitrates, and
Volume 20, Issue 7 Page 390 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking metallic iridium 2E+5 6E-5 2E-7 Y, oxides and hydroxides 1E+5 5E-5 2E-7 77 Iridium-184 D, see 182Ir 8E+3 2E+4 1E-5 3E-8 1E-4 1E-3 W, see 182Ir 3E+4 1E-5 5E-8 Y, see 182Ir 3E+4 1E-5 4E-8 77 Iridium-185 D, see 182Ir 5E+3 1E+4 5E-6 2E-8 7E-5 7E-4 W, see182Ir 1E+4 5E-6 2E-8 Y, see 182Ir 1E+4 4E-6 1E-8 77 Iridium-186 D, see 182Ir 2E+3 8E+3 3E-6 1E-8 3E-5 3E-4 W, see 182Ir 6E+3 3E-6 9E-9 Y, see 182Ir 6E+3 2E-6 8E-9 77 Iridium-187 D, see 182Ir 1E+4 3E+4 1E-5 5E-8 1E-4 1E-3 W, see 182Ir 3E+4 1E-5 4E-8 Y, see 182Ir 3E+4 1E-5 4E-8 77 Iridium-188 D, see 182Ir 2E+3 5E+3 2E-6 6E-9 3E-5 3E-4 W, see 182Ir 4E+3 1E-6 5E-9 Y, see 182Ir 3E+3 1E-6 5E-9 77 Iridium-189 D, see 182Ir 5E+3 5E+3 2E-6 7E-9 LLI wall (5E+3) 7E-5 7E-4 W, see 182Ir 4E+3 2E-6 5E-9 Y, see 182Ir 4E+3 1E-6 5E-9 77 Iridium-190m2 D, see 182Ir 2E+5 2E+5 8E-5 3E-7 2E-3 2E-2 W, see 182Ir 2E+5 9E-5 3E-7 Y, see 182Ir 2E+5 8E-5 3E-7 77 Iridium-190 D, see 182Ir 1E+3 9E+2 4E-7 1E-9 1E-5 1E-4 W, see 182Ir 1E+3 4E-7 1E-9 Y, see 182Ir 9E+2 4E-7 1E-9 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 77 Iridium-192m D, see 182Ir 3E+3 9E+1 4E-8 1E-10 4E-5 4E-4 W, see 182Ir 2E+2 9E-8 3E-10 Y, see 182Ir 2E+1 6E-9 2E-11 77 Iridium-192 D, see 182Ir 9E+2 3E+2 1E-7 4E-10 1E-5 1E-4 W, see 182Ir 4E+2 2E-7 6E-10 Y, see 182Ir 2E+2 9E-8 3E-10 77 Iridium-194m D, see 182Ir 6E+2 9E+1 4E-8 1E-10 9E-6 9E-5 W, see 182Ir 2E+2 7E-8 2E-10 Y, see 182Ir 1E+2 4E-8 1E-10
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 391 Volume 20, Issue 7 77 Iridium-194 D, see 182Ir 1E+3 3E+3 1E-6 4E-9 1E-5 1E-4 W, see 182Ir 2E+3 9E-7 3E-9 Y, see 182Ir 2E+3 8E-7 3E-9 77 Iridium-195m D, see 182Ir 8E+3 2E+4 1E-5 3E-8 1E-4 1E-3 W, see 182Ir 3E+4 1E-5 4E-8 Y, see 182Ir 2E+4 9E-6 3E-8 77 Iridium-195 D, see 182Ir 1E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 182Ir 5E+4 2E-5 7E-8 Y, see 182Ir 4E+4 2E-5 6E-8 78 Platinum-186 D, all compounds 1E+4 4E+4 2E-5 5E-8 2E-4 2E-3 78 Platinum-188 D, all compounds 2E+3 2E+3 7E-7 2E-9 2E-5 2E-4 78 Platinum-189 D, all compounds 1E+4 3E+4 1E-5 4E-8 1E-4 1E-3 78 Platinum-191 D, all compounds 4E+3 8E+3 4E-6 1E-8 5E-5 5E-4 78 Platinum-193m D, all compounds 3E+3 6E+3 3E-6 8E-9 LLI wall (3E+4) 4E-5 4E-4 78 Platinum-193 D, all compounds 4E+4 2E+4 1E-5 3E-8 LLI wall (5E+4) 6E-4 6E-3 78 Platinum-195m D, all compounds 2E+3 4E+3 2E-6 6E-9 LLI wall (2E+3) 3E-5 3E-4 78 Platinum-197m2 D, all compounds 2E+4 4E+4 2E-5 6E-8 2E-4 2E-3 78 Platinum-197 D, all compounds 3E+3 1E+4 4E-6 1E-8 4E-5 4E-4 78 Platinum-1992 D, all compounds 5E+4 1E+5 6E-5 2E-7 7E-4 7E-3 78 Platinum-200 D, all compounds 1E+3 3E+3 1E-6 5E-9 2E-5 2E-4 79 Gold-193 D, all compounds except those given for W and Y 9E+3 3E+4 1E-5 4E-8 1E-4 1E-3 W, halides and nitrates 2E+4 9E-6 3E-8 Y, oxides and hydroxides 2E+4 8E-6 3E-8 79 Gold-194 D, see 193Au 3E+3 8E+3 3E-6 1E-8 4E-5 4E-4 W, see 193Au 5E+3 2E-6 8E-9 Y, see 193Au 5E+3 2E-6 7E-9 79 Gold-195 D see 193Au 5E+3 1E+4 5E-6 2E-8 7E-5 7E-4 W see 193Au 1E+3 6E-7 2E-9 Y see 193Au 4E+2 2E-7 6E-10 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 79 Gold-198m D see 193Au 1E+3 3E+3 1E-6 4E-9 1E-5 1E-4 W see 193Au 1E+3 5E-7 2E-9 Y see 193Au 1E+3 5E-7 2E-9 79 Gold-198 D see 193Au 1E+3 4E+3 2E-6 5E-9 2E-5 2E-4 W see 193Au 2E+3 8E-7 3E-9 Y see 193Au 2E+3 7E-7 2E-9
Volume 20, Issue 7 Page 392 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 79 Gold-199 D see 193Au 3E+3 9E+3 4E-6 1E-8 LLI wall (3E+3) 4E-5 4E-4 W, see 193Au 4E+3 2E-6 6E-9 Y, see 193Au 4E+3 2E-6 5E-9 79 Gold-200m D, see 193Au 1E+3 4E+3 1E-6 5E-9 2E-5 2E-4 W, see 193Au 3E+3 1E-6 4E-9 Y, see 193Au 2E+4 1E-6 3E-9 79 Gold-2002 D, see 193Au 3E+4 6E+4 3E-5 9E-8 4E-4 4E-3 W, see 193Au 8E+4 3E-5 1E-7 Y, see 193Au 7E+4 3E-5 1E-7 79 Gold-2012 D, see 193Au 7E+4 2E+5 9E-5 3E-7 St wall (9E+4) 1E-3 1E-2 W, see 193Au 2E+5 1E-4 3E-7 Y, see 193Au 2E+5 9E-5 3E-7 80 Mercury-193m Vapor 8E+3 4E-6 1E-8 Organic D 4E+3 1E+4 5E-6 2E-8 6E-5 6E-4 D, sulfates 3E+3 9E+3 4E-6 1E-8 4E-5 4E-4 W, oxides, hydroxides, halides, nitrates, and sulfides 8E+3 3E-6 1E-8 80 Mercury-193 Vapor 3E+4 1E-5 4E-8 Organic D 2E+4 6E+4 3E-5 9E-8 3E-4 3E-3 D, see 193mHg 2E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 193mHg 4E+4 2E-5 6E-8 80 Mercury-194 Vapor 3E+1 1E-8 4E-11 Organic D 2E+1 3E+1 1E-8 4E-11 2E-7 2E-6 D, see 193mHg 8E+2 4E+1 2E-8 6E-11 1E-5 1E-4 W, see 193mHg 1E+2 5E-8 2E-10 80 Mercury-195m Vapor 4E+3 2E-6 6E-9 Organic D 3E+3 6E+3 3E-6 8E-9 4E-5 4E-4 D, see 193mHg 2E+3 5E +3 2E-6 7E-9 3E-5 3E-4 W, see 193mHg 4E+3 2E-6 5E-9 80 Mercury-195 Vapor 3E+4 1E-5 4E-8 Organic D 2E+4 5E+4 2E-5 6E-8 2E-4 2E-3 D, see 193mHg 1E+4 4E+ 4 1E-5 5E-8 2E-4 2E-3 W, see 193mHg 3E+4 1E-5 5E-8
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 393 Volume 20, Issue 7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 80 Mercury-197m Vapor 5E+3 2E-6 7E-9 Organic D 4E+3 9E+3 4E-6 1E-8 5E-5 5E-4 D, see 193mHg 3E+3 7E+3 3E-6 1E-8 4E-5 4E-4 W, see 193mHg 5E+3 2E-6 7E-9 80 Mercury-197 Vapor 8E+3 4E-6 1E-8 Organic D 7E+3 1E+4 6E-6 2E-8 9E-5 9E-4 D, see 193mHg 6E+3 1E+4 5E-6 2E-8 8E-5 8E-4 W, see 193mHg 9E+3 4E-6 1E-8 80 Mercury-199m2 Vapor 8E+4 3E-5 1E-7 Organic D 6E+4 2E+5 7E-5 2E-7 St wall (1E+5) 1E-3 1E-2 D, see 193mHg 6E+4 1E+5 6E-5 2E-7 8E-4 8E-3 W, see 193mHg 2E+5 7E-5 2E-7 80 Mercury-203 Vapor 8E+2 4E-7 1E-9 Organic D 5E+2 8E+2 3E-7 1E-9 7E-6 7E-5 D, see 193mHg 2E+3 1E+3 5E-7 2E-9 3E-5 3E-4 W, see 193mHg 1E+3 5E-7 2E-9 81 Thallium-194m2 D, all compounds 5E+4 2E+5 6E-5 2E-7 St wall (7E+4) 1E-3 1E-2 81 Thallium-1942 D, all compounds 3E+5 6E+5 2E-4 8E-7 St wall (3E+5) 4E-3 4E-2 81 Thallium-1952 D, all compounds 6E+4 1E+5 5E-5 2E-7 9E-4 9E-3 81 Thallium-197 D, all compounds 7E+4 1E+5 5E-5 2E-7 1E-3 1E-2 81 Thallium-198m2 D, all compounds 3E+4 5E+4 2E-5 8E-8 4E-4 4E-3 81 Thallium-198 D, all compounds 2E+4 3E+4 1E-5 5E-8 3E-4 3E-3 81 Thallium-199 D, all compounds 6E+4 8E+4 4E-5 1E-7 9E-4 9E-3 81 Thallium-200 D, all compounds 8E+3 1E+4 5E-6 2E-8 1E-4 1E-3 81 Thallium-201 D, all compounds 2E+4 2E+4 9E-6 3E-8 2E-4 2E-3 81 Thallium-202 D, all compounds 4E+3 5E+3 2E-6 7E-9 5E-5 5E-4 81 Thallium-204 D, all compounds 2E+3 2E+3 9E-7 3E-9 2E-5 2E-4 82 Lead-195m2 D, all compounds 6E+4 2E+5 8E-5 3E-7 8E-4 8E-3 82 Lead-198 D, all compounds 3E+4 6E+4 3E-5 9E-8 4E-4 4E-3 82 Lead-1992 D, all compounds 2E+4 7E+4 3E-5 1E-7 3E-4 3E-3 82 Lead-200 D, all compounds 3E+3 6E+3 3E-6 9E-9 4E-5 4E-4 82 Lead-201 D, all compounds 7E+3 2E+4 8E-6 3E-8 1E-4 1E-3 82 Lead-202m D, all compounds 9E+3 3E+4 1E-5 4E-8 1E-4 1E-3 82 Lead-202 D, all compounds 1E+2 5E+1 2E-8 7E-11 2E-6 2E-5 82 Lead-203 D, all compounds 5E+3 9E+3 4E-6 1E-8 7E-5 7E-4 82 Lead-205 D, all compounds 4E+3 1E+3 6E-7 2E-9 5E-5 5E-4 82 Lead-209 D, all compounds 2E+4 6E+4 2E-5 8E-8 3E-4 3E-3 82 Lead-210 D, all compounds 6E1 2E1 1E-10 Bone surf Bone surf
Volume 20, Issue 7 Page 394 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (1E+0)
(4E-1) 6E-13 1E-8 1E-7 82 Lead-2112 D, all compounds 1E+4 6E+2 3E-7 9E-10 2E-4 2E+3 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 82 Lead-212 D, all compounds 8E+1 3E+1 1E-8 5E-11 Bone surf (1E+2) 2E-6 2E-5 82 Lead-2142 D, all compounds 9E+3 8E+2 3E-7 1E-9 1E-4 1E-3 83 Bismuth-2002 D, nitrates 3E+4 8E+4 4E-5 1E-7 4E-4 4E-3 W, all other compounds 1E+5 4E-5 1E-7 83 Bismuth-2012 D, see 200Bi 1E+4 3E+4 1E-5 4E-8 2E-4 2E-3 W, see 200Bi 4E+4 2E-5 5E-8 83 Bismuth-2022 D, see 200Bi 1E+4 4E+4 2E-5 6E-8 2E-4 2E-3 W, see 200Bi 8E+4 3E-5 1E-7 83 Bismuth-203 D, see 200Bi 2E+3 7E+3 3E-6 9E-9 3E-5 3E-4 W, see 200Bi 6E+3 3E-6 9E-9 83 Bismuth-205 D, see 200Bi 1E+3 3E+3 1E-6 3E-9 2E-5 2E-4 W, see 200Bi 1E+3 5E-7 2E-9 83 Bismuth-206 D, see 200Bi 6E+2 1E+3 6E-7 2E-9 9E-6 9E-5 W, see 200Bi 9E+2 4E-7 1E-9 83 Bismuth-207 D, see 200Bi 1E+3 2E+3 7E-7 2E-9 1E-5 1E-4 W, see 200Bi 4E+2 1E-7 5E-10 83 Bismuth-210m D, see 200Bi 4E+1 5E+0 2E-9 Kidneys Kidneys (6E+1)
(6E+0) 9E-12 8E-7 8E-6 W, see 200Bi 7E-1 3E-10 9E-13 83 Bismuth-210 D, see 200Bi 8E+2 2E+2 1E-7 1E-5 1E-4 Kidneys (4E+2) 5E-10 W, see 200Bi 3E+1 1E-8 4E-11 83 Bismuth-2122 D, see 200Bi 5E+3 2E+2 1E-7 3E-10 7E-5 7E-4 W, see 200Bi 3E+2 1E-7 4E-10 83 Bismuth-2132 D, see 200Bi 7E+3 3E+2 1E-7 4E-10 1E-4 1E-3 W, see 200Bi 4E+2 1E-7 5E-10 83 Bismuth-2142 D, see 200Bi 2E+4 8E+2 3E-7 1E-9 St wall (2E+4) 3E-4 3E-3 W, see 200Bi 9E-2 4E-7 1E-9 84 Polonium-2032 D, all compounds except those given for W 3E+4 6E+4 3E-5 9E-8 3E-4 3E-3 W, oxides, hydroxides, and nitrates 9E+4 4E-5 1E-7
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 395 Volume 20, Issue 7 84 Polonium-2052 D, see 203Po 2E+4 4E+4 2E-5 5E-8 3E-4 3E-3 W, see 203Po 7E+4 3E-5 1E-7 84 Polonium-207 D, see 203Po 8E+3 3E+4 1E-5 3E-8 1E-4 1E-3 W, see 203Po 3E+4 1E-5 4E-8 84 Polonium-210 D, see 203Po 3E+0 6E-1 3E-10 9E-13 4E-8 4E-7 W, see 203Po 6E-1 3E-10 9E-13 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 85 Astatine-2072 D, halides 6E+3 3E+3 1E-6 4E-9 8E-5 8E-4 W
2E+3 9E-7 3E-9 85 Astatine-211 D, halides 1E+2 8E+1 3E-8 1E-10 2E-6 2E-5 W
5E+1 2E-8 8E-11 86 Radon-220 With daughters removed 2E+4 7E-6 2E-8 With daughters present 2E+1 9E-9 3E-11 (or 12 working (or 1.0 level months) working level) 86 Radon-222 With daughters removed 1E+4 4E-6 1E-8 With daughters present 1E+2 3E-8 1E-10 (or 4 working (or 0.33 level months) working level) 87 Francium-2222 D, all compounds 2E+3 5E+2 2E-7 6E-10 3E-5 3E-4 87 Francium-2232 D, all compounds 6E+2 8E+2 3E-7 1E-9 8E-6 8E-5 88 Radium-223 W, all compounds 5E+0 7E-1 3E-10 9E-13 Bone surf (9E+0) 1E-7 1E-6 88 Radium-224 W, all compounds 8E+0 2E+0 7E-10 2E-12 Bone surf (2E+1) 2E-7 2E-6 88 Radium-225 W, all compounds 8E+0 7E-1 3E-10 9E-13 Bone surf (2E+1) 2E-7 2E-6 88 Radium-226 W, all compounds 2E+0 6E-1 3E-10 9E-13 Bone surf (5E+0) 6E-8 6E-7 88 Radium-2272 W, all compounds 2E+4 1E+4 6E-6 Bone surf Bone surf (2E+4)
(2E+4) 3E-8 3E-4 3E-3 88 Radium-228 W, all compounds 2E+0 1E+0 5E-10 2E-12 Bone surf (4E+0) 6E-8 6E-7 89 Actinium-224 D, all compounds except those given for W and Y 2E+3 3E+1 1E-8 LLI wall Bone surf (2E+3)
(4E+1) 5E-11 3E-5 3E-4 W, halides and nitrates 5E+1 2E-8 7E-11 Y, oxides and hydroxides 5E+1 2E-8 6E-11
Volume 20, Issue 7 Page 396 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 89 Actinium-225 D, see 224Ac 5E+1 3E-1 1E-10 LLI wall Bone surf (5E+1)
(5E-1) 7E-13 7E-7 7E-6 W, see 224Ac 6E-1 3E-10 9E-13 Y, see 224Ac 6E-1 3E-10 9E-13 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 89 Actinium-226 D, see 224Ac 1E+2 3E+0 1E-9 LLI wall Bone surf (1E+2)
(4E+0) 5E-12 2E-6 2E-5 W, see 224Ac 5E+0 2E-9 7E-12 Y, see 224Ac 5E+0 2E-9 6E-12 89 Actinium-227 D, see 224Ac 2E-1 4E-4 2E-13 Bone surf Bone surf (4E-1)
(8E-4) 1E-15 5E-9 5E-8 W, see 224Ac 2E-3 7E-13 Bone surf (3E-3) 4E-15 Y, see 224Ac 4E-3 2E-12 6E-15 89 Actinium-228 D, see 224Ac 2E+3 9E+0 4E-9 3E-5 3E-4 Bone surf (2E+1) 2E-11 W see 224Ac 4E+1 2E-8 Bone surf (6E+1) 8E-11 Y see 224Ac 4E+1 2E-8 6E-11 90 Thorium-2262 W, all compounds except those given for Y 5E+3 2E+2 6E-8 2E-10 St wall (5E+3) 7E-5 7E-4 Y, oxides and hydroxides 1E+2 6E-8 2E-10 90 Thorium-227 W, see 226Th 1E+2 3E-1 1E-10 5E-13 2E-6 2E-5 Y, see 226Th 3E-1 1E-10 5E-13 90 Thorium-228 W, see 226Th 6E+0 1E-2 4E-12 Bone surf Bone surf (1E+1)
(2E-2) 3E-14 2E-7 2E-6 Y, see 226Th 2E-2 7E-12 2E-14 90 Thorium-229 W, see 226Th 6E-1 9E-4 4E-13 Bone surf Bone surf (1E+0)
(2E-3) 3E-15 2E-8 2E-7 Y, see 226Th 2E-3 1E-12 Bone surf (3E-3) 4E -
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 397 Volume 20, Issue 7 90 Thorium-230 W, see 226Th 4E+0 6E-3 3E-12 Bone surf Bone surf (9E+0)
(2E-2) 2E-141E-7 1E-6 Y, see 226Th 2E-2 6E-12 Bone surf (2E-2) 3E -
90 Thorium-231 W, see 228Th 4E+3 6E+3 3E-6 9E-9 5E-5 5E-4 Y, see 228Th 6E+3 3E-6 9E -
Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 90 Thorium-232 W, see 228Th 7E-1 1E-3 5E-13 Bone surf Bone surf (2E+0)
(3E-3) 4E-15 3E-8 3E-7 Y, see 228Th 3E-3 1E-12 Bone surf (4E-3) 6E-15 90 Thorium-234 W, see 228Th 3E+2 2E+2 8E-8 3E-10 LLI wall (4E+2) 5E-6 5E-5 Y, see 228Th 2E+2 6E-8 2E-10 91 Protactinium-2272 W, all compounds except those given for Y 4E+3 1E+2 5E-8 2E-10 5E-5 5E-4 Y, oxides and hydroxides 1E+2 4E-8 1E-10 91 Protactinium-228 W, see 227Pa 1E+3 1E+1 5E-9 2E-5 2E-4 Bone surf (2E+1) 3E-11 Y, see 227Pa 1E+1 5E-9 2E-11 91 Protactinium-230 W, see 227Pa 6E+2 5E+0 2E-9 7E-12 Bone surf (9E+2) 1E-5 1E-4 Y, see 227Pa 4E+0 1E-9 5E-12 91 Protactinium-231 W, see 227Pa 2E-1 2E-3 6E-13 Bone surf Bone surf (5E-1)
(4E-3) 6E-15 6E-9 6E-8 Y, see 227Pa 4E-3 2E-12 Bone surf (6E-3) 8E-15 91 Protactinium-232 W, see 227Pa 1E+3 2E+1 9E-9 2E-5 2E-4 Bone surf (6E+1) 8E-11 Y, see 227Pa 6E+1 2E-8 Bone surf (7E+1) 1E-10 91 Protactinium-233 W, see 227Pa 1E+3 7E+2 3E-7 1E-9
Volume 20, Issue 7 Page 398 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking LLI wall (2E+3) 2E-5 2E-4 Y, see 227Pa 6E+2 2E-7 8E-10 91 Protactinium-234 W, see 227Pa 2E+3 8E+3 3E-6 1E-8 3E-5 3E-4 Y, see 227Pa 7E+3 3E-6 9E-9 92 Uranium-230 D, UF, UOF, UO(NO) 4E+0 4E-1 2E-10 Bone surf Bone surf (6E+0)
(6E-1) 8E-13 8E-8 8E-7 W, UO, UF, UCl 4E-1 1E-10 5E-13 Y, UO, UO 3E-1 1E-10 4E-13 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 92 Uranium-231 D, see 230U 5E+3 8E+3 3E-6 1E-8 LLI wall (4E+3) 6E-5 6E-4 W, see 230U 6E+3 2E-6 8E-9 Y, see 230U 5E+3 2E-6 6E-9 92 Uranium-232 D, see 230U 2E+0 2E-1 9E-11 Bone surf Bone surf (4E+0)
(4E-1) 6E-13 6E-8 6E-7 W, see 230U 4E-1 2E-10 5E-13 Y, see 230U 8E-3 3E-12 1E-14 92 Uranium-233 D, see 230U 1E+1 1E+0 5E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 7E-1 3E-10 1E-12 Y, see 230U 4E-2 2E-11 5E-14 92 Uranium-2343 D, see 230U 1E+1 1E+0 5E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 7E-1 3E-10 1E-12 Y, see 230U 4E-2 2E-11 5E-14 92 Uranium-2353 D, see 230U 1E+1 1E+0 6E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 8E-1 3E-10 1E-12 Y, see 230U 4E-2 2E-11 6E-14 92 Uranium-236 D, see 230U 1E+1 1E+0 5E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 8E-1 3E-10 1E-12 Y, see 230U 4E-2 2E-11 6E-14 92 Uranium-237 D, see 230U 2E+3 3E+3 1E-6 4E-9
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 399 Volume 20, Issue 7 LLI wall (2E+3) 3E-5 3E-4 W, see 230U 2E+3 7E-7 2E-9 Y, see 230U 2E+3 6E-7 2E-9 92 Uranium-2383 D, see 230U 1E+1 1E+0 6E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 8E-1 3E-10 1E-12 Y, see 230U 4E-2 2E-11 6E-14 92 Uranium-2392 D, see 230U 7E+4 2E+5 8E-5 3E-7 9E-4 9E-3 W, see 230U 2E+5 7E-5 2E-7 Y, see 230U 2E+5 6E-5 2E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 92 Uranium-240 D, see 230U 1E+3 4E+3 2E-6 5E-9 2E-5 2E-4 W, see 230U 3E+3 1E-6 4E-9 Y, see 230U 2E+3 1E-6 3E-9 92 Uranium-natural3 D, see 230U 1E+1 1E+0 5E-10 Bone surf Bone surf (2E+1)
(2E+0) 3E-12 3E-7 3E-6 W, see 230U 8E-1 3E-10 9E-13 Y, see 230U 5E-2 2E-11 9E-24 93 Neptunium-2322 W, all compounds 1E+5 2E+3 7E-7 2E-3 2E-2 Bone surf (5E+2) 6E-9 93 Neptunium-2332 W, all compounds 8E+5 3E+6 1E-3 4E-6 1E-2 1E-1 93 Neptunium-234 W, all compounds 2E+3 3E+3 1E-6 4E-9 3E-5 3E-4 93 Neptunium-235 W, all compounds 2E+4 8E+2 3E-7 LLI wall Bone surf (2E+4)
(1E+3) 2E-9 3E-4 3E-3 93 Neptunium-236 W, all compounds 3E+0 2E-2 9E-12 (1.15E+5 y)
Bone surf Bone surf (6E+0)
(5E-2) 8E-14 9E-8 9E-7 93 Neptunium-236 W, all compounds 3E+3 3E+1 1E-8 (22.5 h)
Bone surf Bone surf (4E+3)
(7E+1) 1E-10 5E-5 5E-4 93 Neptunium-237 W, all compounds 5E-1 4E-3 2E-12 Bone surf Bone surf (1E+0)
(1E-2) 1E-14 2E-8 2E-7 93 Neptunium-238 W, all compounds 1E+3 6E+1 3E-8 2E-5 2E-4 Bone surf (2E+2) 2E-10 93 Neptunium-239 W, all compounds 2E+3 2E+3 9E-7 3E-9 LLI wall (2E+3) 2E-5 2E-4
Volume 20, Issue 7 Page 400 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 93 Neptunium-2402 W, all compounds 2E+4 8E+4 3E-5 1E-7 3E-4 3E-3 94 Plutonium-234 W, all compounds except PuO 8E+3 2E+2 9E-8 3E-10 1E-4 1E-3 Y, PuO 2E+2 8E-8 3E-10 94 Plutonium-2352 W, see 234Pu 9E+5 3E+6 1E-3 4E-6 1E-2 1E-1 Y, see 234Pu 3E+6 1E-3 3E-6 94 Plutonium-236 W, see 234Pu 2E+0 2E-2 8E-12 Bone surf Bone surf (4E+0)
(4E-2) 5E-14 6E-8 6E-7 Y, see 234Pu 4E-2 2E-11 6E-14 94 Plutonium-237 W, see 234Pu 1E+4 3E+3 1E-6 5E-9 2E-4 2E-3 Y, see 234Pu 3E+3 1E-6 4E-9 94 Plutonium-238 W, see 234Pu 9E-1 7E-3 3E-12 Bone surf Bone surf (2E+0)
(1E-2) 2E-14 2E-8 2E-7 Y, see 234Pu 2E-2 8E-12 2E-14 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 94 Plutonium-239 W, see 234Pu 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 Y, see 234Pu 2E-2 7E-12 Bone surf (2E-2) 2E-14 94 Plutonium-240 W, see 234Pu 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 Y, see 234Pu 2E-2 7E-12 Bone surf (2E-2) 2E-14 94 Plutonium-241 W, see 234Pu 4E+1 3E-1 1E-10 Bone surf Bone surf (7E+1)
(6E-1) 8E-13 1E-6 1E-5 Y, see 234Pu 8E-1 3E-10 Bone surf (1E+0) 1E-12 94 Plutonium-242 W, see 234Pu 8E-1 7E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 Y, see 234Pu 2E-2 7E-12 Bone surf (2E-2) 2E-14 94 Plutonium-243 W, see 234Pu 2E+4 4E+4 2E-5 5E-8 2E-4 2E-3 Y, see 234Pu 4E+4 2E-5 5E-8 94 Plutonium-244 W, see 234Pu 8E-1 7E-3 3E-12
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 401 Volume 20, Issue 7 Bone surf Bone surf (2E+0)
(1E-2) 2E-14 2E-8 2E-7 Y, see 234Pu 2E-2 7E-12 Bone surf (2E-2) 2E-14 94 Plutonium-245 W, see 234Pu 2E+3 5E+3 2E-6 6E-9 3E-5 3E-4 Y, see 234Pu 4E+3 2E-6 6E-9 94 Plutonium-246 W, see 234Pu 4E+2 3E+2 1E-7 4E-10 LLI wall (4E+2) 6E-6 6E-5 Y, see 234Pu 3E+2 1E-7 4E-10 95 Americium-2372 W, all compounds 8E+4 3E+5 1E-4 4E-7 1E-3 1E-2 95 Americium-2382 W, all compounds 4E+4 3E+3 1E-6 5E-4 5E-3 Bone surf (6E+3) 9E-9 95 Americium-239 W, all compounds 5E+3 1E+4 5E-6 2E-8 7E-5 7E-4 95 Americium-240 W, all compounds 2E+3 3E+3 1E-6 4E-9 3E-5 3E-4 95 Americium-241 W, all compounds 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 95 Americium-242m W, all compounds 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 95 Americium-242 W, all compounds 4E+3 8E+1 4E-8 5E-5 5E-4 Bone surf (9E+1) 1E-10 95 Americium-243 W, all compounds 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 95 Americium-244m2 W, all compounds 6E+4 4E+3 2E-6 St wall Bone surf (8E+4)
(7E+3) 1E-8 1E-3 1E-2 95 Americium-244 W, all compounds 3E+3 2E+2 8E-8 4E-5 4E-4 Bone surf (3E+2) 4E-10 95 Americium-245 W, all compounds 3E+4 8E+4 3E-5 1E-7 4E-4 4E-3 95 Americium-246m2 W, all compounds 5E+4 2E+5 8E-5 3E-7 St wall (6E+4) 8E-4 8E-3 95 Americium-2462 W, all compounds 3E+4 1E+5 4E-5 1E-7 4E-4 4E-3 96 Curium-238 W, all compounds 2E+4 1E+3 5E-7 2E-9 2E-4 2E-3 96 Curium-240 W, all compounds 6E+1 6E-1 2E-10 Bone surf Bone surf (8E+1)
(6E-1) 9E-13 1E-6 1E-5 96 Curium-241 W, all compounds 1E+3 3E+1 1E-8 2E-5 2E-4 Bone surf
Volume 20, Issue 7 Page 402 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking (4E+1) 5E-11 96 Curium-242 W, all compounds 3E+1 3E-1 1E-10 Bone surf Bone surf (5E+1)
(3E-1) 4E-13 7E-7 7E-6 96 Curium-243 W, all compounds 1E+0 9E-3 4E-12 Bone surf Bone surf (2E+0)
(2E-2) 2E-14 3E-8 3E-7 96 Curium-244 W, all compounds 1E+0 1E-2 5E-12 Bone surf Bone surf (3E+0)
(2E-2) 3E-14 3E-8 3E-7 96 Curium-245 W, all compounds 7E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 96 Curium-246 W, all compounds 7E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 96 Curium-247 W, all compounds 8E-1 6E-3 3E-12 Bone surf Bone surf (1E+0)
(1E-2) 2E-14 2E-8 2E-7 96 Curium-248 W, all compounds 2E-1 2E-3 7E-13 Bone surf Bone surf (4E-1)
(3E-3) 4E-15 5E-9 5E-8 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 96 Curium-2492 W, all compounds 5E+4 2E+4 7E-6 7E-4 7E-3 Bone surf (3E+4) 4E-8 96 Curium-250 W, all compounds 4E-2 3E-4 1E-13 Bone surf Bone surf (6E-2)
(5E-4) 8E-16 9E-10 9E-9 97 Berkelium-245 W, all compounds 2E+3 1E+3 5E-7 2E-9 3E-5 3E-4 97 Berkelium-246 W, all compounds 3E+3 3E+3 1E-6 4E-9 4E-5 4E-4 97 Berkelium-247 W, all compounds 5E-1 4E-3 2E-12 Bone surf Bone surf (1E+0)
(9E-3) 1E-14 2E-8 2E-7 97 Berkelium-249 W, all compounds 2E+2 2E+0 7E-10 Bone surf Bone surf (5E+2)
(4E+0) 5E-12 6E-6 6E-5 97 Berkelium-250 W, all compounds 9E+3 3E+2 1E-7 1E-4 1E-3 Bone surf (7E+2) 1E-9 98 Californium-2442 W, all compounds except those given for Y 3E+4 6E+2 2E-7 8E-10 St wall (3E+4) 4E-4 4E-3 Y, oxides and hydroxides 6E+2 2E-7 8E-10 98 Californium-246 W, see 244Cf 4E+2 9E+0 4E-9 1E-11 5E-6 5E-5 Y, see 244Cf 9E+0 4E-9 1E-11 98 Californium-248 W, see 244Cf 8E+0 6E-2 3E-11
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 403 Volume 20, Issue 7 Bone surf Bone surf (2E+1)
(1E-1) 2E-13 2E-7 2E-6 Y, see 244Cf 1E-1 4E-11 1E-13 98 Californium-249 W, see 244Cf 5E-1 4E-3 2E-12 Bone surf Bone surf (1E+0)
(9E-3) 1E-14 2E-8 2E-7 Y, see 244Cf 1E-2 4E-12 Bone surf (1E-2) 2E-14 98 Californium-250 W, see 244Cf 1E+0 9E-3 4E-12 Bone surf Bone surf (2E+0)
(2E-2) 3E-14 3E-8 3E-7 Y, see 244Cf 3E-2 1E-11 4E-14 98 Californium-251 W, see 244Cf 5E-1 4E-3 2E-12 Bone surf Bone surf (1E+0)
(9E-3) 1E-14 2E-8 2E-7 Y, see 244Cf 1E-2 4E-12 Bone surf (1E-2) 2E-14 98 Californium-252 W, see 244Cf 2E+0 2E-2 8E-12 Bone surf Bone surf (5E+0)
(4E-2) 5E-14 7E-8 7E-7 Y, see 244Cf 3E-2 1E-11 5E-14 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml) 98 Californium-253 W, see 244Cf 2E+2 2E+0 8E-10 3E-12 Bone surf (4E+2) 5E-6 5E-5 Y, see 244Cf 2E+0 7E-10 2E-12 98 Californium-254 W, see 244Cf 2E+0 2E-2 9E-12 3E-14 3E-8 3E-7 Y, see 244Cf 2E-2 7E-12 2E-14 99 Einsteinium-250 W, all compounds 4E+4 5E+2 2E-7 6E-4 6E-3 Bone surf (1E+3) 2E-9 99 Einsteinium-251 W, all compounds 7E+3 9E+2 4E-7 1E-4 1E-3 Bone surf (1E+3) 2E-9 99 Einsteinium-253 W, all compounds 2E+2 1E+0 6E-10 2E-12 2E-6 2E-5 99 Einsteinium-254m W, all compounds 3E+2 1E+1 4E-9 1E-11 LLI wall (3E+2) 4E-6 4E-5 99 Einsteinium-254 W, all compounds 8E+0 7E-2 3E-11 Bone surf Bone surf (2E+1)
(1E-1) 2E-13 2E-7 2E-6 100 Fermium-252 W, all compounds 5E+2 1E+1 5E-9 2E-11 6E-6 6E-5 100 Fermium-253 W, all compounds 1E+3 1E+1 4E-9 1E-11 1E-5 1E-4 100 Fermium-254 W, all compounds 3E+3 9E+1 4E-8 1E-10 4E-5 4E-4 100 Fermium-255 W, all compounds 5E+2 2E+1 9E-9 3E-11 7E-6 7E-5
Volume 20, Issue 7 Page 404 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking 100 Fermium-257 W, all compounds 2E+1 2E-1 7E-11 Bone surf Bone surf (4E+1)
(2E-1) 3E-13 5E-7 5E-6 101 Mendelevium-257 W, all compounds 7E+3 8E+1 4E-8 1E-4 1E-3 Bone surf (9E+1) 1E-10 101 Mendelevium-258 W, all compounds 3E+1 2E-1 1E-10 Bone surf Bone surf (5E+1)
(3E-1) 5E-13 6E-7 6E-6 Any single radionuclide not listed above with decay mode other than alpha emission or spontaneous fission and with radioactive half-life less than 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br /> Submersion1 2E+2 1E-7 1E-9 Any single radionuclide not listed above with decay mode other than alpha emission or spontaneous fission and with radioactive half-life greater than 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br />.
2E-1 1E-10 1E-12 1E-8 1E-7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
Any single radionuclide not listed above that decays by alpha emission or spontaneous fission, or any mixture for which either the identity or the concentration of any radionuclide in the mixture is not known.
4E-4 2E-13 1E-15 2E-9 2E-8 FOOTNOTES:
1 No change 2 No change 3 No change NOTE:
1.
No change 2.
No change
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 405 Volume 20, Issue 7 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
If it is known that Ac-227-D and Cm-250-W are not present 7E-4 3E-13 If, in addition, it is known that Ac-227-W,Y, Th-229-W,Y, Th-230-W, Th-232-W,Y, Pa-231-W,Y, Np-237-W, Pu-239-W, Pu-240-W, Pu-242-W, Am-241-W, Am-242m-W, Am-243-W, Cm-245-W, Cm-246-W, Cm-247-W, Cm-248-W, Bk-247-W, Cf-249-W, and Cf-251-W are not present 7E-3 3E-12 Table I Table II Table III Occupational Values Effluent Releases to Concentrations Sewers Col. 1 Col. 2 Col.3 Col. 1 Col. 2 Oral Monthly Ingestion Inhalation Average Atomic Radionuclide Class ALI ALI DAC Air Water Concentration No.
(Ci)
(Ci)
(Ci/ml)
(Ci/ml)
(Ci/ml)
(Ci/ml)
If, in addition, it is known that Sm-146-W, Sm-147-W, Gd-148-D,W, Gd-152-D,W, Th-228-W,Y, Th-230-Y, U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, Np-236-W, Pu-236-W,Y, Pu-238-W,Y, Pu-239-Y, Pu-240-Y, Pu-242-Y, Pu-244-W,Y, Cm-243-W, Cm-244-W, Cf-248-W, Cf-249-Y, Cf-250-W,Y, Cf-251-Y, Cf-252-WY, and Cf-254-W,Y are not present 7E-2 3E-11 If, in addition, it is known that Pb-210-D, Bi-210m-W, Po-210-D,W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D,W,Y, Th-227-W,Y, U-230-D,W,Y, U-232-D,W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-Y, Es-254-W, Fm-257-W, and Md-258-W are not present 7E-1 3E-10 If, in addition, it is known that Si-32-Y, Ti-44-Y, Fe-60-D, Sr-90-Y, Zr-93-D, Cd-113m-D, Cd-113-D, In-115-D,W, La-138-D, Lu-176-W, Hf-178m-D,W, Hf-182-D,W, Bi-210m-D, Ra-224-W, Ra-228-W, Ac-226-D,W,Y, Pa-230-W,Y, U-233-D,W, U-234-D,W, U-235-D,W, U-236-D,W, U-238-D,W, Pu-241-Y, Bk-249-W, Cf-253-W,Y, and Es-253-W are not present 7E+0 3E-9 If it is known that Ac-227-D,W,Y, Th-229-W,Y, Th-232-W,Y, Pa-231-W,Y, Cm-248-W, and Cm-250-W are not present 1E-14 If, in addition, it is known that Sm-146-W, Gd-148-D,W, Gd-152-D, Th-228-W,Y, Th-230-W,Y, U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, U-Nat-Y, Np-236-W, Np-237-W, Pu-236-W,Y, Pu-238-W,Y, Pu-239-W,Y, Pu-240-W,Y, Pu-242-W,Y, Pu-244-W,Y, Am-241-W,
Volume 20, Issue 7 Page 406 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Am-242m-W, Am-243-W, Cm-243-W, Cm-244-W, Cm-245-W, Cm-246-W, Cm-247-W, Bk-247-W, Cf-249-W,Y, Cf-250-W,Y, Cf-251-W,Y, Cf-252-W,Y, and Cf-254-W,Y are not present 1E-13 If, in addition, it is known that Sm-147-W, Gd-152-W, Pb-210-D, Bi-210m-W, Po-210-D,W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D,W,Y, Th-227-W,Y, U-230-D,W,Y, U-232-D,W, U-Nat-W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-W,Y, Es-254-W, Fm-257-W, and Md-258-W are not present 1E-12 If, in addition it is known that Fe-60, Sr-90, Cd-113m, Cd-113, In-115, I-129, Cs-134, Sm-145, Sm-147, Gd-148, Gd-152, Hg-194 (organic), Bi-210m, Ra-223, Ra-224, Ra-225, Ac-225, Th-228, Th-230, U-233, U-234, U-235, U-236, U-238, U-Nat, Cm-242, Cf-248, Es-254, Fm-257, and Md-258 are not present 1E-6 1E-5 3.
No change 4.
No change ARTICLE 7. MEDICAL USES OF RADIOACTIVE MATERIAL R12-1-703.
License for Medical Use of Radioactive Material A.
No change 1.
No change 2.
No change 3.
No change B.
No change 1.
No change a.
No change b.
No change c.
No change d.
No change 2.
No change a.
No change i.
No change ii.
No change iii. No change iv.
No change b.
No change c.
No change C.
No change 1.
The Agency shall approve an application for a specific license under subsections (A) or (B), for any medical use or uses of radioactive material specified in Groups 100 through 600 1,000, in Exhibit A of this Article, for all of the materials within each group requested in the application if:
a.
No change b.
No change c.
The applicants radiation detection and measuring instrumentation is adequate for conducting the procedures involved in the authorized uses selected from Group 100 through Group 600 1,000; and d.
The applicants radiation safety operating procedures are adequate for handling and disposal of the radioactive material involved in the authorized uses selected from Group 100 through Group 600 1,000.
2.
Any licensee who is authorized to use radioactive material:
a.
In unsealed form under Groups 100, 200, or 300 or 1,000 listed in Exhibit A of this Article, shall do so using radiopharmaceuticals prepared in accordance with R12-1-311(J)(I); or b.
In sealed source form under Groups 400, 500, or 600, or 1,000 listed in Exhibit A of this Article, shall do so using sealed sources that have been manufactured and distributed in accordance with R12-1-311(L)(K);
c.
In any form under group 1,000 listed in Exhibit A of this Article, shall do so using sealed and unsealed sources
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 407 Volume 20, Issue 7 that have been manufactured and distributed in accordance with the specific license issued by the Agency.
3.
No change D.
No change R12-1-705.
Authority and Responsibilities for the Radiation Protection Program A.
No change B.
Licensees that are authorized for two or more different types of uses of radioactive material listed in Groups 300, 400, and 600, and 1,000, or two or more types of units under group 600 or 1,000, shall establish a Radiation Safety Committee (RSC) to oversee all uses of radioactive material permitted by the license. At a minimum, the RSC shall include an autho-rized user of each type of use permitted by the license, the RSO, a representative of the nursing service, and a representa-tive of management who is neither an authorized user nor a RSO.
C.
No change D.
No change R12-1-710.
Radiation Safety Officer Training A.
No change 1.
No change a.
No change i.
No change ii.
No change iii. No change b.
No change i.
No change ii.
No change (1) No change (2) No change iii. No change 2.
No change a.
No change i.
No change ii.
No change iii. No change iv.
No change v.
No change b.
No change i.
No change ii.
No change iii. Securing and controlling byproduct radioactive material; iv.
Using administrative controls to avoid mistakes in the administration of byproduct radioactive material; v.
No change vi. Using emergency procedures to control byproduct radioactive material; and vii. Disposing of byproduct radioactive material; or c.
No change 3.
No change B.
No change 1.
No change 2.
No change C.
No change D.
Individuals who, under subsection (B), need not comply with training requirements described in this Section may serve as preceptors for, and supervisors of, applicants seeking authorization on Agency licenses for the same uses for which these individuals are authorized.
R12-1-711.
Authorized Medical Physicist Training A.
No change 1.
Is certified by a specialty board whose certification process includes all of the training and experience requirements in subsection (A)(2) and(A)(3)(b) and (A)(3)(c) and whose certification has been recognized by the Agency, NRC or an Agreement State; or 2.
Training requirements.
a.
Holds a masters or doctors degree in physics, biophysics, radiological physics, medical physics, or health phys-ics and has completed one year of fulltime training in therapeutic radiological physics and an additional year of full-time work experience under the supervision of an authorized medical physicist at a medical institution that
Volume 20, Issue 7 Page 408 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking includes the physics tasks associated with the sealed source radiation therapy procedures regulated in this Arti-cle; and a.
Hold a masters or doctors degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university; b.
Have 2 years of full-time practical training and/or supervised experience in medical physics:
i.
Under the supervision of a medical physicist who is certified in medical physics by a specialty board recog-nized by the NRC or an Agreement State; or ii.
In clinical radiation facilities providing high-energy, external beam therapy (photons and electrons with energies greater than or equal to 1 million electron volts) and brachytherapy services under the direction of physicians who meet the requirements for authorized users in R12-1-710, R12-1-719, R12-1-721, R12 723, R12-1-727, R12-1-728, or R12-1-744; and c.
Pass an examination, administered by diplomates of the specialty board, that assesses knowledge and compe-tence in clinical radiation therapy, radiation safety, calibration, quality assurance, and treatment planning for external beam therapy, brachytherapy, and stereotactic radiosurgery; or 3.
Training requirements alternative.
a.
Holds a masters or doctors degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university; and has completed 1 year of full-time training in medical physics and an additional year of fulltime work experience under the supervision of an individual who meets the requirements for an authorized medical physicist for the type(s) of use for which the individual is seeking autho-rization. This training and work experience must be conducted in clinical radiation facilities that provide high-energy, external beam therapy (photons and electrons with energies greater than or equal to 1 million electron volts) and brachytherapy services and must include:
i.
Performing sealed source leak tests and inventories; ii.
Performing decay corrections; iii. Performing full calibration and periodic spot checks of external beam treatment units, stereotactic radiosur-gery units, and remote afterloading units as applicable; and iv.
Conducting radiation surveys around external beam treatment units, stereotactic radiosurgery units, and remote afterloading units as applicable; and b.
Has obtained written attestation that the individual has satisfactorily completed the requirements in subsection (A)(3)(c) and (A)(2)(a) and (A)(2)(b) and (A)(3)(c), or (A)(3)(a) and (A)(3)(c); and has achieved a level of com-petency sufficient to function independently as an authorized medical physicist for each type of therapeutic med-ical unit for which the individual is requesting authorized medical physicist status. The written attestation must be signed by a preceptor authorized medical physicist who meets the requirements in section, or equivalent Agreement State requirements for an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status; and c.
Has training for the type(s) of use for which authorization is sought that includes hands-on device operation, safety procedures, clinical use, and the operation of a treatment planning system. This training requirement may be satisfied by satisfactorily completing either a training program provided by the vendor or by training super-vised by an authorized medical physicist authorized for the type(s) of use for which the individual is seeking authorization.
b.
Has obtained written certification that the individual has satisfactorily completed the requirements in subsection (A)(2)(a) and has achieved a level of competency sufficient to function independently as an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status. The written certification shall be signed by a preceptor authorized medical physicist who meets the requirements in this Section or equivalent NRC or Agreement State requirements for an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status.
B.
No change C.
No change D.
Individuals who, under subsection (B), need not comply with training requirements described in this Section may serve as preceptors for, and supervisors of, applicants seeking authorization on Agency licenses for the same uses for which these individuals are authorized.
R12-1-712.
Authorized Nuclear Pharmacist Training A.
A licensee shall require the authorized nuclear pharmacist to be a pharmacist who:
1.
Is certified as a nuclear pharmacist by a specialty board whose certification process includes all of the requirements in subsection (2) and whose certification has been recognized by the Agency, NRC, or an Agreement State.; or To have its certification process recognized, a specialty board shall require all candidates for certification to:
a.
Have graduated from a pharmacy program accredited by the American Council on Pharmaceutical Education (ACPE) or have passed the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination;
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 409 Volume 20, Issue 7 b.
Hold a current, active license to practice pharmacy in Arizona; c.
Provide evidence of having acquired at least 4000 hours0.0463 days <br />1.111 hours <br />0.00661 weeks <br />0.00152 months <br /> of training/experience in nuclear pharmacy practice.
Academic training may be substituted for no more than 2000 hours0.0231 days <br />0.556 hours <br />0.00331 weeks <br />7.61e-4 months <br /> of the required training and experience; and d.
Pass an examination in nuclear pharmacy administered by diplomates of the specialty board, that assesses knowl-edge and competency in procurement, compounding, quality assurance, dispensing, distribution, health and safety, radiation safety, provision of information and consultation, monitoring patient outcomes, research and development; or 2.
No change a.
Didactic 200 hours0.00231 days <br />0.0556 hours <br />3.306878e-4 weeks <br />7.61e-5 months <br /> of classroom and laboratory training in the following areas:
i.
No change ii.
No change iii. No change iv.
No change v.
No change b.
No change i.
No change ii.
No change iii. No change iv.
No change v.
No change 3.
Has obtained written certification attestation, signed by a preceptor authorized nuclear pharmacist, that the individual has satisfactorily completed the requirements in subsection (A)(2) and has achieved a level of competency sufficient to function independently as an authorized nuclear pharmacist.
B.
No change C.
No change D.
Individuals who, under subsection (B), need not comply with training requirements described in this Section may serve as preceptors for, and supervisors of, applicants seeking authorization on Agency licenses for the same uses for which these individuals are authorized.
R12-1-713.
Determination of Prescribed Dosages, and Possession, Use, and Calibration of Instruments A.
No change B.
No change 1.
No change 2.
No change a.
No change b.
An Agency, NRC, or Agreement State licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by FDA.or; c.
A PET radioactive drug producer licensed under R12-1-311 or equivalent NRC or Agreement State require-ments.
C.
No change 1.
No change 2.
No change 3.
No change D.
No change E.
No change F.
No change G.
No change 1.
No change a.
No change b.
No change c.
No change d.
No change e.
No change f.
No change 2.
No change 3.
No change H.
No change 1.
No change 2.
No change 3.
No change
Volume 20, Issue 7 Page 410 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking I.
No change J.
No change R12-1-717.
Release of Individuals Containing Radioactive Material or Implants Containing Radioactive Material A.
A licensee may authorize the release from its control of any individual who has been administered unsealed radioactive material or implants containing radioactive material, if the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv millisieverts (0.5 rem).
B.
A licensee shall provide the released individual, or the individual's parent or guardian, with instructions, including written instructions, on actions recommended to maintain doses to other individuals as low as is reasonably achievable if the total effective dose equivalent to any other individual is likely to exceed 1 mSv millisievert (0.1 rem). If the total effective dose equivalent to a nursing infant or child could exceed 1 mSv millisievert (0.1 rem) assuming there were no interruption of breast-feeding, the instructions shall also include:
1.
No change 2.
No change C.
No change R12-1-719.
Training for Uptake, Dilution, and Excretion Studies A.
Except as provided in R12-1-710, each licensee shall require an authorized user of unsealed radioactive material for the uses authorized under Group 100 to be a physician who has completed the training requirements in 10 CFR 35.190, Janu-ary 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments. the licensee shall require an authorized user of unsealed radioactive material for the uses authorized under Group 100 to be a physician who:
1.
Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agree-ment State and who meets the requirements in subsection (A)(3). To have its certification process recognized, a spe-cialty board shall require all candidates for certification to:
a.
Complete 60 hours6.944444e-4 days <br />0.0167 hours <br />9.920635e-5 weeks <br />2.283e-5 months <br /> of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive material for uptake, dilution, and excretion studies as described in subsection (A)(3); and b.
Pass an examination, administered by diplomates of the specialty board, that assesses knowledge and compe-tence in radiation safety, radionuclide handling, and quality control; or 2.
Is an authorized user under R12-1-721, R12-1-723, NRC, or equivalent Agreement State requirements; or 3.
Has completed 60 hours6.944444e-4 days <br />0.0167 hours <br />9.920635e-5 weeks <br />2.283e-5 months <br /> of training and experience, including a minimum of 8 hours9.259259e-5 days <br />0.00222 hours <br />1.322751e-5 weeks <br />3.044e-6 months <br /> of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material for uptake, dilution, and excretion studies. The training and experience must include:
a.
Classroom and laboratory training in the following areas:
i.
Radiation physics and instrumentation; ii.
Radiation protection; iii. Mathematics pertaining to the use and measurement of radioactivity; iv.
Chemistry of radioactive material for medical use; and v.
Radiation biology; and b.
Work experience, under the supervision of an authorized user who meets the requirements in this Article, NRC, or equivalent Agreement State requirements, involving:
i.
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation sur-veys; ii.
Performing quality control procedures on instruments used to determine the activity of dosages and perform-ing checks for proper operation of survey meters; iii. Calculating, measuring, and safely preparing patient or human research subject dosages; iv.
Using administrative controls to prevent a medical event involving the use of unsealed radioactive material; v.
Using procedures to contain spilled radioactive material safely and using proper decontamination proce-dures; and vi. Administering dosages of radioactive drugs to patients or human research subjects; and c.
Has obtained written attestation, signed by a preceptor authorized user who meets the requirements who meets the requirements of R12-1-710, R12-1-719, R12-1-721, or R12-1-723, NRC, or equivalent Agreement State requirements; that the individual has satisfactorily completed the requirements in subsection (A)(1) or (A)(3) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under Exhibit A of this Article.
B.
No change C.
Individuals who, under R12-1-710(B), need not comply with training requirements described in this Section may serve as preceptors for, and supervisors of, applicants seeking authorization on Agency licenses for the same uses for which these
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 411 Volume 20, Issue 7 individuals are authorized.
R12-1-720.
Permissible Molybdenum-99, Strontium-82, and Strontium-85 Concentrations A.
A licensee may not administer to humans a radiopharmaceutical that contains more than 0.15 kilobecquerel of molybde-num-99 per megabecquerel of technetium-99m (0.15 microcurie of molybdenum-99 per millicurie of technetium-99m) or, more than 0.02 kilobecquerel of strontium-82 per megabecquerel of rubidium-82 chloride injection (0.02 microcurie of strontium-82 per millicurie of rubidium-82 chloride); or more than 0.2 kilobecquerel of strontium-85 per megabecquerel of rubidium-82 chloride injection (0.2 microcurie of strontium-85 per millicurie of rubidium-82).
B.
No change C.
A licensee that uses a strontium-82/rubidium-82 generator for preparing a rubidium-82 radiopharmaceutical shall, before the first patient use of the day, measure the concentration of radionuclides strontium-82 and strontium-85 to demonstrate compliance with subsection (A).
C.D. A licensee shall maintain a record of each molybdenum-99 concentration measurement or strontium-82 and strontium-85 concentrations measurements for three years following completion of the measurement.
R12-1-721.
Training for Imaging and Localization Studies Not Requiring a Written Directive A.
Except as provided in R12-1-710, a licensee shall require an authorized user of unsealed radioactive material for the uses authorized under Group 200 to be a physician who has completed the training requirements in 10 CFR 35.290, January 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments. the licensee shall require an authorized user of unsealed radioactive material for the uses autho-rized under Group 200 to be a physician who:
1.
Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agree-ment State and who meets the requirements in subsection (A)(3). To have its certification process recognized, a spe-cialty board shall require all candidates for certification to:
a.
Complete 700 hours0.0081 days <br />0.194 hours <br />0.00116 weeks <br />2.6635e-4 months <br /> of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive material for imaging and localization studies as described in subsection (3); and b.
Pass an examination, administered by diplomates of the specialty board, that assesses knowledge and compe-tence in radiation safety, radionuclide handling, and quality control; or 2.
Is an authorized user under this Chapter and R12-1-723, NRC, or equivalent Agreement State requirements; or 3.
Has completed 700 hours0.0081 days <br />0.194 hours <br />0.00116 weeks <br />2.6635e-4 months <br /> of training and experience, including a minimum of 80 hours9.259259e-4 days <br />0.0222 hours <br />1.322751e-4 weeks <br />3.044e-5 months <br /> of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material for imaging and localization studies. The training and experience must include:
a.
Classroom and laboratory training in the following areas:
i.
Radiation physics and instrumentation; ii.
Radiation protection; iii. Mathematics pertaining to the use and measurement of radioactivity; iv.
Chemistry of radioactive material for medical use; and v.
Radiation biology; and b.
Work experience, under the supervision of an authorized user who meets the requirements in R12-1-710, R12 721, or R12-1-723 and R12-1-721(A)(3)(b)(vii), NRC, or equivalent Agreement State requirements, involving:
i.
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation sur-veys; ii.
Performing quality control procedures on instruments used to determine the activity of dosages and perform-ing checks for proper operation of survey meters; iii. Calculating, measuring, and safely preparing patient or human research subject dosages; iv.
Using administrative controls to prevent a medical event involving the use of unsealed radioactive material; v.
Using procedures to contain spilled radioactive material safely and using proper decontamination proce-dures; and vi. Administering dosages of radioactive drugs to patients or human research subjects; and vii. Eluting generator systems appropriate for preparation of radioactive drugs for imaging and localization stud-ies, measuring and testing the elate for radionuclide purity, and processing the elate with reagent kits to pre-pare labeled radioactive drugs; and, c.
Has obtained written attestation, signed by a preceptor authorized user who meets the requirements as an autho-rized user for Exhibit A group 200 nuclides, NRC, or equivalent Agreement State requirements, that the individ-ual has satisfactorily completed the requirements in subsection (A)(1) or (A)(3) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under Exhibit A of this Article.
B.
An authorized user candidate who is a cardiologist is limited to nuclear cardiology if the candidate is unable to provide
Volume 20, Issue 7 Page 412 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking proof that he or she has participated in 700 hours0.0081 days <br />0.194 hours <br />0.00116 weeks <br />2.6635e-4 months <br /> of training and experience, required in 10 CFR 35.290(c).
C.B. The training and experience shall have been obtained within the seven years preceding the date of application or the indi-vidual shall have had related continuing education and experience since the required training and experience was com-pleted.
R12-1-723.
Training for Use of Unsealed Radioactive Material Requiring a Written Directive, Including Treatment of Hyperthyroidism, and Treatment of Thyroid Carcinoma A.
Except as provided in R12-1-710, a licensee shall require an authorized user of unsealed radioactive material for the uses authorized under Group 300 to be a physician who has completed the training requirements in 10 CFR 35.390, January 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments. the licensee shall require an authorized user of unsealed radioactive material for the uses autho-rized under Group 300 to be a physician who:
1.
Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agree-ment State and who meets the requirements in subsection (A)(2). To have its certification process recognized, a spe-cialty board shall require all candidates for certification to:
a.
Successfully complete residency training in a radiation therapy or nuclear medicine training program or a pro-gram in a related medical specialty. These residency training programs must include 700 hours0.0081 days <br />0.194 hours <br />0.00116 weeks <br />2.6635e-4 months <br /> of training and experience as described in (A)(2). Eligible training programs must be approved by the Residency Review Com-mittee of the Accreditation Council for Graduate Medical Education, the Royal College of Physicians and Sur-geons of Canada, or the Committee on Post-Graduate Training of the American Osteopathic Association; and b.
Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, and quality assurance, and clinical use of unsealed radioactive material for which a written directive is required; or 2.
Has completed 700 hours0.0081 days <br />0.194 hours <br />0.00116 weeks <br />2.6635e-4 months <br /> of training and experience, including a minimum of 200 hours0.00231 days <br />0.0556 hours <br />3.306878e-4 weeks <br />7.61e-5 months <br /> of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material requiring a written directive. The training and experience must include:
a.
Classroom and laboratory training in the following areas:
i.
Radiation physics and instrumentation; ii.
Radiation protection; iii. Mathematics pertaining to the use and measurement of radioactivity; iv.
Chemistry of radioactive material for medical use; and v.
Radiation biology; and b.
Work experience, under the supervision of an authorized user who meets the requirements in this Article, NRC, or equivalent Agreement State requirements, involving:
i.
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation sur-veys; ii.
Performing quality control procedures on instruments used to determine the activity of dosages and perform-ing checks for proper operation of survey meters; iii. Calculating, measuring, and safely preparing patient or human research subject dosages; iv.
Using administrative controls to prevent a medical event involving the use of unsealed radioactive material; v.
Using procedures to contain spilled radioactive material safely and using proper decontamination proce-dures; vi. Administering dosages of radioactive drugs to patients or human research subjects involving a minimum of three cases in each of the following categories for which the individual is requesting authorized user status:
(1) Oral administration of less than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131, for which a written directive is required (Experience with at least 3 cases in Category (A)(2)(b)(vi)(2) also satisfies this requirement);
(2) Oral administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131; (3) Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV, for which a written directive is required; and/or (4) Parenteral administration of any other radionuclide, for which a written directive is required; and c.
Has obtained written attestation, signed by a preceptor authorized user who meets the requirements as an autho-rized user for Exhibit A group 300 nuclides, NRC, or equivalent Agreement State requirements, that the individ-ual has satisfactorily completed the requirements in subsection (A)(1) or (A)(2) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under Exhibit A of this Article. The written attestation must be signed by a preceptor authorized user who meets the requirements in this Section, NRC, or equivalent Agreement State requirements. The preceptor authorized user, who meets the requirements in subsection (B) must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 413 Volume 20, Issue 7 B.
Except as provided in R12-1-710, a licensee shall require an authorized user of iodine-131 for the treatment of hyperthy-roidism for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries) to be a physician who has completed the training requirements in 10 CFR 35.392, January 1, 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments. 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments.
C.
Except as provided in R12-1-710, a licensee shall require an authorized user of iodine-131 for the treatment of thyroid car-cinoma for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 giga-becquerels (33 millicuries) to be a physician who has completed the training requirements in 10 CFR 35.394, January 1, 2013, incorporated by reference, and available under R12-1-101. This incorporated material contains no future editions or amendments. 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference con-tains no future editions or amendments.
D.
Except as provided in R12-1-710, a licensee shall require an authorized user for the parenteral administration of unsealed radioactive material requiring a written directive to be a physician who has completed the training requirements in 10 CFR 35.396, January 1, 2013, incorporated by reference, and available under R12-1-101. This incorporated material con-tains no future editions or amendments.
D.E. The training and experience shall have been obtained within the seven years preceding the date of application or the indi-vidual shall have had related continuing education and experience since the required training and experience was com-pleted.
R12-1-727.
Training for Use of Manual Brachytherapy Sources and Training for the Use of Strontium-90 Sources for Treatment of Ophthalmic Disease A.
Except as provided in R12-1-710, a licensee shall require an authorized user of a manual brachytherapy source for the uses authorized under Group 400 to be a physician who has completed the training requirements in 10 CFR 35.490, Janu-ary 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments. the licensee shall require an authorized user of a manual brachytherapy source for the uses authorized under this Article to be a physician who:
1.
Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agree-ment State and who meets the requirements in subsection (A)(2). To have its certification process recognized, a spe-cialty board shall require all candidates for certification to:
a.
Successfully complete a minimum of 3 years of residency training in a radiation oncology program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Post-Graduate Training of the American Osteopathic Association; and b.
Pass an examination, administered by diplomates of the specialty board, that tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of manual brachytherapy; or 2.
Has completed a structured educational program in basic radionuclide handling techniques applicable to the use of manual brachytherapy sources that includes:
a.
200 hours0.00231 days <br />0.0556 hours <br />3.306878e-4 weeks <br />7.61e-5 months <br /> of classroom and laboratory training in the following areas:
i.
Radiation physics and instrumentation; ii.
Radiation protection; iii. Mathematics pertaining to the use and measurement of radioactivity; iv.
Radiation biology; and b.
500 hours0.00579 days <br />0.139 hours <br />8.267196e-4 weeks <br />1.9025e-4 months <br /> of work experience, under the supervision of an authorized user who meets the requirements in this Section, or equivalent NRC or Agreement State requirements at a medical institution, involving:
i.
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation sur-veys; ii.
Checking survey meters for proper operation; iii. Preparing, implanting, and removing brachytherapy sources; iv.
Maintaining running inventories of material on hand; v.
Using administrative controls to prevent a medical event involving the use of radioactive material; vi. Using emergency procedures to control radioactive material; and c.
Has completed 3 years of supervised clinical experience in radiation oncology, under an authorized user who meets the requirements in this Section, or equivalent Agreement State requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on
Volume 20, Issue 7 Page 414 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by subsection (A)(2)(b); and d.
Has obtained written attestation, signed by a preceptor authorized user who meets the requirements in this Sec-tion, NRC, or equivalent Agreement State requirements, that the individual has satisfactorily completed the requirements in subsection (A)(1) or (A)(2) and has achieved a level of competency sufficient to function inde-pendently as an authorized user of manual brachytherapy sources for the medical uses authorized under Exhibit A of this Article.
B.
Except as provided in R12-1-710, a licensee shall require an authorized user of strontium-90 for ophthalmic radiotherapy to be a physician who has completed the training requirements in 10 CFR 35.491, January 1, 2013, incorporated by refer-ence, and available under R12-1-101. This incorporated material contains no future editions or amendments. 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administra-tion, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments.
C.
No change R12-1-728.
Training for Use of Sealed Sources for Diagnosis A.
Except as provided in R12-1-710, the licensee shall require the authorized user of a diagnostic sealed source for use in a device authorized under Group 500 to be a physician, dentist, or podiatrist who has completed the training requirements in 10 CFR 35.590, January 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments.: Is certified by a medical specialty board whose certification pro-cess has been recognized by the NRC or an Agreement State and who meets the requirements in subsections (A)(1) and (2); or 1.
Has completed 8 hours9.259259e-5 days <br />0.00222 hours <br />1.322751e-5 weeks <br />3.044e-6 months <br /> of classroom and laboratory training in basic radionuclide handling techniques specifically applicable to the use of the device. The training must include:
a.
Radiation physics and instrumentation; b.
Radiation protection; c.
Mathematics pertaining to the use and measurement of radioactivity; d.
Radiation biology; and 2.
Has completed training in the use of the device for the uses requested.
B.
No change R12-1-744.
Training for Use of Remote Afterloader Units, Teletherapy Units, and Gamma Stereotactic Radiosur-gery Units A.
Except as provided in R12-1-710, a licensee shall require an authorized user of a sealed source for a use authorized under Group 600 to be a physician who has completed the training requirements in 10 CFR 35.690, January 1, 2006, which is incorporated by reference, published by the Office of the Federal Register, National Archives and Records Administra-tion, Washington, DC 20408, and on file with the Agency. This incorporation by reference contains no future editions or amendments.:
1.
Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agree-ment State and who meets the requirements in subsection (A)(2). To have its certification process recognized, a spe-cialty board shall require all candidates to:
a.
Successfully complete a minimum of 3 years of residency training in a radiation therapy program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Post-Graduate Training of the American Osteopathic Association; and b.
Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of stereotactic radiosurgery, remote afterloaders and external beam therapy; or 2.
Has completed a structured educational program in basic radionuclide techniques applicable to the use of a sealed source in a therapeutic medical unit that includes:
a.
200 hours0.00231 days <br />0.0556 hours <br />3.306878e-4 weeks <br />7.61e-5 months <br /> of classroom and laboratory training in the following areas:
i.
Radiation physics and instrumentation; ii.
Radiation protection; iii. Mathematics pertaining to the use and measurement of radioactivity; iv.
Chemistry of radioactive material for medical use; and v.
Radiation biology; and b.
500 hours0.00579 days <br />0.139 hours <br />8.267196e-4 weeks <br />1.9025e-4 months <br /> of work experience, under the supervision of an authorized user who meets the requirements in this Section, or equivalent Agreement State or NRC requirements at a medical institution, involving:
i.
Reviewing full calibration measurements and periodic spot-checks;
Arizona Administrative Register / Secretary of State Notices of Final Rulemaking February 14, 2014 Page 415 Volume 20, Issue 7 ii.
Preparing treatment plans and calculating treatment doses and times; iii. Using administrative controls to prevent a medical event involving the use of radioactive material; iv.
Implementing emergency procedures to be followed in the event of the abnormal operation of the medical unit or console; v.
Checking and using survey meters; and vi. Selecting the proper dose and how it is to be administered; and c.
Has completed 3 years of supervised clinical experience in radiation therapy, under an authorized user who meets the requirements in this Section, or equivalent Agreement State or NRC requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by subsection (A)(2)(b); and d.
Has obtained written attestation that the individual has satisfactorily completed the requirements in subsection (A)(1) or (A)(2), and has achieved a level of competency sufficient to function independently as an authorized user of each type of therapeutic medical unit for which the individual is requesting authorized user status. The written attestation must be signed by a preceptor authorized user who meets the requirements in this Section, or equivalent Agreement State or NRC requirements for an authorized user for each type of therapeutic medical unit for which the individual is requesting authorized user status; and.
e.
Has received training in device operation, safety procedures, and clinical use for the type(s) of use for which authorization is sought. This training requirement may be satisfied by satisfactory completion of a training pro-gram provided by the vendor for new users or by receiving training supervised by an authorized user or autho-rized medical physicist, as appropriate, who is authorized for the type(s) of use for which the individual is seeking authorization.
B.
No change Exhibit A. Medical Use Groups Group 100 Included is the use of any unsealed radioactive material for use in uptake, dilution, or excretion studies and not requiring a written directive: The radioactive material in this group shall be:
1.
Obtained from a manufacturer or preparer licensed under R12-1-703(C)(2)(a), or equivalent NRC or Agreement State requirements; or 2.
Obtained from a PET radioactive drug producer licensed under R12-1-703 or equivalent NRC or an Agreement State license excluding production of PET radionuclides prepared Prepared by an authorized nuclear pharmacist who meets the requirements in R12-1-712, a physician who is an authorized user and who meets the requirements specified in R12-1-721, or R12-1-723 and R12-1-721(A)(3)(b)(vii), or an individual under the supervision of either as specified in R12-1-706; or 3.
And if If a research protocol:
a Obtained from and prepared by an Agreement State or NRC licensee for use in basic research in accordance with a Radioactive Drug Research Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by FDA; or b.
Prepared by the licensee for use in basic research in accordance with a Radioactive Drug Research Committee-approved application or an Investigational New Drug (IND) protocol accepted by FDA.
Group 200 Included is the use of any unsealed radioactive material for use in imaging and localization not requiring a written directive.
PET radiopharmaceuticals may be used if the licensee meets the requirements in R12-1-716. The radioactive material in this group shall be:
1.
Obtained from a manufacturer or preparer licensed under R12-1-703(C)(2)(a), or equivalent NRC or Agreement State requirements; or 2.
Obtained from a PET radioactive drug producer licensed under R12-1-703 or equivalent NRC or an Agreement State license excluding production of PET radionuclides prepared Prepared by an authorized nuclear pharmacist who meets the requirements in R12-1-712, a physician who is an authorized user and who meets the requirements specified in R12-1-721 or R12-1-723 and R12-1-721(A)(3)(b)(vii), or an individual under the supervision of either as specified in R12-1-706; or 3.
And if If a research protocol:
a.
Obtained from and prepared by an Agreement State or NRC licensee for use in basic research in accordance with a Radioactive Drug Research Committee-approved application or an Investigational New Drug (IND) protocol accepted by FDA; or b.
Prepared by the licensee for use in basic research in accordance with a Radioactive Drug Research Committee-approved application or an Investigational New Drug (IND) protocol accepted by FDA.
Group 300
Volume 20, Issue 7 Page 416 February 14, 2014 Arizona Administrative Register / Secretary of State Notices of Final Rulemaking Included is the use of any unsealed radioactive material for medical use (radiopharmaceutical) for which a written directive is required. The radioactive material in this group shall be:
1.
Obtained from a manufacturer or preparer licensed under R12-1-703(C)(2)(a) or equivalent NRC or Agreement State requirements; or 2.
Obtained from a PET radioactive drug producer licensed under R12-1-703 or equivalent NRC or an Agreement State license excluding production of PET radionuclides prepared Prepared by an authorized nuclear pharmacist who meets the requirements in R12-1-712, a physician who is an authorized user and who meets the requirements specified in R12-1-721 or R12-1-723, or an individual under the supervision of either as specified in R12-1-706; or 3.
And if If a research protocol:
a.
Obtained from and prepared by an Agreement State or NRC licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or b.
Prepared by the licensee for use in basic research in accordance with an Investigational New Drug (IND) proto-col accepted by FDA.
Group 400 No change 1.
No change 2.
No change Group 500 No change Group 600 No change 1.
No change 2.
No change Group 1000 A licensee may use radioactive material or a radiation source approved for medical use which is not specifically addressed in R12-1-309(A)(4) if:
1.
The applicant or licensee has submitted the information required by this Article; and 2.
The applicant or licensee has received written approval from the Agency in a license or license amendment and uses the material in accordance with the rules and specific conditions the Agency considers necessary for the medical use of the material.
ARTICLE 10. NOTICES, INSTRUCTIONS, AND REPORTS TO IONIZING RADIATION WORKERS; INSPECTIONS R12-1-1004.
Notifications and Reports to Individuals A.
No change B.
Each licensee or registrant shall make dose information available to workers as shown in records maintained by the licensee or registrant under the provisions of Article 4. Each licensee or registrant shall provide annual notification of exposure to radiation or radioactive material for each worker, as shown in records maintained by the licensee or registrant under R12-1-419 (E)(D) if:.
1.
The individuals occupational dose exceeds 1 mSv (100 mrem) TEDE or 1 mSv (100 mrem) to any individual organ or tissue; or 2.
The individual requests his or her annual dose report.
C.
No change D.
No change